{
  "meta": {
    "id": "test10",
    "title": "General Pharmacology",
    "category": "Subject Wise / Mixed"
  },
  "questions": [
    {
      "text": "Drug X was given as continuous intravenous infusion at 2 mg/min. The clearance of the drug is 100 ml/min. With a half-life of 1.8 hours, what would be the steady state plasma concentration of a drug?",
      "options": [
        {
          "label": "A",
          "text": "200 mg/mL",
          "correct": false
        },
        {
          "label": "B",
          "text": "0.36 mg/mL",
          "correct": false
        },
        {
          "label": "C",
          "text": "0.02 mg/mL",
          "correct": true
        },
        {
          "label": "D",
          "text": "3.6 mg/ML",
          "correct": false
        }
      ],
      "correct_answer": "C. 0.02 mg/mL",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) 0.02 mg/mL</strong></p>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 The steady state plasma concentration of a drug administered as a continuous IV infusion is calculated by dividing the maintenance dose rate by the drug's clearance . For a dose rate of 2 mg/min and clearance of 100 mL/min , the SSPC is 0.02 mg/ml</li><li>\u27a4 steady state plasma concentration</li><li>\u27a4 drug administered as a continuous IV infusion</li><li>\u27a4 calculated</li><li>\u27a4 dividing the maintenance dose rate</li><li>\u27a4 drug's clearance</li><li>\u27a4 dose rate of 2 mg/min</li><li>\u27a4 clearance of 100 mL/min</li><li>\u27a4 SSPC is 0.02 mg/ml</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "2ed7e057",
      "audio": ""
    },
    {
      "text": "A 45-year-old patient with a chronic condition is being considered for a new medication. The pharmacokinetic profile of the drug is being evaluated to understand how it distributes in the body. The medical team is particularly interested in determining how extensively the drug might distribute into the patient's tissues. Which parameter is the primary indicator that a drug has extensively distributed into the body's tissues?",
      "options": [
        {
          "label": "A",
          "text": "Large Volume of distribution",
          "correct": true
        },
        {
          "label": "B",
          "text": "Small Volume of distribution",
          "correct": false
        },
        {
          "label": "C",
          "text": "Renal excretion",
          "correct": false
        },
        {
          "label": "D",
          "text": "Salivary excretion",
          "correct": false
        }
      ],
      "correct_answer": "A. Large Volume of distribution",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Large Volume of distribution</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B: Small Volume of Distribution: This suggests that the drug is largely confined to the bloodstream and has not extensively distributed into the tissues . Drugs with a small volume of distribution are often highly plasma protein-bound and do not easily cross cell membranes.</li><li>\u2022 Option B: Small Volume of Distribution:</li><li>\u2022 drug is largely confined to the bloodstream</li><li>\u2022 not extensively distributed into the tissues</li><li>\u2022 Drugs</li><li>\u2022 small volume of distribution</li><li>\u2022 highly plasma protein-bound</li><li>\u2022 Option C: Renal Excretion: While renal excretion is a vital part of drug elimination , it does not directly indicate tissue distribution. It tells us more about how the body eliminates the drug, primarily through the kidneys.</li><li>\u2022 Option C: Renal Excretion:</li><li>\u2022 vital part of drug elimination</li><li>\u2022 Option D: Salivary Excretion: Like renal excretion, salivary excretion is another pathway for drug elimination but does not directly reflect the extent of drug distribution in the body's tissues.</li><li>\u2022 Option D: Salivary Excretion:</li><li>\u2022 salivary excretion</li><li>\u2022 pathway for drug elimination</li><li>\u2022 Therefore, among the options provided, a Large Volume of Distribution is the most indicative of a drug's distribution in tissues.</li><li>\u2022 Large Volume of Distribution</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 It is important to understand that to determine the extent of a drug's distribution into body tissues , we have to evaluate the volume of distribution . A large volume of distribution indicates widespread distribution into various tissue compartments beyond the vascular space.</li><li>\u27a4 important to understand</li><li>\u27a4 determine the extent of a drug's distribution into body tissues</li><li>\u27a4 evaluate the volume of distribution</li><li>\u27a4 large volume of distribution</li><li>\u27a4 widespread distribution into various tissue compartments</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "0d7cd126",
      "audio": ""
    },
    {
      "text": "A new pharmacological agent, designed to treat chronic hypertension, has shown promising results in early laboratory and animal studies. The pharmaceutical company is now ready to progress to the next phase of testing, which will focus on evaluating the drug's effectiveness in a small population of human subjects and establishing a safe dosage range. Phase II in a clinical drug trial is also known as:",
      "options": [
        {
          "label": "A",
          "text": "Human pharmacology and safety",
          "correct": false
        },
        {
          "label": "B",
          "text": "Therapeutic exploration and dose ranging",
          "correct": true
        },
        {
          "label": "C",
          "text": "Therapeutic confirmatory",
          "correct": false
        },
        {
          "label": "D",
          "text": "Post marketing surveillance",
          "correct": false
        }
      ],
      "correct_answer": "B. Therapeutic exploration and dose ranging",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/10/screenshot-2024-05-10-141934.png"
      ],
      "explanation": "<p><strong>Ans. B) Therapeutic exploration and dose ranging</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Human Pharmacology and Safety : This is usually associated with Phase I clinical trials , which primarily assess a drug's safety , tolerability , pharmacokinetics , and pharmacodynamics in a small group of healthy volunteers.</li><li>\u2022 Option A.</li><li>\u2022 Human Pharmacology and Safety</li><li>\u2022 Phase I clinical trials</li><li>\u2022 primarily assess a drug's safety</li><li>\u2022 tolerability</li><li>\u2022 pharmacokinetics</li><li>\u2022 pharmacodynamics</li><li>\u2022 Option C. Therapeutic Confirmatory : This typically refers to Phase III clinical trials , which are conducted on larger populations and are designed to confirm the drug's efficacy , monitor side effects , and compare it to standard or equivalent treatments.</li><li>\u2022 Option C.</li><li>\u2022 Therapeutic Confirmatory</li><li>\u2022 Phase III clinical trials</li><li>\u2022 conducted on larger populations</li><li>\u2022 confirm the drug's efficacy</li><li>\u2022 monitor side effects</li><li>\u2022 Option D. Post-Marketing Surveillance : Known as Phase IV , this phase occurs after the drug has been approved for public use . It involves long-term surveillance of drug effects in the general population to detect any rare or long-term adverse outcomes.</li><li>\u2022 Option D.</li><li>\u2022 Post-Marketing Surveillance</li><li>\u2022 Phase IV</li><li>\u2022 phase occurs after the drug has been approved for public use</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The primary aim of Phase II in clinical drug trials , termed \"Therapeutic Exploration and Dose Ranging,\" is to assess the drug's effectiveness in patients and establish a safe dosage range, while continuing to evaluate safety.</li><li>\u27a4 primary aim of Phase II</li><li>\u27a4 clinical drug trials</li><li>\u27a4 \"Therapeutic Exploration and Dose Ranging,\"</li><li>\u27a4 assess the drug's effectiveness</li><li>\u27a4 patients</li><li>\u27a4 establish a safe dosage range,</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "123d635e",
      "audio": ""
    },
    {
      "text": "What of the following is true about plasma half-life?",
      "options": [
        {
          "label": "A",
          "text": "Is the same as bioavailability",
          "correct": false
        },
        {
          "label": "B",
          "text": "It is directly proportional to clearance",
          "correct": false
        },
        {
          "label": "C",
          "text": "It is inversely proportional to volume of distribution",
          "correct": false
        },
        {
          "label": "D",
          "text": "It is constant for the drugs eliminated by first order kinetics",
          "correct": true
        }
      ],
      "correct_answer": "D. It is constant for the drugs eliminated by first order kinetics",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) It is constant for the drugs eliminated by first order kinetics</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Is the same as bioavailability:</li><li>\u2022 Option A. Is the same as bioavailability:</li><li>\u2022 This statement is incorrect. Bioavailability refers to the fraction of an administered dose of a drug that reaches the systemic circulation in its active form . In contrast, plasma half-life is the time required for the concentration of the drug in the plasma to reduce to half its original value. These are distinct pharmacokinetic properties.</li><li>\u2022 Bioavailability</li><li>\u2022 fraction of an administered dose</li><li>\u2022 drug that reaches the systemic circulation</li><li>\u2022 active form</li><li>\u2022 Option B. It is directly proportional to clearance:</li><li>\u2022 Option B. It is directly proportional to clearance:</li><li>\u2022 This is incorrect. Plasma half-life is inversely related to clearance . Clearance is the rate at which a drug is removed from the body. If a drug is cleared quickly from the body (high clearance), its plasma half-life will be shorter, and vice versa.</li><li>\u2022 Plasma half-life is inversely related to clearance</li><li>\u2022 Option C. It is inversely proportional to volume of distribution:</li><li>\u2022 Option C. It is inversely proportional to volume of distribution:</li><li>\u2022 This statement is actually a misunderstanding. Plasma half-life is not solely dependent on the volume of distribution . The relationship between half-life, volume of distribution, and clearance is given by the formula: half-life = (0.693 \u00d7 volume of distribution) / clearance. Thus, half-life is directly proportional to the volume of distribution and inversely proportional to clearance.</li><li>\u2022 Plasma half-life is not solely dependent on the volume of distribution</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 For drugs eliminated via first-order kinetics , the plasma half-life remains constant because a fixed percentage of the drug is metabolized per unit time , regardless of the drug's concentration in the plasma.</li><li>\u27a4 drugs eliminated via first-order kinetics</li><li>\u27a4 plasma half-life remains constant</li><li>\u27a4 fixed percentage of the drug</li><li>\u27a4 metabolized per unit time</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "174f919f",
      "audio": ""
    },
    {
      "text": "A 56-year-old male with a history of chronic pain managed with various analgesics is being evaluated for altered drug responsiveness. His recent medical history is significant for a new diagnosis of nephrotic syndrome. Understanding the principles of pharmacokinetics, you know that this may affect drug disposition. Which of the following statements regarding plasma protein binding is inaccurate?",
      "options": [
        {
          "label": "A",
          "text": "The free fraction of the drug is pharmacologically active",
          "correct": false
        },
        {
          "label": "B",
          "text": "Acidic drugs generally bind to plasma albumin",
          "correct": false
        },
        {
          "label": "C",
          "text": "There is no effect of nephrotic syndrome on plasma protein binding",
          "correct": true
        },
        {
          "label": "D",
          "text": "Lignocaine is bound to alpha 1 acid glycoprotein",
          "correct": false
        }
      ],
      "correct_answer": "C. There is no effect of nephrotic syndrome on plasma protein binding",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) There is no effect of nephrotic syndrome on plasma protein binding</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. The free fraction of the drug is pharmacologically active : This is true . Only the free (unbound) fraction of a drug in plasma is available to interact with its target receptors and produce a pharmacological effect.</li><li>\u2022 Option A.</li><li>\u2022 The free fraction of the drug is pharmacologically active</li><li>\u2022 true</li><li>\u2022 Option B. Acidic drugs generally bind to plasma albumin : This statement is correct. Albumin, being the most abundant plasma protein, typically binds to acidic drugs, such as barbiturates.</li><li>\u2022 Option B.</li><li>\u2022 Acidic drugs generally bind to plasma albumin</li><li>\u2022 correct.</li><li>\u2022 Option D. Lignocaine is bound to alpha 1 acid glycoprotein : This is true . Lignocaine (lidocaine), a basic drug, predominantly binds to alpha 1 acid glycoprotein.</li><li>\u2022 Option D.</li><li>\u2022 Lignocaine is bound to alpha 1 acid glycoprotein</li><li>\u2022 true</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Nephrotic syndrome can significantly affect plasma protein binding by reducing plasma albumin levels, which alters the binding capacity for many drugs , potentially increasing the pharmacologically active free fraction.</li><li>\u27a4 affect plasma protein binding by reducing plasma albumin levels,</li><li>\u27a4 alters the binding capacity for many drugs</li><li>\u27a4 increasing the pharmacologically active free fraction.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "e1b096f7",
      "audio": ""
    },
    {
      "text": "If the rate of elimination of a drug is directly proportional to its plasma concentration, the order of kinetics is?",
      "options": [
        {
          "label": "A",
          "text": "Zero",
          "correct": false
        },
        {
          "label": "B",
          "text": "Pseudo - zero",
          "correct": false
        },
        {
          "label": "C",
          "text": "First",
          "correct": true
        },
        {
          "label": "D",
          "text": "Second",
          "correct": false
        }
      ],
      "correct_answer": "C. First",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/09/24/screenshot-2024-09-24-155123.jpg"
      ],
      "explanation": "<p><strong>Ans. C) First</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Zero: Zero-order kinetics occurs when the rate of elimination is constant, regardless of the drug's concentration. A fixed amount of drug is eliminated per unit time.</li><li>\u2022 Option A. Zero:</li><li>\u2022 rate of elimination is constant,</li><li>\u2022 Option B. Pseudo zero: This is other name of zero order kinetics only .</li><li>\u2022 Option B. Pseudo zero:</li><li>\u2022 other name</li><li>\u2022 zero order kinetics only</li><li>\u2022 Option D. Second: Second-order kinetics is less common in pharmacology and occurs when the drug elimination rate is proportional to the square of the drug's concentration . It's more typical in chemical reactions involving two reactant molecules.</li><li>\u2022 Option D. Second:</li><li>\u2022 Second-order kinetics</li><li>\u2022 less common</li><li>\u2022 pharmacology</li><li>\u2022 drug elimination rate is proportional to the square of the drug's concentration</li><li>\u2022 Therefore, the correct answer is C. First-order kinetics.</li><li>\u2022 C. First-order kinetics.</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "10dcb44f",
      "audio": ""
    },
    {
      "text": "All the following statements about transdermal drug delivery systems are true except?",
      "options": [
        {
          "label": "A",
          "text": "Adhesive patches can be applied to chest, abdomen or back",
          "correct": false
        },
        {
          "label": "B",
          "text": "The drug is delivered at a constant rate",
          "correct": false
        },
        {
          "label": "C",
          "text": "Transdermal drug delivery is a good option in emergency situations",
          "correct": true
        },
        {
          "label": "D",
          "text": "Fentanyl is used as a transdermal patch",
          "correct": false
        }
      ],
      "correct_answer": "C. Transdermal drug delivery is a good option in emergency situations",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Transdermal drug delivery is a good option in emergency situations</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Adhesive patches can be applied to chest, abdomen or back : This is true. Transdermal patches are commonly applied to these areas where the skin is relatively permeable and where the patch can remain undisturbed for the duration of its intended use.</li><li>\u2022 Option A.</li><li>\u2022 Adhesive patches can be applied to chest, abdomen or back</li><li>\u2022 true.</li><li>\u2022 Option B. The drug is delivered at a constant rate : True . Transdermal patches are designed to deliver drugs at a controlled, steady rate through the skin and into the bloodstream.</li><li>\u2022 Option B.</li><li>\u2022 The drug is delivered at a constant rate</li><li>\u2022 True</li><li>\u2022 Option D. Fentanyl is used as a transdermal patch : True . Fentanyl is one of the medications that can be delivered through the skin using a transdermal patch, primarily for the management of chronic pain.</li><li>\u2022 Option D.</li><li>\u2022 Fentanyl is used as a transdermal patch</li><li>\u2022 True</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 Transdermal drug delivery systems provide controlled and steady medication delivery, but due to their slow rate of absorption , they are not suitable for emergency situations where rapid drug effect is necessary.</li><li>\u27a4 Transdermal drug delivery systems</li><li>\u27a4 controlled and steady medication delivery,</li><li>\u27a4 slow rate of absorption</li><li>\u27a4 not suitable for emergency situations</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "de461837",
      "audio": ""
    },
    {
      "text": "Which of the following set of drugs can be considered as physiological antagonists?",
      "options": [
        {
          "label": "A",
          "text": "Adrenaline and Isoprenaline",
          "correct": false
        },
        {
          "label": "B",
          "text": "Histamine and adrenaline",
          "correct": true
        },
        {
          "label": "C",
          "text": "Isoprenaline and propranolol",
          "correct": false
        },
        {
          "label": "D",
          "text": "All the above",
          "correct": false
        }
      ],
      "correct_answer": "B. Histamine and adrenaline",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans.\u00a0B) Histamine and adrenaline</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Adrenaline and Isoprenaline : These are both sympathomimetic agents that act on adrenergic receptors , not physiological antagonists.</li><li>\u2022 Option A.</li><li>\u2022 Adrenaline and Isoprenaline</li><li>\u2022 both sympathomimetic agents</li><li>\u2022 act on adrenergic receptors</li><li>\u2022 Option C. Isoprenaline and Propranolol : Isoprenaline is an agonist of \u03b2-adrenergic receptors , while propranolol is a \u03b2-adrenergic receptor antagonist. They are pharmacological antagonists because they bind to the same receptor with opposing actions.</li><li>\u2022 Option C.</li><li>\u2022 Isoprenaline and Propranolol</li><li>\u2022 Isoprenaline</li><li>\u2022 agonist of \u03b2-adrenergic receptors</li><li>\u2022 Option D. All the above : This option is incorrect because it includes both physiological antagonists (histamine and adrenaline) and pharmacological antagonists (isoprenaline and propranolol).</li><li>\u2022 Option D.</li><li>\u2022 All the above</li><li>\u2022 includes both physiological antagonists</li><li>\u2022 pharmacological antagonists</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 Physiological antagonists are those that produce opposite action by acting on different receptors eg. Histamine and adrenaline</li><li>\u2022 Physiological antagonists</li><li>\u2022 produce opposite action</li><li>\u2022 acting on different receptors</li><li>\u2022 Histamine and adrenaline</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "f28d0a32",
      "audio": ""
    },
    {
      "text": "A pharmaceutical company is preparing an advertisement leaflet for a new medication that will be promoted to healthcare providers. As part of the regulatory compliance team, you are reviewing the content to ensure all necessary information is included and aligns with FDA guidelines for pharmaceutical advertising. Which of the following pieces of information is NOT required to be included in the drug advertisement leaflet intended for healthcare professionals?",
      "options": [
        {
          "label": "A",
          "text": "Reference of research papers for the claims made by the company.",
          "correct": false
        },
        {
          "label": "B",
          "text": "Expiry Date",
          "correct": true
        },
        {
          "label": "C",
          "text": "Rare, but serious life-threatening adverse effects",
          "correct": false
        },
        {
          "label": "D",
          "text": "Common, but not so serious adverse effects",
          "correct": false
        }
      ],
      "correct_answer": "B. Expiry Date",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Expiry Date</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A.</li><li>\u2022 References to research papers</li><li>\u2022 Option C. Information on rare, but serious life-threatening adverse effects : This information is crucial and must be included to provide a complete risk assessment for the healthcare provider.</li><li>\u2022 Option C.</li><li>\u2022 Information on rare, but serious life-threatening adverse effects</li><li>\u2022 provide a complete risk assessment</li><li>\u2022 healthcare provider.</li><li>\u2022 Option D. Information on common, but less serious adverse effects : Knowing the side effect profile , including common and non-serious adverse effects , is essential for healthcare providers to make informed decisions about prescribing a drug.</li><li>\u2022 Option D.</li><li>\u2022 Information on common, but less serious adverse effects</li><li>\u2022 side effect profile</li><li>\u2022 common and non-serious adverse effects</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The expiry date is not required on promotional drug literature , as it varies by batch; instead, it is a crucial detail on the drug's label for patient safety.</li><li>\u27a4 expiry date</li><li>\u27a4 not required on promotional drug literature</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "4e4ab871",
      "audio": ""
    },
    {
      "text": "A pharmaceutical company is conducting research to develop a new drug targeting a protein receptor recently identified through genomic studies. This receptor has a structure indicating it is likely part of a known family of receptors; however, scientists have yet to discover a natural substance in the body that activates or binds to it. Which of the following is true about Orphan Receptors?",
      "options": [
        {
          "label": "A",
          "text": "These are receptors at which Orphan Drugs act",
          "correct": false
        },
        {
          "label": "B",
          "text": "These are receptors for which there is no endogenous mediator or ligand",
          "correct": true
        },
        {
          "label": "C",
          "text": "These are receptors which cause adverse effects only",
          "correct": false
        },
        {
          "label": "D",
          "text": "These are receptors that bind specific drugs, but no pharmacological response is elicited",
          "correct": false
        }
      ],
      "correct_answer": "B. These are receptors for which there is no endogenous mediator or ligand",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) These are receptors for which there is no endogenous mediator or ligand</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. These are receptors at which Orphan Drugs act: This statement is incorrect. Orphan drugs are medications that are developed for the treatment of rare diseases, often referred to as \"orphan diseases.\" The term \"orphan receptors\" is not related to orphan drugs in this context.</li><li>\u2022 Option A.</li><li>\u2022 These are receptors at which Orphan Drugs act:</li><li>\u2022 Orphan drugs are medications</li><li>\u2022 treatment of rare diseases,</li><li>\u2022 Option C. These are receptors which cause adverse effects only: This statement is incorrect. Orphan receptors are not defined by the effects (adverse or therapeutic) they produce but rather by the lack of identified natural ligands.</li><li>\u2022 Option C.</li><li>\u2022 These are receptors which cause adverse effects only:</li><li>\u2022 Orphan receptors</li><li>\u2022 not defined by the effects</li><li>\u2022 lack of identified natural ligands.</li><li>\u2022 Option D. These are receptors that bind specific drugs, but no pharmacological response is elicited: This statement is incorrect. Orphan receptors may or may not bind specific drugs . Such receptors where drug binds and produce no pharmacological responses are called silent receptors. Plasma proteins are considered such receptors.</li><li>\u2022 Option D.</li><li>\u2022 These are receptors that bind specific drugs, but no pharmacological response is elicited:</li><li>\u2022 Orphan receptors</li><li>\u2022 may not bind specific drugs</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Orphan receptors are characterized by the absence of a known endogenous ligand and not by their drug binding capabilities or the effects they mediate.</li><li>\u27a4 Orphan receptors</li><li>\u27a4 absence of a known endogenous ligand</li><li>\u27a4 not by their drug binding capabilities</li><li>\u27a4 effects they mediate.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "dc45f0e3",
      "audio": ""
    },
    {
      "text": "A 39-year-old man presents to the clinic for management of chronic pain. He has a history of non-adherence to oral medications and is seeking alternative routes of administration. He inquires about the use of transdermal therapeutic systems for his condition. When considering the rate of systemic absorption of drugs administered through the skin, which of the following correctly orders anatomical sites from the fastest to the slowest absorption rate?",
      "options": [
        {
          "label": "A",
          "text": "Plantar surface> scalp> forearm>postauricular skin > scrotum",
          "correct": false
        },
        {
          "label": "B",
          "text": "Postauricular skin > forearm > scrotum > scalp > plantar surface",
          "correct": false
        },
        {
          "label": "C",
          "text": "Scrotum > postauricular skin > forearm > scalp > plantar surface",
          "correct": true
        },
        {
          "label": "D",
          "text": "Scrotum > forearm > scalp >postauricular skin > plantar surface",
          "correct": false
        }
      ],
      "correct_answer": "C. Scrotum > postauricular skin > forearm > scalp > plantar surface",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Scrotum > postauricular skin > forearm > scalp > plantar surface</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 The absorption rate through the skin is influenced by the anatomical site's skin thickness, hair follicle density , capillary density, lipid content, and degree of hydration . The correct sequence from fastest to slowest is:</li><li>\u2022 absorption rate through the skin</li><li>\u2022 influenced by the anatomical site's skin thickness,</li><li>\u2022 hair follicle density</li><li>\u2022 capillary density,</li><li>\u2022 lipid content,</li><li>\u2022 degree of hydration</li><li>\u2022 Scrotum : Has thin skin with high permeability. Postauricular skin (behind the ear) : Relatively thin and well-perfused, allowing for good absorption. Forearm : More commonly used for drug absorption testing, has moderate absorption rates. Scalp : While well-vascularized, the presence of hair and thicker skin can decrease the rate of absorption compared to other areas. Plantar surface : The skin of the palms and soles is the thickest, making absorption slower.</li><li>\u2022 Scrotum : Has thin skin with high permeability.</li><li>\u2022 Scrotum</li><li>\u2022 Postauricular skin (behind the ear) : Relatively thin and well-perfused, allowing for good absorption.</li><li>\u2022 Postauricular skin (behind the ear)</li><li>\u2022 Forearm : More commonly used for drug absorption testing, has moderate absorption rates.</li><li>\u2022 Forearm</li><li>\u2022 Scalp : While well-vascularized, the presence of hair and thicker skin can decrease the rate of absorption compared to other areas.</li><li>\u2022 Scalp</li><li>\u2022 Plantar surface : The skin of the palms and soles is the thickest, making absorption slower.</li><li>\u2022 Plantar surface</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The rate of systemic absorption of a drug through the skin is fastest in areas with thinner skin and rich blood supply, such as the scrotum and postauricular area, and slowest through thick skin like that of the plantar surface.</li><li>\u27a4 rate of systemic absorption</li><li>\u27a4 drug through the skin is fastest in areas</li><li>\u27a4 thinner skin</li><li>\u27a4 rich blood supply,</li><li>\u27a4 scrotum and postauricular area,</li><li>\u27a4 slowest through thick skin</li><li>\u27a4 plantar surface.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "18b5f8b6",
      "audio": ""
    },
    {
      "text": "Given image shows the Log DRC of a drug alone (A) and in the presence of antagonists (B and C). Identify the type of antagonism shown in curve B and curve C?",
      "options": [
        {
          "label": "A",
          "text": "B is competitive and C is non-competitive antagonist",
          "correct": true
        },
        {
          "label": "B",
          "text": "B is non-competitive an C is competitive antagonist",
          "correct": false
        },
        {
          "label": "C",
          "text": "Both are competitive antagonists",
          "correct": false
        },
        {
          "label": "D",
          "text": "Both are non-competitive antagonists",
          "correct": false
        }
      ],
      "correct_answer": "A. B is competitive and C is non-competitive antagonist",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/08/24/11.jpg"
      ],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) B is competitive, and C is non competitive antagonist</strong></p>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 On a dose-response curve , competitive antagonism is characterized by a rightward shift of the curve with no change in maximal response, whereas non-competitive antagonism results in a decrease in maximal response without a significant shift in potency.</li><li>\u27a4 dose-response curve</li><li>\u27a4 competitive antagonism</li><li>\u27a4 rightward shift of the curve with no change in maximal response,</li><li>\u27a4 non-competitive antagonism</li><li>\u27a4 decrease in maximal response</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "6da57741",
      "audio": ""
    },
    {
      "text": "A patient was administered a fixed dose of a drug and the initial plasma concentration was found to be 1000 mcg/dl. It follows first order kinetics. Its plasma concentration was found to be 500 mcg/dl after 2 hours. What is the likely plasma concentration of the drug, if measured after 8 hours of administration?",
      "options": [
        {
          "label": "A",
          "text": "125mcg/dl",
          "correct": false
        },
        {
          "label": "B",
          "text": "62.5mcg/dl",
          "correct": true
        },
        {
          "label": "C",
          "text": "0 mcg/dl",
          "correct": false
        },
        {
          "label": "D",
          "text": "31.25 mcg/dl",
          "correct": false
        }
      ],
      "correct_answer": "B. 62.5mcg/dl",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) 62.5 mcg/dl</strong></p>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 When a drug follows first-order kinetics , the plasma concentration decreases by half with each half-life ; therefore, after 8 hours (or four half-lives), the plasma concentration of a drug will be reduced to 1/16 of its initial level .</li><li>\u27a4 drug follows first-order kinetics</li><li>\u27a4 plasma concentration decreases by half</li><li>\u27a4 each half-life</li><li>\u27a4 after 8 hours</li><li>\u27a4 plasma concentration of a drug will be reduced to 1/16</li><li>\u27a4 initial level</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "3254ae83",
      "audio": ""
    },
    {
      "text": "A new drug X is given orally to a healthy volunteer in a dose of 100 mg. Plasma concentration of the drug is measured at hourly intervals and a graph is plotted between plasma concentration and time as shown below in Fig. Which of the following statements about drug X is TRUE?",
      "options": [
        {
          "label": "A",
          "text": "Its Cmax is 20 \u03bcg/dl",
          "correct": false
        },
        {
          "label": "B",
          "text": "AUC from the above graph reflects the rate of absorption of the drug",
          "correct": false
        },
        {
          "label": "C",
          "text": "Tmax for drug X is 7 hours",
          "correct": false
        },
        {
          "label": "D",
          "text": "Instead of 100 mg drug X should be given in divided doses",
          "correct": true
        }
      ],
      "correct_answer": "D. Instead of 100 mg drug X should be given in divided doses",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/08/24/12.jpg"
      ],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Instead of 100 mg, drug X should be given in divided doses.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Its Cmax is 20 \u03bcg/dl : This is incorrect. Cmax refers to the peak plasma concentration of a drug after administration . In the graph, the Cmax appears to be higher than 20 \u03bcg/dl, around 27 \u03bcg/dl.</li><li>\u2022 Option A.</li><li>\u2022 Its Cmax is 20 \u03bcg/dl</li><li>\u2022 Cmax refers</li><li>\u2022 peak plasma concentration</li><li>\u2022 drug after administration</li><li>\u2022 Option B . AUC from the above graph reflects the rate of absorption of the drug : This is incorrect. The area under the curve (AUC) is related to the extent of absorption of the drug into the systemic circulation , not the rate. The rate of absorption is typically inferred from the Tmax and the steepness of the curve leading up to Cmax.</li><li>\u2022 Option B</li><li>\u2022 AUC from the above graph reflects the rate of absorption of the drug</li><li>\u2022 area under the curve</li><li>\u2022 extent of absorption of the drug</li><li>\u2022 systemic circulation</li><li>\u2022 Option C. Tmax for drug X is 7 hours : This is incorrect. Tmax is the time it takes for a drug to reach its maximum concentration in plasma . In the graph, the Tmax seems to be 4 hours, not 7 hours.</li><li>\u2022 Option C.</li><li>\u2022 Tmax for drug X is 7 hours</li><li>\u2022 Tmax</li><li>\u2022 time it takes for a drug</li><li>\u2022 reach its maximum concentration</li><li>\u2022 plasma</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 When a single dose of a drug results in a plasma concentration that exceeds the toxic threshold , the drug should be administered in divided doses to avoid toxicity .</li><li>\u27a4 single dose of a drug</li><li>\u27a4 plasma concentration</li><li>\u27a4 exceeds the toxic threshold</li><li>\u27a4 administered in divided doses</li><li>\u27a4 avoid toxicity</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "d0bbe154",
      "audio": ""
    },
    {
      "text": "Nitroglycerine is effective when administered sublingually because it is?",
      "options": [
        {
          "label": "A",
          "text": "Non ionized and lipid soluble",
          "correct": true
        },
        {
          "label": "B",
          "text": "Ionized and lipid soluble",
          "correct": false
        },
        {
          "label": "C",
          "text": "Non ionized and Water insoluble",
          "correct": false
        },
        {
          "label": "D",
          "text": "Ionized and water insoluble",
          "correct": false
        }
      ],
      "correct_answer": "A. Non ionized and lipid soluble",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Non ionized and lipid soluble</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Ionized and lipid soluble : This is incorrect. Typically, ionized forms of drugs are not lipid-soluble. Lipid solubility is usually associated with the non-ionized form of a drug.</li><li>\u2022 Option B.</li><li>\u2022 Ionized and lipid soluble</li><li>\u2022 ionized forms of drugs</li><li>\u2022 not lipid-soluble.</li><li>\u2022 Option C. Non-ionized and Water insoluble : This is not the best answer. While being non-ionized may assist in lipid solubility , water insolubility isn't a favorable characteristic for sublingual absorption , as some degree of water solubility is often necessary for a drug to be absorbed into the mucosal tissue.</li><li>\u2022 Option C.</li><li>\u2022 Non-ionized and Water insoluble</li><li>\u2022 non-ionized</li><li>\u2022 assist in lipid solubility</li><li>\u2022 water insolubility</li><li>\u2022 sublingual absorption</li><li>\u2022 Option D. Ionized and water insoluble : This is incorrect. Drugs that are ionized and water-insoluble would not readily diffuse across the lipid membranes of the oral mucosa .</li><li>\u2022 Option D.</li><li>\u2022 Ionized and water insoluble</li><li>\u2022 Drugs</li><li>\u2022 ionized and water-insoluble</li><li>\u2022 not readily diffuse</li><li>\u2022 lipid membranes</li><li>\u2022 oral mucosa</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 Nitroglycerin is effective when administered sublingually because its non-ionized, lipid-soluble form allows for rapid absorption through the oral mucosa and into systemic circulation , bypassing hepatic first-pass metabolism .</li><li>\u27a4 Nitroglycerin</li><li>\u27a4 effective</li><li>\u27a4 administered sublingually</li><li>\u27a4 non-ionized, lipid-soluble form</li><li>\u27a4 rapid absorption</li><li>\u27a4 oral mucosa</li><li>\u27a4 systemic circulation</li><li>\u27a4 bypassing hepatic first-pass metabolism</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "5ea50e67",
      "audio": ""
    },
    {
      "text": "Which of the following is wrongly matched regarding drug elimination?",
      "options": [
        {
          "label": "A",
          "text": "Calcium channel blockers: CYP3A4",
          "correct": false
        },
        {
          "label": "B",
          "text": "Carvedilol: CYP2D6",
          "correct": false
        },
        {
          "label": "C",
          "text": "Digoxin: p-glycoprotein",
          "correct": false
        },
        {
          "label": "D",
          "text": "Simvastatin: Glucuronide conjugation",
          "correct": true
        }
      ],
      "correct_answer": "D. Simvastatin: Glucuronide conjugation",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Simvastatin: Glucuronide conjugation</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Calcium channel blockers: CYP3A4 : This is correct . Many calcium channel blockers are metabolized by the CYP3A4 enzyme.</li><li>\u2022 Option A.</li><li>\u2022 Calcium channel blockers: CYP3A4</li><li>\u2022 correct</li><li>\u2022 Option B. Carvedilol: CYP2D6 : This is correct . Carvedilol is metabolized by CYP2D6 among other enzymes.</li><li>\u2022 Option B.</li><li>\u2022 Carvedilol: CYP2D6</li><li>\u2022 correct</li><li>\u2022 Option C. Digoxin: p-glycoprotein : This is correct. Digoxin is a substrate for p-glycoprotein, which plays a role in its elimination.</li><li>\u2022 Option C.</li><li>\u2022 Digoxin: p-glycoprotein</li><li>\u2022 correct.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 While simvastatin metabolites may undergo glucuronide conjugation , the primary enzyme responsible for simvastatin metabolism is CYP3A4; thus, drugs that affect CYP3A4 activity can alter simvastatin's plasma concentration .</li><li>\u27a4 simvastatin metabolites</li><li>\u27a4 glucuronide conjugation</li><li>\u27a4 primary enzyme</li><li>\u27a4 simvastatin metabolism is CYP3A4;</li><li>\u27a4 affect CYP3A4 activity</li><li>\u27a4 alter simvastatin's plasma concentration</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "e255e3aa",
      "audio": ""
    },
    {
      "text": "A 55-year-old man with a history of fungal infection is being treated with multiple medications. He is also taking a drug known to interact with several other medications by inhibiting hepatic cytochrome P450 enzymes, leading to increased concentrations of co-administered drugs. Which of the following drugs is most likely to cause such an interaction by inhibiting cytochrome P450 enzymes?",
      "options": [
        {
          "label": "A",
          "text": "Ketoconazole",
          "correct": true
        },
        {
          "label": "B",
          "text": "Rifampicin",
          "correct": false
        },
        {
          "label": "C",
          "text": "Phenytoin",
          "correct": false
        },
        {
          "label": "D",
          "text": "Phenobarbitone",
          "correct": false
        }
      ],
      "correct_answer": "A. Ketoconazole",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/10/screenshot-2024-05-10-153907.png"
      ],
      "explanation": "<p><strong>Ans. A) Ketoconazole</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Rifampicin : Incorrect. Rifampicin is a known inducer of cytochrome P450 enzymes , which can decrease plasma levels of drugs metabolized by these enzymes.</li><li>\u2022 Option B.</li><li>\u2022 Rifampicin</li><li>\u2022 inducer of cytochrome P450 enzymes</li><li>\u2022 Option C. Phenytoin : Incorrect. Phenytoin is also an inducer of cytochrome P450 enzymes.</li><li>\u2022 Option C.</li><li>\u2022 Phenytoin</li><li>\u2022 inducer of cytochrome P450 enzymes.</li><li>\u2022 Option D. Phenobarbitone : Incorrect. Phenobarbitone, like rifampicin and phenytoin, induces cytochrome P450 enzymes .</li><li>\u2022 Option D.</li><li>\u2022 Phenobarbitone</li><li>\u2022 induces cytochrome P450 enzymes</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 Ketoconazole is an inhibitor of cytochrome P450 enzymes , which can lead to increased concentrations of drugs metabolized by these enzymes when administered concomitantly .</li><li>\u27a4 Ketoconazole</li><li>\u27a4 inhibitor of cytochrome P450 enzymes</li><li>\u27a4 lead to increased concentrations of drugs</li><li>\u27a4 enzymes when administered concomitantly</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "85da8e2e",
      "audio": ""
    },
    {
      "text": "While reviewing the pharmacology of various medications, a medical student notes that drug-protein interactions can significantly influence the pharmacokinetics and effects of medications. Which of the following statements regarding drug-protein binding in the plasma is incorrect?",
      "options": [
        {
          "label": "A",
          "text": "Acidic drugs bind to albumin in plasma",
          "correct": false
        },
        {
          "label": "B",
          "text": "Basic drugs bind to alpha-1 acid glycoprotein in plasma",
          "correct": false
        },
        {
          "label": "C",
          "text": "Drugs having higher affinity for a plasma protein can displace the other drug from the same protein",
          "correct": false
        },
        {
          "label": "D",
          "text": "Sex steroid hormones do not bind to any protein in plasma",
          "correct": true
        }
      ],
      "correct_answer": "D. Sex steroid hormones do not bind to any protein in plasma",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Sex steroid hormones do not bind to any protein in plasma.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Acidic drugs bind to albumin in plasma. This statement is correct . Acidic drugs often bind to albumin, which is the main protein in human blood plasma. Albumin carries a negative charge and can bind to various acidic drugs, affecting their distribution and availability in the body.</li><li>\u2022 Option A.</li><li>\u2022 Acidic drugs bind to albumin in plasma.</li><li>\u2022 correct</li><li>\u2022 Option B. Basic drugs bind to alpha-1 acid glycoprotein in plasma. This statement is also correct . Alpha-1 acid glycoprotein is a plasma protein that primarily binds to basic (positively charged) drugs. The binding affinity of drugs to this protein can influence their pharmacokinetics and pharmacodynamics.</li><li>\u2022 Option B.</li><li>\u2022 Basic drugs bind to alpha-1 acid glycoprotein in plasma.</li><li>\u2022 correct</li><li>\u2022 Option C. Drugs having higher affinity for a plasma protein can displace the other drug from the same protein. This statement is correct . If two drugs bind to the same plasma protein (like albumin) and one has a higher affinity for the protein, it can displace the other. This displacement can increase the concentration of the free (unbound) form of the displaced drug, potentially leading to increased activity or toxicity.</li><li>\u2022 Option C.</li><li>\u2022 Drugs having higher affinity for a plasma protein can displace the other drug from the same protein.</li><li>\u2022 correct</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 Sex steroid hormones do bind to plasma proteins , specifically to Sex Hormone Binding Globulin (SHBG) and albumin , which can influence their bioavailability and action in the body .</li><li>\u27a4 Sex steroid hormones</li><li>\u27a4 bind to plasma proteins</li><li>\u27a4 Sex Hormone Binding Globulin</li><li>\u27a4 albumin</li><li>\u27a4 influence their bioavailability</li><li>\u27a4 action in the body</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "18e4add6",
      "audio": ""
    },
    {
      "text": "The response vs log dose curve of 4 drugs A, B, C, D are given below all are true except?",
      "options": [
        {
          "label": "A",
          "text": "A, B, C have common mechanism of action and D have different mechanism of action",
          "correct": false
        },
        {
          "label": "B",
          "text": "A is the most potent drug",
          "correct": false
        },
        {
          "label": "C",
          "text": "C is the most potent drug",
          "correct": true
        },
        {
          "label": "D",
          "text": "The efficacy of drug A and B is similar",
          "correct": false
        }
      ],
      "correct_answer": "C. C is the most potent drug",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/08/24/13.jpg"
      ],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) C is the most potent drug</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. A, B, C have a common mechanism of action and D have a different mechanism of action : This could be inferred if drugs A, B, and C have the same maximal efficacy, then they usually have similar mechanism of action.</li><li>\u2022 Option A.</li><li>\u2022 A, B, C have a common mechanism of action and D have a different mechanism of action</li><li>\u2022 inferred if drugs A, B, and C</li><li>\u2022 same maximal efficacy, then they usually have similar mechanism of action.</li><li>\u2022 Option B. A is the most potent drug : This is correct if we assume that potency is being determined solely by the dose needed to achieve a particular effect . Drug A requires the lowest dose to achieve its effects, as indicated by its position furthest to the left on the dose axis, signifying that it is the most potent.</li><li>\u2022 Option B.</li><li>\u2022 A is the most potent drug</li><li>\u2022 correct</li><li>\u2022 assume that potency</li><li>\u2022 determined solely by the dose needed</li><li>\u2022 achieve a particular effect</li><li>\u2022 Option D. The efficacy of drug A and B is similar : This is correct if we consider efficacy to be the maximal effect a drug can produce . Drugs A and B appear to reach a similar maximum response, which indicates similar efficacy.</li><li>\u2022 Option D.</li><li>\u2022 The efficacy of drug A and B is similar</li><li>\u2022 correct</li><li>\u2022 efficacy to be the maximal effect</li><li>\u2022 drug can produce</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 The potency of a drug is determined by the concentration required to achieve a certain effect , with a more leftward position on a dose-response curve indicating greater potency . Efficacy is the maximal effect a drug can produce , with a higher plateau on the curve representing greater efficacy.</li><li>\u27a4 potency of a drug</li><li>\u27a4 determined by the concentration required</li><li>\u27a4 achieve a certain effect</li><li>\u27a4 more leftward position</li><li>\u27a4 dose-response curve</li><li>\u27a4 greater potency</li><li>\u27a4 Efficacy</li><li>\u27a4 maximal effect</li><li>\u27a4 drug can produce</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "f82f75ba",
      "audio": ""
    },
    {
      "text": "A patient with renal impairment is being considered for a new medication. During a review of the patient's pharmacotherapy, it is noted that the drug in question has a low volume of distribution. What does a low volume of distribution imply about this drug\u2019s distribution in the body?",
      "options": [
        {
          "label": "A",
          "text": "It has low bioavailability",
          "correct": false
        },
        {
          "label": "B",
          "text": "It does not accumulate in tissues",
          "correct": true
        },
        {
          "label": "C",
          "text": "It has low absorption",
          "correct": false
        },
        {
          "label": "D",
          "text": "It is not metabolized in the body",
          "correct": false
        }
      ],
      "correct_answer": "B. It does not accumulate in tissues",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) It does not accumulate in tissues</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Low bioavailability : Incorrect. Low bioavailability refers to the proportion of a drug that enters systemic circulation when introduced into the body and is not directly related to the volume of distribution.</li><li>\u2022 Option A.</li><li>\u2022 Low bioavailability</li><li>\u2022 proportion of a drug</li><li>\u2022 enters systemic circulation</li><li>\u2022 Option C. Low absorption : Incorrect. Absorption pertains to how well a drug is taken up into the body from the site of administration and is not directly related to volume of distribution.</li><li>\u2022 Option C.</li><li>\u2022 Low absorption</li><li>\u2022 Absorption pertains</li><li>\u2022 well a drug is taken up into the body</li><li>\u2022 Option D. Not metabolized in the body : Incorrect. Metabolism refers to the chemical modification or degradation of a drug and is not indicative of volume of distribution.</li><li>\u2022 Option D.</li><li>\u2022 Not metabolized in the body</li><li>\u2022 Metabolism</li><li>\u2022 chemical modification</li><li>\u2022 degradation of a drug</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 The volume of distribution of a drug reflects its distribution within the body ; a low volume of distribution suggests that the drug is largely retained within the plasma and does not extensively distribute into the tissues.</li><li>\u27a4 volume of distribution</li><li>\u27a4 drug reflects</li><li>\u27a4 distribution within the body</li><li>\u27a4 low volume of distribution</li><li>\u27a4 drug is largely retained within the plasma</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "e680fe84",
      "audio": ""
    },
    {
      "text": "A pharmaceutical company is developing a new drug and is considering various routes of administration. Which route of administration would ensure that the bioavailability of the drug is 100%, meaning the entire dose reaches the systemic circulation unchanged?",
      "options": [
        {
          "label": "A",
          "text": "Subcutaneous",
          "correct": false
        },
        {
          "label": "B",
          "text": "Intravenous",
          "correct": true
        },
        {
          "label": "C",
          "text": "Intramuscular",
          "correct": false
        },
        {
          "label": "D",
          "text": "Intradermal",
          "correct": false
        }
      ],
      "correct_answer": "B. Intravenous",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/10/screenshot-2024-05-10-155303.png"
      ],
      "explanation": "<p><strong>Ans. B) Intravenous</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Subcutaneous : Incorrect. While bioavailability is generally high with subcutaneous administration , it is not always 100% due to potential for incomplete absorption.</li><li>\u2022 Option A.</li><li>\u2022 Subcutaneous</li><li>\u2022 bioavailability</li><li>\u2022 high with subcutaneous administration</li><li>\u2022 Option C. Intramuscular : Incorrect. Although intramuscular administration has high bioavailability , it is not always 100%, as some of the drug may be metabolized before entering systemic circulation.</li><li>\u2022 Option C.</li><li>\u2022 Intramuscular</li><li>\u2022 intramuscular administration</li><li>\u2022 high bioavailability</li><li>\u2022 Option D. Intradermal : Incorrect. Intradermal administration is typically used for sensitivity tests and vaccinations and does not guarantee 100% bioavailability.</li><li>\u2022 Option D.</li><li>\u2022 Intradermal</li><li>\u2022 Intradermal administration</li><li>\u2022 sensitivity tests</li><li>\u2022 vaccinations</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 Intravenous administration guarantees 100% bioavailability because the drug is delivered directly into the systemic circulation without any barriers to absorption or loss due to first-pass metabolism.</li><li>\u27a4 Intravenous administration</li><li>\u27a4 100% bioavailability</li><li>\u27a4 drug is delivered directly</li><li>\u27a4 systemic circulation</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "8f72e316",
      "audio": ""
    },
    {
      "text": "A 40-year-old man with chronic angina is prescribed a medication that is known to undergo significant hepatic first-pass metabolism. Which of the following routes of drug administration would not bypass the hepatic first-pass effect for this medication?",
      "options": [
        {
          "label": "A",
          "text": "Oral",
          "correct": true
        },
        {
          "label": "B",
          "text": "Intravenous",
          "correct": false
        },
        {
          "label": "C",
          "text": "Sublingual",
          "correct": false
        },
        {
          "label": "D",
          "text": "Subcutaneous",
          "correct": false
        }
      ],
      "correct_answer": "A. Oral",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Oral</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Intravenous : Incorrect. The intravenous route bypasses the hepatic first-pass effect by delivering the drug directly into the systemic circulation .</li><li>\u2022 Option B.</li><li>\u2022 Intravenous</li><li>\u2022 intravenous route bypasses</li><li>\u2022 hepatic first-pass effect</li><li>\u2022 delivering the drug directly</li><li>\u2022 systemic circulation</li><li>\u2022 Option C. Sublingual : Incorrect. The sublingual route bypasses the hepatic first-pass metabolism by allowing the drug to directly enter the systemic circulation via the oral mucosa.</li><li>\u2022 Option C.</li><li>\u2022 Sublingual</li><li>\u2022 sublingual route bypasses</li><li>\u2022 hepatic first-pass metabolism</li><li>\u2022 Option D. Subcutaneous : Incorrect. The subcutaneous route bypasses the liver and allows the drug to slowly absorb into the systemic circulation .</li><li>\u2022 Option D.</li><li>\u2022 Subcutaneous</li><li>\u2022 subcutaneous route bypasses</li><li>\u2022 liver</li><li>\u2022 drug to slowly absorb</li><li>\u2022 systemic circulation</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 The oral route of administration subjects drugs to hepatic first-pass metabolism , which can substantially reduce the bioavailability of drugs that are extensively metabolized by the liver .</li><li>\u27a4 oral route</li><li>\u27a4 administration subjects drugs</li><li>\u27a4 hepatic first-pass metabolism</li><li>\u27a4 reduce the bioavailability of drugs</li><li>\u27a4 metabolized by the liver</li><li>\u27a4 Drugs with high first pass metabolism include:</li><li>\u27a4 L: Lignocaine</li><li>\u27a4 P: Propranolol</li><li>\u27a4 G: Glyceryl tri nitrate (nitroglycerine)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "d2dea6f2",
      "audio": ""
    },
    {
      "text": "A 50-year-old woman with chronic atrial fibrillation is prescribed a drug that requires rapid attainment of therapeutic plasma concentration. Loading dose of a drug depends upon?",
      "options": [
        {
          "label": "A",
          "text": "Volume of distribution",
          "correct": true
        },
        {
          "label": "B",
          "text": "Clearance",
          "correct": false
        },
        {
          "label": "C",
          "text": "Half life",
          "correct": false
        },
        {
          "label": "D",
          "text": "Bioavailability",
          "correct": false
        }
      ],
      "correct_answer": "A. Volume of distribution",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Volume of distribution</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Clearance : Incorrect for loading dose. Clearance is the volume of plasma from which the drug is completely removed per unit time and is more relevant to determining the maintenance dose.</li><li>\u2022 Option B.</li><li>\u2022 Clearance</li><li>\u2022 Clearance is the volume of plasma</li><li>\u2022 drug is completely removed per unit time</li><li>\u2022 Option C. Half-life : Incorrect for loading dose. Half-life is the time taken for the plasma concentration of a drug to reduce to half its initial value and influences the dosing interval and maintenance doses rather than the loading dose.</li><li>\u2022 Option C.</li><li>\u2022 Half-life</li><li>\u2022 Half-life</li><li>\u2022 time taken for the plasma concentration of a drug</li><li>\u2022 reduce to half its initial value</li><li>\u2022 influences the dosing interval</li><li>\u2022 maintenance doses</li><li>\u2022 Option D. Bioavailability : Incorrect for loading dose. Bioavailability refers to the fraction of an administered dose that reaches systemic circulation in an active form and does not directly impact the calculation of a loading dose.</li><li>\u2022 Option D.</li><li>\u2022 Bioavailability</li><li>\u2022 Bioavailability</li><li>\u2022 fraction of an administered dose</li><li>\u2022 reaches systemic circulation</li><li>\u2022 active form</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 The loading dose of a drug is calculated based on the volume of distribution and the desired plasma concentration to rapidly achieve therapeutic levels in the plasma .</li><li>\u27a4 loading dose of a drug</li><li>\u27a4 calculated</li><li>\u27a4 volume of distribution</li><li>\u27a4 desired plasma concentration</li><li>\u27a4 therapeutic levels in the plasma</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "e122a0f4",
      "audio": ""
    },
    {
      "text": "A pharmaceutical company presents data for a new medication at a conference. One of the presenters mentions that the medication has a high therapeutic index. Which aspect of the drug's profile is being referred to?",
      "options": [
        {
          "label": "A",
          "text": "Potency",
          "correct": false
        },
        {
          "label": "B",
          "text": "Efficacy",
          "correct": false
        },
        {
          "label": "C",
          "text": "Safety",
          "correct": true
        },
        {
          "label": "D",
          "text": "Duration of action of a drug",
          "correct": false
        }
      ],
      "correct_answer": "C. Safety",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Safety</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Potency : Incorrect. Potency refers to the amount of drug needed to produce a certain effect , and is not directly related to the therapeutic index.</li><li>\u2022 Option A.</li><li>\u2022 Potency</li><li>\u2022 Potency</li><li>\u2022 amount of drug</li><li>\u2022 produce a certain effect</li><li>\u2022 Option B. Efficacy : Incorrect. Efficacy is the maximum effect that can be achieved with a drug , and while important, it is distinct from the therapeutic index.</li><li>\u2022 Option B.</li><li>\u2022 Efficacy</li><li>\u2022 Efficacy</li><li>\u2022 maximum effect</li><li>\u2022 achieved with a drug</li><li>\u2022 Option D. Duration of action of a drug : Incorrect. Duration of action relates to how long a drug produces its effect , not the therapeutic index.</li><li>\u2022 Option D.</li><li>\u2022 Duration of action of a drug</li><li>\u2022 Duration of action</li><li>\u2022 how long a drug produces its effect</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 The therapeutic index is a quantification of a drug's safety , reflecting the margin between therapeutically effective doses and doses that produce adverse effects . A higher therapeutic index indicates a wider safety margin.</li><li>\u27a4 therapeutic index</li><li>\u27a4 quantification of a drug's safety</li><li>\u27a4 reflecting the margin</li><li>\u27a4 therapeutically effective doses</li><li>\u27a4 doses that produce adverse effects</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "61a0c9fb",
      "audio": ""
    },
    {
      "text": "A 65-year-old man with a history of chronic fungal infections and tuberculosis is undergoing treatment with several medications. Considering potential drug-drug interactions, which of the following medications is most likely to induce cytochrome P450 enzymes, potentially decreasing the efficacy of other concurrently administered drugs?",
      "options": [
        {
          "label": "A",
          "text": "Erythromycin",
          "correct": false
        },
        {
          "label": "B",
          "text": "Ketoconazole",
          "correct": false
        },
        {
          "label": "C",
          "text": "Itraconazole",
          "correct": false
        },
        {
          "label": "D",
          "text": "Rifampicin",
          "correct": true
        }
      ],
      "correct_answer": "D. Rifampicin",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/16/screenshot-2024-08-16-102435.jpg"
      ],
      "explanation": "<p><strong>Ans. D) Rifampicin</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A . Erythromycin : Incorrect. Erythromycin is a known inhibitor of CYP enzymes , particularly CYP3A4.</li><li>\u2022 Option A</li><li>\u2022 Erythromycin</li><li>\u2022 Erythromycin</li><li>\u2022 inhibitor of CYP enzymes</li><li>\u2022 Option B. Ketoconazole : Incorrect. Ketoconazole is a strong inhibitor of CYP3A4 .</li><li>\u2022 Option B.</li><li>\u2022 Ketoconazole</li><li>\u2022 Ketoconazole</li><li>\u2022 strong inhibitor of CYP3A4</li><li>\u2022 Option C. Itraconazole : Incorrect. Itraconazole , like ketoconazole, is also a potent inhibitor of CYP3A4 .</li><li>\u2022 Option C.</li><li>\u2022 Itraconazole</li><li>\u2022 Itraconazole</li><li>\u2022 potent inhibitor of CYP3A4</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 Rifampicin is a potent inducer of CYP enzymes and can significantly decrease the plasma concentrations of co-administered drugs by increasing their metabolism , which is a critical consideration for drug interactions in multi-drug regimens.</li><li>\u27a4 Rifampicin</li><li>\u27a4 potent inducer of CYP enzymes</li><li>\u27a4 decrease the plasma concentrations of co-administered drugs</li><li>\u27a4 increasing their metabolism</li><li>\u27a4 CYP Enzyme Inducers and Inhibitors</li><li>\u27a4 CYP Enzyme Inducers and Inhibitors</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "418191c0",
      "audio": ""
    },
    {
      "text": "A new investigational drug is about to enter the clinical trial phase. Phase 1 clinical trial is done for:",
      "options": [
        {
          "label": "A",
          "text": "Drug safety",
          "correct": true
        },
        {
          "label": "B",
          "text": "Pharmacodynamics",
          "correct": false
        },
        {
          "label": "C",
          "text": "Efficacy",
          "correct": false
        },
        {
          "label": "D",
          "text": "Rare adverse effects",
          "correct": false
        }
      ],
      "correct_answer": "A. Drug safety",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/10/screenshot-2024-05-10-160500.png"
      ],
      "explanation": "<p><strong>Ans. A) Drug safety</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Pharmacodynamics : Incorrect for primary focus. Although pharmacodynamics are assessed in phase 1 , the primary focus is on safety , not the drug's effects on the body.</li><li>\u2022 Option B.</li><li>\u2022 Pharmacodynamics</li><li>\u2022 pharmacodynamics are assessed in phase 1</li><li>\u2022 primary focus is on safety</li><li>\u2022 Option C. Efficacy : Incorrect for phase 1. Efficacy is typically the focus of phase 2 and phase 3 clinical trials , where the drug is given to patients to assess its therapeutic effect.</li><li>\u2022 Option C.</li><li>\u2022 Efficacy</li><li>\u2022 Efficacy</li><li>\u2022 focus of phase 2</li><li>\u2022 phase 3 clinical trials</li><li>\u2022 Option D. Rare adverse effects : Incorrect for phase 1. Rare adverse effects are generally identified in phase 4 post-marketing surveillance once the drug has been approved and is used in a larger population.</li><li>\u2022 Option D.</li><li>\u2022 Rare adverse effects</li><li>\u2022 Rare adverse effects</li><li>\u2022 identified in phase 4 post-marketing surveillance</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 The primary objective of phase 1 clinical trials is to assess the safety and tolerability of a drug in humans and to establish the maximum tolerable dose .</li><li>\u27a4 primary objective of phase 1 clinical trials</li><li>\u27a4 assess the safety</li><li>\u27a4 tolerability of a drug</li><li>\u27a4 humans</li><li>\u27a4 establish the maximum tolerable dose</li><li>\u27a4 Phases of Clinical Trial</li><li>\u27a4 Phases of Clinical Trial</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "3fd912e7",
      "audio": ""
    },
    {
      "text": "A 43-year-old man presents to the pharmacy with a prescription for paracetamol, to manage his post-operative pain following minor surgery. After taking the medication as prescribed, he reports persistent pain and no relief. Upon investigation, it is discovered that the tablets contained only 200 mg of paracetamol, despite being labeled as 500 mg. The patient asks the pharmacist to explain the nature of the discrepancy in the medication provided. What type of drug error does this scenario represent?",
      "options": [
        {
          "label": "A",
          "text": "Misbranded drug",
          "correct": true
        },
        {
          "label": "B",
          "text": "Spurious drug",
          "correct": false
        },
        {
          "label": "C",
          "text": "Adulterated drug",
          "correct": false
        },
        {
          "label": "D",
          "text": "Fake drug",
          "correct": false
        }
      ],
      "correct_answer": "A. Misbranded drug",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Misbranded drug</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B: Spurious drugs are those that are intentionally designed to mimic the physical appearance of legitimate , often popular, drugs in order to deceive the consumer. They may or may not contain the correct active ingredient and are typically manufactured by unlicensed entities.</li><li>\u2022 Option B:</li><li>\u2022 Spurious drugs</li><li>\u2022 mimic the physical appearance of legitimate</li><li>\u2022 Option C: Adulterated drugs contain a harmful or non-therapeutic substance , which may be a result of poor manufacturing processes or the deliberate addition of a cheaper substance to reduce costs. These drugs can be injurious to health.</li><li>\u2022 Option C:</li><li>\u2022 Adulterated drugs</li><li>\u2022 harmful or non-therapeutic substance</li><li>\u2022 result of poor manufacturing processes</li><li>\u2022 Option D: Fake drugs , while not a term typically used in formal classifications, would generally refer to products that are not what they purport to be at all and contain no active ingredient or a completely different ingredient than advertised.</li><li>\u2022 Option D:</li><li>\u2022 Fake drugs</li><li>\u2022 refer to products that are not what they purport</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 A drug that contains a lesser amount of active ingredient than stated on the label is classified as a misbranded drug according to the definitions provided by drug regulatory authorities.</li><li>\u27a4 drug that contains a lesser amount of active ingredient</li><li>\u27a4 stated on the label</li><li>\u27a4 misbranded drug</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "73f0aefb",
      "audio": ""
    },
    {
      "text": "A 57-year-old woman with a history of rheumatoid arthritis is prescribed a medication that requires storage at a \"cool place only.\" She inquires about the appropriate way to store her medication to ensure its efficacy. Based on the storage instructions, which temperature range should the patient maintain for her medication?",
      "options": [
        {
          "label": "A",
          "text": "8\u201315 \u00b0C",
          "correct": true
        },
        {
          "label": "B",
          "text": "2\u20138 \u00b0C",
          "correct": false
        },
        {
          "label": "C",
          "text": "0 \u00b0C",
          "correct": false
        },
        {
          "label": "D",
          "text": "25\u201328 \u00b0C",
          "correct": false
        }
      ],
      "correct_answer": "A. 8\u201315 \u00b0C",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) 8\u201315 \u00b0C</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option C: A temperature of 0\u00b0C would be at the freezing point of water and is not considered a \"cool\" but rather a \"frozen\" condition , which is too cold for medications labeled to be stored at a \"cool place.\"</li><li>\u2022 Option C:</li><li>\u2022 temperature of 0\u00b0C</li><li>\u2022 freezing point of water</li><li>\u2022 not</li><li>\u2022 \"cool\"</li><li>\u2022 \"frozen\" condition</li><li>\u2022 Option D: A range of 25\u201328\u00b0C would generally be too warm for medications requiring \"cool\" storage, as it approaches room temperature in many climates.</li><li>\u2022 Option D:</li><li>\u2022 range of 25\u201328\u00b0C</li><li>\u2022 too warm for medications</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The proper storage temperature for medications labeled to be kept in a \"cool place, \" which is between 8\u201315\u00b0C as defined in the United States.</li><li>\u27a4 proper storage temperature for medications</li><li>\u27a4 kept in a \"cool place,</li><li>\u27a4 between 8\u201315\u00b0C</li><li>\u27a4 United States.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "aa11de55",
      "audio": ""
    },
    {
      "text": "Which of the following is a type of placebo?",
      "options": [
        {
          "label": "A",
          "text": "Sham surgery",
          "correct": true
        },
        {
          "label": "B",
          "text": "Physiotherapy",
          "correct": false
        },
        {
          "label": "C",
          "text": "Cognitive Behavioral Therapy",
          "correct": false
        },
        {
          "label": "D",
          "text": "Herbal medicine which is not known to be effective",
          "correct": false
        }
      ],
      "correct_answer": "A. Sham surgery",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Sham surgery</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Physiotherapy: Physiotherapy is a therapeutic practice that involves physical techniques , such as exercise, massage, or manipulation, to improve body function . It is a genuine treatment method for various conditions and is not considered a placebo.</li><li>\u2022 Option B. Physiotherapy:</li><li>\u2022 therapeutic practice</li><li>\u2022 involves physical techniques</li><li>\u2022 exercise, massage,</li><li>\u2022 manipulation, to improve body function</li><li>\u2022 Option C. Cognitive Behavioral Therapy (CBT): CBT is a type of psychotherapy that helps people understand and change their thoughts and behaviors. It is a well-established treatment for various mental health conditions and is not a placebo.</li><li>\u2022 Option C. Cognitive Behavioral Therapy (CBT):</li><li>\u2022 type of psychotherapy</li><li>\u2022 people understand</li><li>\u2022 change their thoughts and behaviors.</li><li>\u2022 Option D. Herbal medicine which is not known to be effective: If an herbal medicine is not known to be effective , it could potentially be used as a placebo in clinical trials . However, the key aspect of a placebo is that it is known to be inert or ineffective for the condition being treated . Simply being \"not known to be effective\" does not automatically make an herbal medicine a placebo; it must also be proven to have no therapeutic effect for the specific condition being studied.</li><li>\u2022 Option D. Herbal medicine which is not known to be effective:</li><li>\u2022 herbal medicine</li><li>\u2022 not known to be effective</li><li>\u2022 used as a placebo in clinical trials</li><li>\u2022 inert or ineffective for the condition being treated</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The correct answer is Sham surgery, which is used as a placebo control in clinical trials to determine the effectiveness of surgical procedures and to isolate the therapeutic effect from the placebo effect.</li><li>\u27a4 Sham surgery,</li><li>\u27a4 used as a placebo control in clinical trials</li><li>\u27a4 determine the effectiveness of surgical procedures</li><li>\u27a4 isolate the therapeutic effect</li><li>\u27a4 placebo effect.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "be32d0e8",
      "audio": ""
    },
    {
      "text": "A patient comes 6 hours after consuming morphine and presents with pinpoint pupils and respiratory depression. The half-life of morphine is 3 hours and Volume of distribution (Vd) is 200 L. Plasma concentration of morphine at this time is 0.5 microgram/ml. Calculate the initial morphine dose consumed?",
      "options": [
        {
          "label": "A",
          "text": "100 mg",
          "correct": false
        },
        {
          "label": "B",
          "text": "400 mg",
          "correct": true
        },
        {
          "label": "C",
          "text": "10 mg",
          "correct": false
        },
        {
          "label": "D",
          "text": "50 mg",
          "correct": false
        }
      ],
      "correct_answer": "B. 400 mg",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) 400 mg</strong></p>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 It is important to undertstand that to calculate the initial dose of a drug from its known volume of distribution and plasma concentration after a certain time has elapsed , accounting for its half-life , to determine the loading dose . In this case, the initial dose of morphine consumed is 400 mg , determined by multiplying the volume of distribution by the estimated initial plasma concentration.</li><li>\u27a4 calculate the initial dose</li><li>\u27a4 drug</li><li>\u27a4 known volume of distribution</li><li>\u27a4 plasma concentration</li><li>\u27a4 time has elapsed</li><li>\u27a4 half-life</li><li>\u27a4 determine the loading dose</li><li>\u27a4 initial dose of morphine</li><li>\u27a4 400 mg</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "f275dc3a",
      "audio": ""
    },
    {
      "text": "A 25-year-old woman presents to the clinic with symptoms of a malar rash, joint pain, and fatigue. She has no significant past medical history and reports that she started taking a medication for her recent diagnosis of tuberculosis. Additionally, she has been using an over-the-counter medication for occasional nasal congestion. She denies using any herbal supplements or illicit drugs. Her laboratory tests show positive antinuclear antibodies (ANA) and anti-histone antibodies. Which of the following drugs is not associated with causation of Drug induced lupus?",
      "options": [
        {
          "label": "A",
          "text": "Isoniazid",
          "correct": false
        },
        {
          "label": "B",
          "text": "Procainamide",
          "correct": false
        },
        {
          "label": "C",
          "text": "Hydralazine",
          "correct": false
        },
        {
          "label": "D",
          "text": "Amphetamine",
          "correct": true
        }
      ],
      "correct_answer": "D. Amphetamine",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Amphetamine</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A: Isoniazid is an antitubercular medication that is known to cause drug-induced lupus erythematosus (DILE).</li><li>\u2022 Option A:</li><li>\u2022 Isoniazid</li><li>\u2022 antitubercular medication</li><li>\u2022 cause drug-induced lupus erythematosus</li><li>\u2022 Option B: Procainamide , an antiarrhythmic agent , and hydralazine , an antihypertensive medication , are both well-documented causes of DILE.</li><li>\u2022 Option B:</li><li>\u2022 Procainamide</li><li>\u2022 antiarrhythmic agent</li><li>\u2022 hydralazine</li><li>\u2022 antihypertensive medication</li><li>\u2022 Option D: Amphetamines are central nervous system stimulants and are not typically associated with the induction of lupus .</li><li>\u2022 Option D:</li><li>\u2022 Amphetamines</li><li>\u2022 central nervous system stimulants</li><li>\u2022 not</li><li>\u2022 associated with the induction of lupus</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Amphetamine is not associated with the causation of drug-induced lupus , in contrast to certain drugs like isoniazid, procainamide, and hydralazine , which are known to precipitate DILE.</li><li>\u27a4 Amphetamine</li><li>\u27a4 not</li><li>\u27a4 causation of drug-induced lupus</li><li>\u27a4 drugs like isoniazid, procainamide,</li><li>\u27a4 hydralazine</li><li>\u27a4 Most common drugs that precipitate a DILE or systemic lupus erythematosus like syndrome, including:</li><li>\u27a4 Most common drugs that precipitate a DILE or systemic lupus erythematosus like syndrome, including:</li><li>\u27a4 S: S ulfonamides</li><li>\u27a4 S: S</li><li>\u27a4 H: H ydralazine</li><li>\u27a4 H: H</li><li>\u27a4 I: I soniazid</li><li>\u27a4 I: I</li><li>\u27a4 P: P rocainamide</li><li>\u27a4 P: P</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "3dc7dfa9",
      "audio": ""
    },
    {
      "text": "A 58-year-old man with a history of hypertension presents to the emergency department with severe eye pain, blurred vision, and headache. On examination, his right eye is red, the cornea is cloudy, and the pupil is moderately dilated and non-reactive to light. Intraocular pressure is markedly elevated. He is diagnosed with acute angle-closure glaucoma, and treatment with acetazolamide is initiated. Acetazolamide is a noncompetitive inhibitor of carbonic anhydrase enzyme. The effects of acetazolamide include:",
      "options": [
        {
          "label": "A",
          "text": "Increase in Km and Vmax",
          "correct": false
        },
        {
          "label": "B",
          "text": "Decrease in Km",
          "correct": false
        },
        {
          "label": "C",
          "text": "Decrease in Vmax",
          "correct": true
        },
        {
          "label": "D",
          "text": "No change in Vmax",
          "correct": false
        }
      ],
      "correct_answer": "C. Decrease in Vmax",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/10/screenshot-2024-05-10-161814.png"
      ],
      "explanation": "<p><strong>Ans. C) Decrease in Vmax</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A: An increase in Km and Vmax would not be consistent with any type of enzyme inhibition ; it would suggest an increase in both enzyme affinity and the maximum rate of the reaction, which is not characteristic of inhibitors.</li><li>\u2022 Option A:</li><li>\u2022 increase in Km</li><li>\u2022 Vmax</li><li>\u2022 not</li><li>\u2022 consistent with any type of enzyme inhibition</li><li>\u2022 Option B: A decrease in Km would indicate an increase in the affinity of the enzyme for the substrate , which is not a feature of noncompetitive inhibition.</li><li>\u2022 Option B:</li><li>\u2022 decrease in Km</li><li>\u2022 increase in the affinity of the enzyme for the substrate</li><li>\u2022 Option D: No change in Vmax would suggest that the inhibitor does not affect the catalytic function of the enzyme , which is not true for noncompetitive inhibitors.</li><li>\u2022 Option D:</li><li>\u2022 No change in Vmax</li><li>\u2022 inhibitor does not affect the catalytic function of the enzyme</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Acetazolamide , a noncompetitive inhibitor of carbonic anhydrase , decreases the Vmax (maximum rate) of the enzyme without affecting the Km (substrate affinity).</li><li>\u27a4 Acetazolamide</li><li>\u27a4 noncompetitive inhibitor</li><li>\u27a4 carbonic anhydrase</li><li>\u27a4 decreases the Vmax</li><li>\u27a4 enzyme without affecting the Km</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "cab612e5",
      "audio": ""
    },
    {
      "text": "ED50 of a drug is a measure of its?",
      "options": [
        {
          "label": "A",
          "text": "Safety",
          "correct": false
        },
        {
          "label": "B",
          "text": "Potency",
          "correct": true
        },
        {
          "label": "C",
          "text": "Efficacy",
          "correct": false
        },
        {
          "label": "D",
          "text": "Therapeutic Index",
          "correct": false
        }
      ],
      "correct_answer": "B. Potency",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Potency</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Safety : This is typically assessed by the therapeutic index , which is the ratio of the toxic dose (TD50) to the effective dose (ED50). It provides a measure of the drug's safety margin.</li><li>\u2022 Option A. Safety</li><li>\u2022 assessed by the therapeutic index</li><li>\u2022 ratio of the toxic dose</li><li>\u2022 Option C. Efficacy : This refers to the maximum effect a drug can produce , regardless of dose. A drug's efficacy is not determined by the ED50 but rather by its ability to achieve the desired therapeutic effect.</li><li>\u2022 Option C. Efficacy</li><li>\u2022 maximum effect a drug can produce</li><li>\u2022 Option D. Therapeutic Index : As mentioned, this is the ratio of the toxic dose (TD50) to the effective dose (ED50) for a drug, providing a measure of its safety.</li><li>\u2022 Option D. Therapeutic Index</li><li>\u2022 ratio of the toxic dose</li><li>\u2022 effective dose</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 ED50 of a drug indicates its potency , which is the dose required to produce the desired therapeutic effect in 50% of the population .</li><li>\u27a4 ED50 of a drug</li><li>\u27a4 potency</li><li>\u27a4 dose required to produce</li><li>\u27a4 desired therapeutic effect in 50% of the population</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "234f7079",
      "audio": ""
    },
    {
      "text": "A 45-year-old man is brought to the clinic by his wife due to concerns about the effectiveness of his medication regimen. He has been taking aspirin for his cardiovascular health, phenobarbitone for a seizure disorder, and diazepam as needed for anxiety. The patient also mentions he has been experiencing frequent bouts of diarrhea. The wife is concerned that the diarrhea may be affecting the absorption of his medications. Regarding the absorption profile of these drugs in relation to their acidic or basic nature and gastrointestinal transit time, which of the following statements is INCORRECT?",
      "options": [
        {
          "label": "A",
          "text": "Aspirin is present in mainly non-ionized form in the stomach, hence can be easily absorbed",
          "correct": false
        },
        {
          "label": "B",
          "text": "Diazepam is mostly absorbed from the intestine",
          "correct": false
        },
        {
          "label": "C",
          "text": "Phenobarbitone can be absorbed from the stomach but most of the absorption occurs in the small intestine due to its large surface area",
          "correct": false
        },
        {
          "label": "D",
          "text": "Diseases decreasing the transit time of drugs like diarrhea will increase the drug absorption in the intestine",
          "correct": true
        }
      ],
      "correct_answer": "D. Diseases decreasing the transit time of drugs like diarrhea will increase the drug absorption in the intestine",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Diseases decreasing the transit time of drugs like diarrhea will increase the drug absorption in the intestine</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A: Aspirin , being an acidic drug , is non-ionized in the acidic environment of the stomach , which increases its lipid solubility and allows it to be easily absorbed through the gastric mucosa.</li><li>\u2022 Option A:</li><li>\u2022 Aspirin</li><li>\u2022 acidic drug</li><li>\u2022 non-ionized in the acidic environment</li><li>\u2022 stomach</li><li>\u2022 Option B: Diazepam , a basic drug, is more likely to be in a non-ionized, lipid-soluble form in the relatively higher pH of the intestine, facilitating its absorption there.</li><li>\u2022 Option B:</li><li>\u2022 Diazepam</li><li>\u2022 non-ionized, lipid-soluble form</li><li>\u2022 Option C: Phenobarbitone , although acidic, has a significant amount of absorption in the intestine due to the larger surface area and longer transit time compared to the stomach.</li><li>\u2022 Option C: Phenobarbitone</li><li>\u2022 amount of absorption in the intestine</li><li>\u2022 larger surface area</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Diseases which decrease the transit time in the intestine , such as diarrhea , typically reduce the absorption of drugs .</li><li>\u27a4 Diseases</li><li>\u27a4 decrease the transit time</li><li>\u27a4 intestine</li><li>\u27a4 diarrhea</li><li>\u27a4 reduce the absorption of drugs</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "5e6aaad9",
      "audio": ""
    },
    {
      "text": "All the following are Phase II reactions except:",
      "options": [
        {
          "label": "A",
          "text": "Cyclization",
          "correct": true
        },
        {
          "label": "B",
          "text": "Methylation",
          "correct": false
        },
        {
          "label": "C",
          "text": "Acetylation",
          "correct": false
        },
        {
          "label": "D",
          "text": "Glycine conjugation",
          "correct": false
        }
      ],
      "correct_answer": "A. Cyclization",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Cyclization</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 Option B: Methylation : This is a synthetic reaction that involves the addition of a methyl group to a molecule . It is considered a Phase II or conjugation reaction.</li><li>\u2022 Option B: Methylation</li><li>\u2022 synthetic reaction</li><li>\u2022 addition of a methyl group to a molecule</li><li>\u2022 Option C: Acetylation : This involves the addition of an acetyl group to a molecule and is also a Phase II reaction.</li><li>\u2022 Option C: Acetylation</li><li>\u2022 addition of an acetyl group to a molecule</li><li>\u2022 Option D: Glycine Conjugation : This involves the combination of a molecule with glycine to make it more water-soluble for excretion . It is a typical Phase II reaction.</li><li>\u2022 Option D: Glycine Conjugation</li><li>\u2022 combination of a molecule with glycine</li><li>\u2022 more water-soluble for excretion</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 Cyclization is a Phase I reaction , not a Phase II reaction, which involves conjugation processes such as methylation, acetylation , and glycine conjugation to increase the water solubility of drugs for excretion .</li><li>\u27a4 Cyclization</li><li>\u27a4 Phase I reaction</li><li>\u27a4 conjugation processes</li><li>\u27a4 methylation, acetylation</li><li>\u27a4 glycine conjugation</li><li>\u27a4 increase the water solubility of drugs</li><li>\u27a4 excretion</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "92635413",
      "audio": ""
    },
    {
      "text": "A 60-year-old man with a history of atrial fibrillation and renal cell carcinoma is being treated with multiple medications. He presents to the clinic with subtherapeutic blood levels of several drugs, despite adherence to his medication regimen. The physician suspects that the drugs may be subject to P-glycoprotein mediated drug interactions, which could be altering their pharmacokinetics, particularly their absorption and excretion. Which of the following medications, if prescribed to the patient, is least likely to inhibit P-glycoprotein, thereby not contributing to increased blood levels of co-administered drugs that are P-glycoprotein substrates?",
      "options": [
        {
          "label": "A",
          "text": "Phenobarbitone",
          "correct": true
        },
        {
          "label": "B",
          "text": "Erythromycin",
          "correct": false
        },
        {
          "label": "C",
          "text": "Verapamil",
          "correct": false
        },
        {
          "label": "D",
          "text": "Quinidine",
          "correct": false
        }
      ],
      "correct_answer": "A. Phenobarbitone",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/10/screenshot-2024-05-10-163041.png"
      ],
      "explanation": "<p><strong>Ans. A) Phenobarbitone</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 Option B. Erythromycin : It is a known inhibitor of P-glycoprotein , potentially increasing the levels of drugs that are substrates of this transporter.</li><li>\u2022 Option B. Erythromycin</li><li>\u2022 known inhibitor of P-glycoprotein</li><li>\u2022 increasing the levels of drugs</li><li>\u2022 Option C. Verapamil : This drug is a well-documented inhibitor of P-glycoprotein and can interact with other drugs by increasing their systemic exposure.</li><li>\u2022 Option C. Verapamil</li><li>\u2022 well-documented inhibitor of P-glycoprotein</li><li>\u2022 Option D. Quinidine : It is an inhibitor of P-glycoprotein , which could increase plasma concentrations of other drugs that are P-glycoprotein substrates.</li><li>\u2022 Option D. Quinidine</li><li>\u2022 inhibitor of P-glycoprotein</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 Phenobarbitone is an inducer , not an inhibitor, of P-glycoprotein, which can decrease the plasma levels of drugs that are substrates of this efflux transporter .</li><li>\u27a4 Phenobarbitone</li><li>\u27a4 inducer</li><li>\u27a4 P-glycoprotein,</li><li>\u27a4 decrease the plasma levels of drugs</li><li>\u27a4 substrates of this efflux transporter</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "206294c4",
      "audio": ""
    },
    {
      "text": "A 55-year-old man with a history of hypertension is seen in the clinic for blood pressure management. The patient reports varying levels of blood pressure control, and the physician suspects that this might be due to individual variations in drug response. In discussing this issue with a group of medical students, the physician asks - variation in sensitivity of response to different doses of a drug in different individuals is obtained from?",
      "options": [
        {
          "label": "A",
          "text": "Graded Dose Response Curve",
          "correct": false
        },
        {
          "label": "B",
          "text": "Quantal Dose response Curve",
          "correct": true
        },
        {
          "label": "C",
          "text": "Log Dose Response Curve",
          "correct": false
        },
        {
          "label": "D",
          "text": "Therapeutic Index",
          "correct": false
        }
      ],
      "correct_answer": "B. Quantal Dose response Curve",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Quantal Dose response curve</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Graded Dose Response Curve: This type of curve shows the relationship between the dose of a drug and the gradation of the effect (response) in a single individual or tissue . It doesn\u2019t directly reflect variations among different individuals.</li><li>\u2022 Option A.</li><li>\u2022 Graded Dose Response Curve:</li><li>\u2022 type of curve</li><li>\u2022 relationship between the dose of a drug</li><li>\u2022 gradation of the effect</li><li>\u2022 single individual or tissue</li><li>\u2022 Option C. Log Dose Response Curve: This is a variation of the graded dose-response curve , where the dose is plotted on a logarithmic scale . This format can make it easier to see the relationship between dose and response, especially over a wide range of doses, but it does not specifically address the variation in sensitivity among different individuals.</li><li>\u2022 Option C.</li><li>\u2022 Log Dose Response Curve:</li><li>\u2022 variation of the graded dose-response curve</li><li>\u2022 dose is plotted on a logarithmic scale</li><li>\u2022 Option D. Therapeutic Index: The therapeutic index is a ratio that compares the toxic dose to the therapeutic dose of a drug , used to assess its safety. While it provides information about the safety margin of the drug, it does not directly show the variation in sensitivity to the drug among different individuals.</li><li>\u2022 Option D.</li><li>\u2022 Therapeutic Index:</li><li>\u2022 ratio that compares the toxic dose</li><li>\u2022 therapeutic dose of a drug</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 The Quantal Dose Response Curve is used to determine the variation in sensitivity to different doses of a drug among different individuals in a population .</li><li>\u27a4 Quantal Dose Response Curve</li><li>\u27a4 determine the variation</li><li>\u27a4 sensitivity to different doses</li><li>\u27a4 drug among different individuals in a population</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "9145240a",
      "audio": ""
    },
    {
      "text": "A 70-year-old woman with chronic kidney disease and hypertension is admitted to the hospital for management of medication-related complications. She is currently on multiple medications, including one that is known to have high plasma protein binding. The medical team is concerned about the potential for drug interactions and the efficacy of hemodialysis in removing this drug in the event of an overdose. A discussion ensues regarding the pharmacokinetic characteristics of drugs with high plasma protein binding.Regarding the pharmacokinetics of drugs with high plasma protein binding, which of the following statements is most accurate?",
      "options": [
        {
          "label": "A",
          "text": "It has low glomerular filtration",
          "correct": true
        },
        {
          "label": "B",
          "text": "It has less drug interactions",
          "correct": false
        },
        {
          "label": "C",
          "text": "It is likely to have a higher volume of distribution",
          "correct": false
        },
        {
          "label": "D",
          "text": "It can be easily filtered by dialysis",
          "correct": false
        }
      ],
      "correct_answer": "A. It has low glomerular filtration",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) It has low glomerular filtration</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 Option B: It has less drug interactions : This is incorrect. Drugs with high plasma protein binding are more likely to have drug-drug interactions , particularly those involving displacement from binding sites.</li><li>\u2022 Option B: It has less drug interactions</li><li>\u2022 Drugs with high plasma protein binding</li><li>\u2022 drug-drug interactions</li><li>\u2022 Option C: It is likely to have a higher volume of distribution : This is incorrect. A high plasma protein binding typically correlates with a lower volume of distribution because the drug tends to remain within the vascular compartment.</li><li>\u2022 Option C: It is likely to have a higher volume of distribution</li><li>\u2022 high plasma protein binding</li><li>\u2022 correlates with a lower volume of distribution</li><li>\u2022 Option D: It can be easily filtered by dialysis : This is incorrect. Drugs with high plasma protein binding are not easily removed by hemodialysis due to their strong affinity for plasma proteins , which keeps them within the bloodstream.</li><li>\u2022 Option D: It can be easily filtered by dialysis</li><li>\u2022 Drugs</li><li>\u2022 high plasma protein binding</li><li>\u2022 not easily removed</li><li>\u2022 hemodialysis</li><li>\u2022 strong affinity for plasma proteins</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 Drugs with high plasma protein binding have low glomerular filtration rates because they are largely restricted to the vascular compartment and not freely filtered by the kidneys .</li><li>\u27a4 Drugs with high plasma protein binding</li><li>\u27a4 low glomerular filtration rates</li><li>\u27a4 vascular compartment</li><li>\u27a4 not freely filtered by the kidneys</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "be3e04cb",
      "audio": ""
    },
    {
      "text": "Based on the provided figure, which of the following statements about the bioavailability of a drug is INCORRECT?",
      "options": [
        {
          "label": "A",
          "text": "Bioavailability of a drug given orally is calculated as AUC (iv)/ AUC (oral)",
          "correct": true
        },
        {
          "label": "B",
          "text": "Bioavailability of a drug given orally is calculated as AUC (oral)/ AUC (iv)",
          "correct": false
        },
        {
          "label": "C",
          "text": "Oral drugs often undergo first-pass metabolism",
          "correct": false
        },
        {
          "label": "D",
          "text": "Bioavailability is the fraction of the drug that reaches the systemic circulation in unchanged form",
          "correct": false
        }
      ],
      "correct_answer": "A. Bioavailability of a drug given orally is calculated as AUC (iv)/ AUC (oral)",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/08/24/2-2.jpg"
      ],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Bioavailability of a drug given orally is calculated as AUC (iv)/ AUC (oral)</strong></p>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 Bioavailability of an orally administered drug is calculated as the ratio of the AUC from oral administration to the AUC from IV administration .</li><li>\u27a4 Bioavailability</li><li>\u27a4 orally administered drug</li><li>\u27a4 ratio of the AUC</li><li>\u27a4 oral administration to the AUC</li><li>\u27a4 IV administration</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "cf02309a",
      "audio": ""
    },
    {
      "text": "A 55-year-old male patient (60 kg) is going to be treated with an experimental drug, Drug X, for an irregular heart rhythm. If the Vd is 1 L/kg and the desired steady state plasma concentration is 2.5 mg/L, which of the following is the most appropriate intravenous loading dose for Drug X?",
      "options": [
        {
          "label": "A",
          "text": "150 mg",
          "correct": true
        },
        {
          "label": "B",
          "text": "2.5 mg",
          "correct": false
        },
        {
          "label": "C",
          "text": "24 mg",
          "correct": false
        },
        {
          "label": "D",
          "text": "10 mg",
          "correct": false
        }
      ],
      "correct_answer": "A. 150 mg",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) 150 mg</strong></p>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 The correct intravenous loading dose of a drug can be calculated by multiplying the volume of distribution by the desired plasma concentration ; in this case, 60 L \u00d7 2.5 mg/L = 150 mg .</li><li>\u27a4 intravenous loading dose</li><li>\u27a4 drug can be calculated by multiplying the volume</li><li>\u27a4 distribution by the desired plasma concentration</li><li>\u27a4 60 L \u00d7 2.5 mg/L = 150 mg</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "05e7e931",
      "audio": ""
    },
    {
      "text": "A patient required 180 mg ceftriaxone. The vial contains 500 mg/ 5ml of ceftriaxone. You have a 2 ml syringe with 10 divisions per ml. How many divisions in the 2 ml syringe will you fill to give 180 mg ceftriaxone?",
      "options": [
        {
          "label": "A",
          "text": "9",
          "correct": false
        },
        {
          "label": "B",
          "text": "18",
          "correct": true
        },
        {
          "label": "C",
          "text": "10",
          "correct": false
        },
        {
          "label": "D",
          "text": "12",
          "correct": false
        }
      ],
      "correct_answer": "B. 18",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) 18</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Here more of common sense is required and simple principles of posology are to be applied , 500 mg/5 ml means 100 mg/ml .</li><li>\u2022 more of common sense is required</li><li>\u2022 simple principles of posology</li><li>\u2022 applied</li><li>\u2022 500 mg/5 ml means 100 mg/ml</li><li>\u2022 Since 100 mg is present is 1 ml, therefore, 180 mg of drug is present in 1.8 ml.</li><li>\u2022 100 mg is present is 1 ml,</li><li>\u2022 180 mg of drug is present in 1.8 ml.</li><li>\u2022 Now it is clear that we must administer 1.8 ml of the above solutions to administer the desired amount of drug. Last thing is to calculate is, how many divisions to administer to give 1.8 ml.</li><li>\u2022 administer 1.8 ml of the above solutions to administer the desired amount of drug.</li><li>\u2022 10 division per ml means each 0.1 ml is equal to 1 division.</li><li>\u2022 10 division per ml</li><li>\u2022 0.1 ml is equal to 1 division.</li><li>\u2022 Therefore, 1.8 ml will be equal to 18 divisions.</li><li>\u2022 1.8 ml will be equal to 18 divisions.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 To administer 180 mg of ceftriaxone from a solution with a concentration of 500 mg/5 ml using a 2 ml syringe with 10 divisions per ml , fill the syringe to 18 divisions.</li><li>\u27a4 administer 180 mg of ceftriaxone</li><li>\u27a4 solution with a concentration of 500 mg/5 ml</li><li>\u27a4 2 ml syringe with 10 divisions per ml</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "84dd236c",
      "audio": ""
    },
    {
      "text": "A 48-year-old woman with a history of chronic urticaria comes to the clinic for a consultation regarding her medication regimen. She reports no significant relief from her symptoms despite adherence to her prescribed medications. The physician suspects that genetic variations in drug metabolism may be influencing her response to treatment and decides to evaluate her medications based on their metabolic pathways, particularly acetylation, as individual variations in this process can alter drug effectiveness and toxicity. Which of the following drugs prescribed to this patient is not primarily metabolized by acetylation, potentially contributing to the ineffectiveness of her treatment?",
      "options": [
        {
          "label": "A",
          "text": "Hydrocortisone",
          "correct": true
        },
        {
          "label": "B",
          "text": "Dapsone",
          "correct": false
        },
        {
          "label": "C",
          "text": "Procainamide",
          "correct": false
        },
        {
          "label": "D",
          "text": "Hydralazine",
          "correct": false
        }
      ],
      "correct_answer": "A. Hydrocortisone",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Hydrocortisone</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 Option B. Dapsone : An antibacterial commonly used in the treatment of leprosy and dermatological conditions , dapsone is metabolized by acetylation.</li><li>\u2022 Option B. Dapsone</li><li>\u2022 antibacterial</li><li>\u2022 used in the treatment of leprosy</li><li>\u2022 dermatological conditions</li><li>\u2022 Option C. Procainamide : An antiarrhythmic agent that is metabolized through acetylation . Variations in acetylation rates can affect its efficacy and side effect profile.</li><li>\u2022 Option C. Procainamide</li><li>\u2022 antiarrhythmic agent</li><li>\u2022 metabolized through acetylation</li><li>\u2022 Option D. Hydralazine : Used primarily for hypertension , hydralazine is metabolized through acetylation . Slow acetylators may have a higher risk of drug-induced lupus erythematosus.</li><li>\u2022 Option D. Hydralazine</li><li>\u2022 primarily for hypertension</li><li>\u2022 hydralazine is metabolized</li><li>\u2022 acetylation</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 Hydrocortisone is not metabolized by acetylation , unlike other drugs such as dapsone , procainamide , and hydralazine , which can influence individual responses to drug therapy due to variations in acetylation rates .</li><li>\u27a4 Hydrocortisone</li><li>\u27a4 not metabolized by acetylation</li><li>\u27a4 drugs such as dapsone</li><li>\u27a4 procainamide</li><li>\u27a4 hydralazine</li><li>\u27a4 influence individual responses</li><li>\u27a4 drug therapy</li><li>\u27a4 acetylation rates</li><li>\u27a4 The drugs metabolized by acetylation include:</li><li>\u27a4 S: S ulfonamides (including Dapsone)</li><li>\u27a4 S: S</li><li>\u27a4 H: H ydralazine</li><li>\u27a4 H: H</li><li>\u27a4 I: I soniazid</li><li>\u27a4 I: I</li><li>\u27a4 P: P rocainamide</li><li>\u27a4 P: P</li><li>\u27a4 All these drugs can cause SLE like syndrome.</li><li>\u27a4 All these drugs can cause SLE like syndrome.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "9958b127",
      "audio": ""
    },
    {
      "text": "42-year-old woman with a history of hypertension and heart failure is evaluated for a change in her medication regimen. She has difficulty adhering to her current regimen due to the complexity and number of medications. Her physician is considering prescribing a fixed dose combination (FDC) medication to simplify her regimen. Which of the following is a potential advantage of fixed dose combination of drugs?",
      "options": [
        {
          "label": "A",
          "text": "Increases efficacy of drugs",
          "correct": false
        },
        {
          "label": "B",
          "text": "Decreases side effects",
          "correct": false
        },
        {
          "label": "C",
          "text": "Improves patient compliance improved",
          "correct": false
        },
        {
          "label": "D",
          "text": "All the above",
          "correct": true
        }
      ],
      "correct_answer": "D. All the above",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) All the above</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A : FDCs can increase the efficacy of drugs through synergistic effects , as seen in combinations like sulfamethoxazole and trimethoprim.</li><li>\u2022 Option A</li><li>\u2022 FDCs</li><li>\u2022 increase the efficacy of drugs</li><li>\u2022 synergistic effects</li><li>\u2022 Option B : They can decrease side effects if the components act by different mechanisms , or one component's side effects are counteracted by another, like a diuretic with a potassium-sparing agent.</li><li>\u2022 Option B</li><li>\u2022 decrease side effects</li><li>\u2022 components act by different mechanisms</li><li>\u2022 Option C : FDCs can improve patient compliance by reducing pill burden and simplifying the medication regimen .</li><li>\u2022 Option C</li><li>\u2022 FDCs can improve patient compliance</li><li>\u2022 reducing pill burden</li><li>\u2022 simplifying the medication regimen</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 Fixed dose combinations can offer advantages such as increased drug efficacy , decreased side effects , and improved patient compliance due to convenience and synergistic effects of the combined drugs.</li><li>\u27a4 Fixed dose combinations</li><li>\u27a4 increased drug efficacy</li><li>\u27a4 decreased side effects</li><li>\u27a4 improved patient compliance</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "922fee5d",
      "audio": ""
    },
    {
      "text": "In the provided drug response curve graph, what type of drug does the red-lined curve, represent?",
      "options": [
        {
          "label": "A",
          "text": "Partial agonist",
          "correct": false
        },
        {
          "label": "B",
          "text": "Full agonist",
          "correct": false
        },
        {
          "label": "C",
          "text": "Inverse agonist",
          "correct": true
        },
        {
          "label": "D",
          "text": "Antagonist",
          "correct": false
        }
      ],
      "correct_answer": "C. Inverse agonist",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/09/29/whatsapp-image-2023-09-29-at-120333.jpeg"
      ],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/10/screenshot-2024-05-10-165152.png"
      ],
      "explanation": "<p><strong>Ans. C) Inverse agonist</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A: Partial Agonist : This would produce a response , but its maximal effect is less than a full agonist , even when all receptors are occupied . The curve for a partial agonist would be above the baseline (indicating a positive response) but would not reach the same maximum as the full agonist.</li><li>\u2022 Option A: Partial Agonist</li><li>\u2022 produce a response</li><li>\u2022 maximal effect</li><li>\u2022 less than a full agonist</li><li>\u2022 receptors are occupied</li><li>\u2022 curve for a partial agonist</li><li>\u2022 above the baseline</li><li>\u2022 Option B: Full Agonist : This binds to the receptor and produces a maximum biological response. The curve would be expected to reach the highest point above the baseline in the graph, indicating the full efficacy of the drug.</li><li>\u2022 Option B: Full Agonist</li><li>\u2022 binds to the receptor</li><li>\u2022 produces a maximum biological response.</li><li>\u2022 Option D: Antagonist : An antagonist would not produce any response itself ; it would only block the effect of an agonist . The curve for a pure antagonist would be flat, aligning with the baseline because it does not activate the receptor nor produce a response on its own.</li><li>\u2022 Option D: Antagonist</li><li>\u2022 antagonist</li><li>\u2022 not produce any response itself</li><li>\u2022 block the effect of an agonist</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 The red-lined curve that dips below the baseline represents an inverse agonist , which binds to a receptor and reduces its activity below the basal level .</li><li>\u27a4 red-lined curve</li><li>\u27a4 dips below the baseline</li><li>\u27a4 inverse agonist</li><li>\u27a4 receptor and reduces its activity below the basal level</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "608f1255",
      "audio": ""
    },
    {
      "text": "What does IP in the figure shown stands for:",
      "options": [
        {
          "label": "A",
          "text": "Drug is an instant release preparation",
          "correct": false
        },
        {
          "label": "B",
          "text": "Meant for intra pulmonary use",
          "correct": false
        },
        {
          "label": "C",
          "text": "The standards according to Indian Pharmacopoeia",
          "correct": true
        },
        {
          "label": "D",
          "text": "Drug tested preclinically via Intraperitoneal route",
          "correct": false
        }
      ],
      "correct_answer": "C. The standards according to Indian Pharmacopoeia",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/08/24/10.jpg"
      ],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) The standards according to Indian Pharmacopoeia</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 Option A : \"Instant release preparation\" refers to the formulation of the drug that affects how quickly it is released into the bloodstream; however, \"IP\" does not indicate this.</li><li>\u2022 Option A</li><li>\u2022 \"Instant release preparation\"</li><li>\u2022 formulation of the drug</li><li>\u2022 how quickly it is released into the bloodstream;</li><li>\u2022 Option B : \"Intra pulmonary use\" suggests that the drug is to be used within the lungs , typically inhalation drugs fall under this category, but \"IP\" does not denote this.</li><li>\u2022 Option B</li><li>\u2022 \"Intra pulmonary use\"</li><li>\u2022 drug is to be used within the lungs</li><li>\u2022 Option D : \"Intraperitoneal route \" is a method of drug administration used in research, but \"IP\" on a drug package does not relate to this.</li><li>\u2022 Option D</li><li>\u2022 \"Intraperitoneal route</li><li>\u2022 method of drug administration</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 The \"IP\" on a medication package indicates that the drug conforms to the standards set by the Indian Pharmacopoeia.</li><li>\u27a4 \"IP\" on a medication package</li><li>\u27a4 drug conforms to the standards set by the Indian Pharmacopoeia.</li><li>\u27a4 IP stands for Indian Pharmacopoeia BP: British Pharmacopoeia USP: United Nations Pharmacopoeia BNF: British National Formulary</li><li>\u27a4 IP stands for Indian Pharmacopoeia</li><li>\u27a4 BP: British Pharmacopoeia</li><li>\u27a4 USP: United Nations Pharmacopoeia</li><li>\u27a4 BNF: British National Formulary</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "b88e75e8",
      "audio": ""
    },
    {
      "text": "In the given diagram, two inhibitors X and Y are shown. Which of the following statements is true for \u2018X\u2019 type of inhibition?",
      "options": [
        {
          "label": "A",
          "text": "V max increases, Km unchanged",
          "correct": false
        },
        {
          "label": "B",
          "text": "Km increases, Vmax unchanged",
          "correct": true
        },
        {
          "label": "C",
          "text": "Km and Vmax both unchanged",
          "correct": false
        },
        {
          "label": "D",
          "text": "Both Km and Vmax increases",
          "correct": false
        }
      ],
      "correct_answer": "B. Km increases, Vmax unchanged",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/08/24/12_5JQ6FpO.jpg"
      ],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/08/24/13_4B8S9nr.jpg"
      ],
      "explanation": "<p><strong>Ans. B) Km increases, Vmax unchanged</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Curve X shows competitive inhibition . In competitive inhibition , the inhibitor competes for the same binding site . Hence, Km increases but Vmax remains unchanged . Whereas in non-competitive inhibition Vmax decreases and Km remains same .</li><li>\u2022 Curve X shows competitive inhibition .</li><li>\u2022 Curve X</li><li>\u2022 competitive inhibition</li><li>\u2022 In competitive inhibition , the inhibitor competes for the same binding site . Hence, Km increases but Vmax remains unchanged .</li><li>\u2022 competitive inhibition</li><li>\u2022 inhibitor competes</li><li>\u2022 same binding site</li><li>\u2022 Km increases</li><li>\u2022 Vmax remains unchanged</li><li>\u2022 Whereas in non-competitive inhibition Vmax decreases and Km remains same .</li><li>\u2022 non-competitive inhibition Vmax decreases</li><li>\u2022 Km remains same</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 In competitive inhibition , the inhibitor competes with the substrate for binding to the active site , resulting in an increased Km , while the Vmax remains unchanged because the inhibition can be overcome by increasing the substrate concentration .</li><li>\u27a4 competitive inhibition</li><li>\u27a4 inhibitor competes with the substrate</li><li>\u27a4 binding to the active site</li><li>\u27a4 increased Km</li><li>\u27a4 Vmax remains unchanged</li><li>\u27a4 inhibition can be overcome by increasing the substrate concentration</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "185fdd27",
      "audio": ""
    },
    {
      "text": "Identify the route of administration shown in the given figure?",
      "options": [
        {
          "label": "A",
          "text": "Intravenous",
          "correct": false
        },
        {
          "label": "B",
          "text": "Intramuscular",
          "correct": false
        },
        {
          "label": "C",
          "text": "Intraosseous",
          "correct": true
        },
        {
          "label": "D",
          "text": "Intra Articular",
          "correct": false
        }
      ],
      "correct_answer": "C. Intraosseous",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/08/24/14.jpg"
      ],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/10/screenshot-2024-05-10-171233.png",
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/10/screenshot-2024-05-10-171240.png",
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/10/screenshot-2024-05-10-171248.png"
      ],
      "explanation": "<p><strong>Ans. C) Intraosseous</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A : Intravenous administration involves inserting a needle or catheter into a vein</li><li>\u2022 Option A</li><li>\u2022 Intravenous administration</li><li>\u2022 inserting a needle or catheter</li><li>\u2022 vein</li><li>\u2022 Option B : Intramuscular injections are given into the muscle, and they do not use the type of rigid fixation device shown in the image.</li><li>\u2022 Option B</li><li>\u2022 Intramuscular injections</li><li>\u2022 into the muscle,</li><li>\u2022 Option D : Intra Articular injections are administered into a joint space , not the bone marrow or the area shown in the image.</li><li>\u2022 Option D</li><li>\u2022 Intra Articular injections</li><li>\u2022 administered into a joint space</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 The intraosseous route of administration involves delivering medications directly into the bone marrow when intravenous access is not available, as often used in pediatric emergencies.</li><li>\u27a4 intraosseous route of administration</li><li>\u27a4 delivering medications directly into the bone marrow</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "40536e81",
      "audio": ""
    },
    {
      "text": "A drug delivery system is shown in the given diagram. By which route, this system can be delivered to the patient?",
      "options": [
        {
          "label": "A",
          "text": "Subcutaneous",
          "correct": false
        },
        {
          "label": "B",
          "text": "Transdermal",
          "correct": true
        },
        {
          "label": "C",
          "text": "Dermal implant",
          "correct": false
        },
        {
          "label": "D",
          "text": "Iontophoresis",
          "correct": false
        }
      ],
      "correct_answer": "B. Transdermal",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/08/24/15.jpg"
      ],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Transdermal</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 Option A : Subcutaneous administration involves injections given into the tissue layer between the skin and the muscle , not applicable to the patch system shown.</li><li>\u2022 Option A</li><li>\u2022 Subcutaneous administration</li><li>\u2022 injections</li><li>\u2022 into the tissue layer between the skin</li><li>\u2022 muscle</li><li>\u2022 Option C : Dermal implants are devices placed under the skin for long-term drug delivery ; they are different from the patch shown.</li><li>\u2022 Option C</li><li>\u2022 Dermal implants</li><li>\u2022 devices placed under the skin</li><li>\u2022 long-term drug delivery</li><li>\u2022 Option D : Iontophoresis is a technique that uses electrical currents to drive ions , including medications , through the skin. It does not refer to the type of passive drug delivery system shown in the diagram.</li><li>\u2022 Option D</li><li>\u2022 Iontophoresis</li><li>\u2022 technique that uses electrical currents</li><li>\u2022 drive ions</li><li>\u2022 medications</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 The transdermal drug delivery system delivers medication through the skin into systemic circulation and offers a steady absorption rate with minimal first-pass metabolism .</li><li>\u27a4 transdermal drug delivery system delivers medication</li><li>\u27a4 skin into systemic circulation</li><li>\u27a4 steady absorption rate</li><li>\u27a4 minimal first-pass metabolism</li><li>\u27a4 Common Drugs available as transdermal patch are. Fentanyl Nicotine Nitroglycerine Clonidine Testosterone Scopolamine</li><li>\u27a4 Common Drugs available as transdermal patch are. Fentanyl Nicotine Nitroglycerine Clonidine Testosterone Scopolamine</li><li>\u27a4 Fentanyl Nicotine Nitroglycerine Clonidine Testosterone Scopolamine</li><li>\u27a4 Fentanyl</li><li>\u27a4 Nicotine</li><li>\u27a4 Nitroglycerine</li><li>\u27a4 Clonidine</li><li>\u27a4 Testosterone</li><li>\u27a4 Scopolamine</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "e0e4320d",
      "audio": ""
    },
    {
      "text": "Which of the following combinations show pharmacological antagonism?",
      "options": [
        {
          "label": "A",
          "text": "Adrenaline and Isoprenaline",
          "correct": false
        },
        {
          "label": "B",
          "text": "Histamine and adrenaline",
          "correct": false
        },
        {
          "label": "C",
          "text": "Isoprenaline and propranolol",
          "correct": true
        },
        {
          "label": "D",
          "text": "All the above",
          "correct": false
        }
      ],
      "correct_answer": "C. Isoprenaline and propranolol",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/10/screenshot-2024-05-10-171919.png"
      ],
      "explanation": "<p><strong>Ans. C) Isoprenaline and propranolol</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A : Adrenaline and isoprenaline both stimulate the heart and increase heart rate . They are agonists, not pharmacological antagonists.</li><li>\u2022 Option A</li><li>\u2022 Adrenaline</li><li>\u2022 isoprenaline both stimulate the heart</li><li>\u2022 increase heart rate</li><li>\u2022 Option B : Although adrenaline can counteract the effects of histamine (such as in allergic reactions), it works via different receptors (adrenergic versus histaminergic). This is an example of physiological antagonism, not pharmacological antagonism.</li><li>\u2022 Option B</li><li>\u2022 adrenaline can counteract the effects of histamine</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 Pharmacological antagonism occurs when a drug (propranolol) binds to the same receptor as an agonist (isoprenaline) and inhibits its action, without activating the receptor itself.</li><li>\u27a4 Pharmacological antagonism</li><li>\u27a4 drug</li><li>\u27a4 binds to the same receptor as an agonist</li><li>\u27a4 inhibits its action,</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "c5771202",
      "audio": ""
    },
    {
      "text": "A drug X is secreted through renal tubules, tubular secretion of this drug can be confirmed if renal clearance of drug X is:",
      "options": [
        {
          "label": "A",
          "text": "More than the glomerular filtration",
          "correct": true
        },
        {
          "label": "B",
          "text": "Equal to the glomerular filtration",
          "correct": false
        },
        {
          "label": "C",
          "text": "Less than the glomerular filtration",
          "correct": false
        },
        {
          "label": "D",
          "text": "More than volume of distribution",
          "correct": false
        }
      ],
      "correct_answer": "A. More than the glomerular filtration",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) More than the glomerular filtration</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B : A renal clearance equal to glomerular filtration suggests that the drug is not being significantly reabsorbed or secreted after filtration .</li><li>\u2022 Option B</li><li>\u2022 renal clearance equal to glomerular filtration</li><li>\u2022 drug is not being significantly reabsorbed</li><li>\u2022 secreted after filtration</li><li>\u2022 Option C : A renal clearance less than the glomerular filtration rate implies that the drug is being reabsorbed by the tubules after glomerular filtration.</li><li>\u2022 Option C</li><li>\u2022 renal clearance less than the glomerular filtration rate</li><li>\u2022 drug is being reabsorbed by the tubules</li><li>\u2022 glomerular filtration.</li><li>\u2022 Option D : The volume of distribution is a pharmacokinetic parameter that relates the amount of drug in the body to the concentration of the drug in the blood or plasma . It does not directly correspond to renal clearance mechanisms.</li><li>\u2022 Option D</li><li>\u2022 volume of distribution</li><li>\u2022 pharmacokinetic parameter</li><li>\u2022 relates the amount of drug in the body</li><li>\u2022 concentration of the drug in the blood or plasma</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 The presence of tubular secretion can be inferred when the renal clearance of a drug exceeds its glomerular filtration rate. This suggests that the drug is being actively secreted into the tubular lumen, contributing to its overall elimination from the body.</li><li>\u27a4 presence of tubular secretion</li><li>\u27a4 inferred when the renal clearance of a drug exceeds its glomerular filtration rate.</li><li>\u27a4 secreted into the tubular lumen,</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "f0a91436",
      "audio": ""
    },
    {
      "text": "A patient, Rajesh, with a history of wheezing, coughing and shortness of breath is being evaluated in the asthma clinic. Several drug treatments with different routes are under consideration. Which of the following statements about routes of administration is most correct?",
      "options": [
        {
          "label": "A",
          "text": "Administration of a bronchodilator drug by inhaled aerosol is usually associated with more adverse effects than administration of this drug by mouth",
          "correct": false
        },
        {
          "label": "B",
          "text": "The first pass effect is the result of elimination of a drug after administration and before it enters systemic circulation",
          "correct": true
        },
        {
          "label": "C",
          "text": "Bioavailability of most drugs is greater with rectal administration than with sublingual administration",
          "correct": false
        },
        {
          "label": "D",
          "text": "Administration of a drug by transdermal patch is often faster but is associated with more first pass metabolism than oral administration",
          "correct": false
        }
      ],
      "correct_answer": "B. The first pass effect is the result of elimination of a drug after administration and before it enters systemic circulation",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) The first pass effect is the result of elimination of a drug after administration and before it enters systemic circulation.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 Option A : This is incorrect because inhaled aerosols deliver medication directly to the lungs , leading to fewer systemic adverse effects compared to oral administration, which involves the entire body.</li><li>\u2022 Option A</li><li>\u2022 inhaled aerosols deliver medication directly to the lungs</li><li>\u2022 Option C : Generally, sublingual administration offers higher bioavailability than rectal administration because it bypasses the first pass metabolism through the liver.</li><li>\u2022 Option C</li><li>\u2022 sublingual administration</li><li>\u2022 higher bioavailability than rectal administration</li><li>\u2022 Option D : This is incorrect. Transdermal patches usually have slower absorption rates due to the nature of skin permeation but avoid first pass metabolism since the drug is absorbed directly into systemic circulation.</li><li>\u2022 Option D</li><li>\u2022 Transdermal patches</li><li>\u2022 slower absorption rates</li><li>\u2022 nature of skin permeation</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 The first pass effect refers to the drug's metabolism in the liver after oral administration, which can significantly reduce the amount of active drug that reaches systemic circulation . This effect is avoided with routes such as sublingual and transdermal administration.</li><li>\u27a4 first pass effect</li><li>\u27a4 drug's metabolism in the liver</li><li>\u27a4 reduce the amount of active drug</li><li>\u27a4 reaches systemic circulation</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "5fc3e82f",
      "audio": ""
    },
    {
      "text": "A three-year-old child is brought to the emergency department having just ingested a large overdose of an antihistaminic drug. This drug is a weak base capable of entering most tissues including the brain. On physical examination the heart rate is 100/ minute, blood pressure is 110/60 mm Hg, and the respiratory rate is 20/ minute. In this case of poisoning:",
      "options": [
        {
          "label": "A",
          "text": "Urinary excretion would be accelerated by the administration of NH4Cl, an acidifying agent",
          "correct": true
        },
        {
          "label": "B",
          "text": "Urinary excretion would be accelerated by administration of NaHCO 3, an alkalinizing agent",
          "correct": false
        },
        {
          "label": "C",
          "text": "More of the drug would be ionized at blood pH than at stomach pH",
          "correct": false
        },
        {
          "label": "D",
          "text": "Absorption of the drug would be faster from the stomach than from the small intestine",
          "correct": false
        }
      ],
      "correct_answer": "A. Urinary excretion would be accelerated by the administration of NH4Cl, an acidifying agent",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Urinary excretion would be accelerated by administration of NH4Cl, an acidifying agent</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 Option B : Alkalinizing the urine with NaHCO3 would reduce the ionization of the weak base , potentially decreasing its excretion.</li><li>\u2022 Option B</li><li>\u2022 Alkalinizing the urine</li><li>\u2022 NaHCO3</li><li>\u2022 reduce the ionization of the weak base</li><li>\u2022 Option C : This is incorrect because the drug , being a weak base , is more ionized at an acidic pH (as in the stomach) than at the slightly alkaline blood pH.</li><li>\u2022 Option C</li><li>\u2022 drug</li><li>\u2022 being a weak base</li><li>\u2022 ionized at an acidic pH</li><li>\u2022 Option D : This is incorrect because weak bases are better absorbed in more alkaline environments , so absorption would generally be faster in the alkaline small intestine than in the acidic stomach.</li><li>\u2022 Option D</li><li>\u2022 weak bases</li><li>\u2022 better absorbed in more alkaline environments</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 To accelerate the urinary excretion of a weakly basic drug , acidify the urine , which promotes the ionization of the drug , thus reducing its reabsorption and increasing its elimination .</li><li>\u27a4 accelerate the urinary excretion</li><li>\u27a4 weakly basic drug</li><li>\u27a4 acidify the urine</li><li>\u27a4 promotes the ionization of the drug</li><li>\u27a4 reducing its reabsorption</li><li>\u27a4 increasing its elimination</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "3e1376cd",
      "audio": ""
    },
    {
      "text": "Dose response curves of salbutamol for bronchodilation and tachycardia are widely separated on the dose axis. This information suggests that salbutamol is?",
      "options": [
        {
          "label": "A",
          "text": "Highly potent cardiac stimulant",
          "correct": false
        },
        {
          "label": "B",
          "text": "Highly efficacious bronchodilator",
          "correct": false
        },
        {
          "label": "C",
          "text": "Highly toxic drug",
          "correct": false
        },
        {
          "label": "D",
          "text": "Highly selective drug",
          "correct": true
        }
      ],
      "correct_answer": "D. Highly selective drug",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/08/24/16.jpg"
      ],
      "explanation": "<p><strong>Ans. D) Highly selective drug</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A: Highly potent cardiac stimulant : Potency refers to the amount of drug needed to produce a given effect. The fact that the dose-response curves for bronchodilation and tachycardia are widely separated suggests that higher doses are required to produce tachycardia compared to bronchodilation. This does not necessarily indicate that salbutamol is a highly potent cardiac stimulant. Instead, it suggests that at therapeutic doses, its cardiac stimulating effects are less pronounced.</li><li>\u2022 Option A:</li><li>\u2022 Highly potent cardiac stimulant</li><li>\u2022 Potency</li><li>\u2022 amount of drug needed to produce a given effect.</li><li>\u2022 dose-response curves for bronchodilation</li><li>\u2022 tachycardia</li><li>\u2022 widely separated</li><li>\u2022 higher doses</li><li>\u2022 required to produce tachycardia</li><li>\u2022 Option B: Highly efficacious bronchodilator : Efficacy refers to the maximum effect a drug can produce, regardless of dose. While salbutamol is an efficacious bronchodilator, the separation of dose-response curves on its own doesn't primarily speak to its efficacy; it more directly speaks to its selectivity.</li><li>\u2022 Option B:</li><li>\u2022 Highly efficacious bronchodilator</li><li>\u2022 Efficacy</li><li>\u2022 maximum effect a drug can produce,</li><li>\u2022 Option C: Highly toxic drug: Toxicity refers to the degree to which a substance can harm humans or animals . The separation of the dose-response curves for therapeutic and side effects does not imply high toxicity. Instead, it suggests that the drug can be used effectively at a dose that minimally produces side effects.</li><li>\u2022 Option C:</li><li>\u2022 Highly toxic drug:</li><li>\u2022 degree to which a substance can harm humans</li><li>\u2022 animals</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 The separation of the dose-response curves for bronchodilation and tachycardia in salbutamol indicates that it is a highly selective drug , capable of producing its desired effect with less risk of certain side effects at therapeutic doses.</li><li>\u2022 separation of the dose-response curves</li><li>\u2022 bronchodilation and tachycardia in salbutamol</li><li>\u2022 highly selective drug</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "403d336e",
      "audio": ""
    },
    {
      "text": "Which of the following is not converted into an active metabolite?",
      "options": [
        {
          "label": "A",
          "text": "Lisinopril",
          "correct": true
        },
        {
          "label": "B",
          "text": "Methyl dopa",
          "correct": false
        },
        {
          "label": "C",
          "text": "Cyclophosphamide",
          "correct": false
        },
        {
          "label": "D",
          "text": "Diazepam",
          "correct": false
        }
      ],
      "correct_answer": "A. Lisinopril",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Lisinopril</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Methyl dopa: Methyl dopa is an antihypertensive medication. It is a prodrug that is metabolized in the body to alpha-methylnorepinephrine, which is an active metabolite . This metabolite acts centrally to lower blood pressure.</li><li>\u2022 Option B. Methyl dopa:</li><li>\u2022 Methyl dopa</li><li>\u2022 prodrug that is metabolized in the body</li><li>\u2022 alpha-methylnorepinephrine,</li><li>\u2022 active metabolite</li><li>\u2022 Option C. Cyclophosphamide: Cyclophosphamide is an alkylating agent used in chemotherapy. It is a prodrug that requires metabolic activation, primarily by liver enzymes, to form its active metabolites , phosphoramide mustard and acrolein, which are responsible for its therapeutic and toxic effects.</li><li>\u2022 Option C. Cyclophosphamide:</li><li>\u2022 alkylating agent</li><li>\u2022 chemotherapy.</li><li>\u2022 prodrug that requires metabolic activation,</li><li>\u2022 liver enzymes,</li><li>\u2022 active metabolites</li><li>\u2022 phosphoramide mustard</li><li>\u2022 acrolein,</li><li>\u2022 Option D. Diazepam: Diazepam is a benzodiazepine used for its anxiolytic, anticonvulsant, and muscle relaxant properties . It is metabolized into several active metabolites , including nordiazepam (desmethyldiazepam), temazepam, and oxazepam.</li><li>\u2022 Option D. Diazepam:</li><li>\u2022 benzodiazepine</li><li>\u2022 anxiolytic, anticonvulsant,</li><li>\u2022 muscle relaxant properties</li><li>\u2022 metabolized into several active metabolites</li><li>\u2022 nordiazepam</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 Lisinopril is an ACE inhibitor that is effective without biotransformation into an active metabolite, unlike other drugs such as methyl dopa, cyclophosphamide , and diazepam, which require metabolic conversion to exert their therapeutic effects.</li><li>\u27a4 Lisinopril</li><li>\u27a4 ACE inhibitor</li><li>\u27a4 active metabolite,</li><li>\u27a4 methyl dopa, cyclophosphamide</li><li>\u27a4 diazepam,</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "8c82630c",
      "audio": ""
    },
    {
      "text": "Which of the following trials can be performed to determine the maximal tolerated dose (MTD) of a drug?",
      "options": [
        {
          "label": "A",
          "text": "Case control study",
          "correct": false
        },
        {
          "label": "B",
          "text": "Phase II Randomized control trials",
          "correct": false
        },
        {
          "label": "C",
          "text": "Phase I trial",
          "correct": true
        },
        {
          "label": "D",
          "text": "Phase IV Randomized control trials",
          "correct": false
        }
      ],
      "correct_answer": "C. Phase I trial",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/10/whatsapp-image-2024-05-10-at-54113-pm.jpeg"
      ],
      "explanation": "<p><strong>Ans. C) Phase I trial</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Case Control Study:</li><li>\u2022 Option A. Case Control Study:</li><li>\u2022 Case control studies are retrospective analyses that compare patients with a specific outcome (e.g., those with an adverse reaction to a drug) to those without that outcome. They are not designed to determine MTD but rather to investigate potential causes or associations after the fact.</li><li>\u2022 Case control studies are retrospective analyses that compare patients with a specific outcome (e.g., those with an adverse reaction to a drug) to those without that outcome. They are not designed to determine MTD but rather to investigate potential causes or associations after the fact.</li><li>\u2022 retrospective analyses</li><li>\u2022 compare patients with a specific outcome</li><li>\u2022 those without that outcome.</li><li>\u2022 Option B. Phase II Randomized Control Trials:</li><li>\u2022 Option B. Phase II Randomized Control Trials:</li><li>\u2022 Phase II trials are designed to assess efficacy and further evaluate the safety of a drug , usually in a larger group of patients than in Phase I. While Phase II trials do gather more safety data and can refine the understanding of a drug's MTD, their primary goal is not to determine MTD but to establish preliminary evidence of therapeutic effect.</li><li>\u2022 Phase II trials are designed to assess efficacy and further evaluate the safety of a drug , usually in a larger group of patients than in Phase I. While Phase II trials do gather more safety data and can refine the understanding of a drug's MTD, their primary goal is not to determine MTD but to establish preliminary evidence of therapeutic effect.</li><li>\u2022 Phase II trials</li><li>\u2022 assess efficacy</li><li>\u2022 evaluate the safety of a drug</li><li>\u2022 larger group of patients than in Phase I.</li><li>\u2022 Option D. Phase IV Randomized Control Trials:</li><li>\u2022 Option D. Phase IV Randomized Control Trials:</li><li>\u2022 Phase IV trials occur after a drug has been approved for market. They involve post-marketing surveillance to detect rare adverse events and to collect information on long-term efficacy and safety . These trials are not designed to determine MTD but to monitor the drug's performance in a real-world setting across a broad population.</li><li>\u2022 Phase IV trials occur after a drug has been approved for market. They involve post-marketing surveillance to detect rare adverse events and to collect information on long-term efficacy and safety . These trials are not designed to determine MTD but to monitor the drug's performance in a real-world setting across a broad population.</li><li>\u2022 Phase IV trials</li><li>\u2022 after a drug has been approved for market.</li><li>\u2022 post-marketing surveillance</li><li>\u2022 detect rare adverse events</li><li>\u2022 collect information on long-term efficacy and safety</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 The maximal tolerated dose of a drug is primarily determined during Phase I clinical trials, where safety is the main focu s, and dosing is carefully controlled to observe the emergence of adverse effects, thereby establishing the MTD.</li><li>\u2022 maximal tolerated dose</li><li>\u2022 drug is primarily determined during Phase I clinical trials,</li><li>\u2022 safety is the main focu</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "d3696dd3",
      "audio": ""
    },
    {
      "text": "What is the rationale behind xenobiotic metabolism by CYP enzymes?",
      "options": [
        {
          "label": "A",
          "text": "Increase in water solubility",
          "correct": true
        },
        {
          "label": "B",
          "text": "Increase in lipid solubility",
          "correct": false
        },
        {
          "label": "C",
          "text": "Nonionic to an active metabolite",
          "correct": false
        },
        {
          "label": "D",
          "text": "Makes it suitable to evaporate through skin surface",
          "correct": false
        }
      ],
      "correct_answer": "A. Increase in water solubility",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Increase in water solubility</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B: Increase in lipid solubility: This option is incorrect. Increasing the lipid solubility of xenobiotics would be counterproductive, as it would make them more likely to accumulate in the body , potentially leading to toxicity.</li><li>\u2022 Option B: Increase in lipid solubility:</li><li>\u2022 counterproductive,</li><li>\u2022 accumulate in the body</li><li>\u2022 Option C: Conversion from nonionic to an active metabolite: While some CYP enzyme actions convert prodrugs to their active forms, this is not the primary rationale for xenobiotic metabolism. The main purpose is to enhance solubility for elimination, not necessarily activation.</li><li>\u2022 Option C: Conversion from nonionic to an active metabolite:</li><li>\u2022 CYP enzyme actions convert prodrugs</li><li>\u2022 active forms,</li><li>\u2022 not the primary rationale for xenobiotic metabolism.</li><li>\u2022 Option D: Makes it suitable to evaporate through skin surface: This is incorrect. Xenobiotic metabolism by CYP enzymes is not primarily aimed at making substances evaporate through the skin. The skin is not a major route for eliminating most xenobiotics; the focus is on making them more water-soluble for renal and biliary excretion.</li><li>\u2022 Option D: Makes it suitable to evaporate through skin surface:</li><li>\u2022 Xenobiotic metabolism by CYP enzymes</li><li>\u2022 not</li><li>\u2022 aimed at making substances evaporate through the skin.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 The primary role of cytochrome P450 enzymes in xenobiotic metabolism is to increase water solubility, thereby facilitating the excretion of these compounds through the kidneys or bile.</li><li>\u27a4 primary role of cytochrome P450 enzymes</li><li>\u27a4 xenobiotic metabolism</li><li>\u27a4 increase water solubility,</li><li>\u27a4 facilitating the excretion</li><li>\u27a4 kidneys or bile.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "82f54945",
      "audio": ""
    },
    {
      "text": "Which route, other than the intravenous route, allows titration of effect of the dose and thus controlled delivery of drugs to patients?",
      "options": [
        {
          "label": "A",
          "text": "Oral route",
          "correct": false
        },
        {
          "label": "B",
          "text": "Rectal route",
          "correct": false
        },
        {
          "label": "C",
          "text": "Transdermal route",
          "correct": false
        },
        {
          "label": "D",
          "text": "Inhalational route",
          "correct": true
        }
      ],
      "correct_answer": "D. Inhalational route",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Inhalational route</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A: Oral Route</li><li>\u2022 Option A: Oral Route</li><li>\u2022 The oral route of drug administration is the most common and convenient route , but it does not typically allow for rapid titration. Absorption can be variable due to factors such as gastric pH, food intake, and gastrointestinal motility, and it is subject to first-pass metabolism. Adjusting the effect of a drug moment-to-moment is not feasible with oral administration.</li><li>\u2022 The oral route of drug administration is the most common and convenient route , but it does not typically allow for rapid titration. Absorption can be variable due to factors such as gastric pH, food intake, and gastrointestinal motility, and it is subject to first-pass metabolism. Adjusting the effect of a drug moment-to-moment is not feasible with oral administration.</li><li>\u2022 oral route of drug administration</li><li>\u2022 common</li><li>\u2022 convenient route</li><li>\u2022 not</li><li>\u2022 allow for rapid titration.</li><li>\u2022 Absorption can be variable</li><li>\u2022 factors such as gastric pH, food intake, and gastrointestinal motility,</li><li>\u2022 Option B: Rectal Route</li><li>\u2022 Option B: Rectal Route</li><li>\u2022 The rectal route can bypass some of the first-pass metabolism seen with oral administration and can be useful when oral administration is not possible (e.g., due to vomiting). However, it does not typically allow for rapid titration of drug effects due to slower and less predictable absorption.</li><li>\u2022 The rectal route can bypass some of the first-pass metabolism seen with oral administration and can be useful when oral administration is not possible (e.g., due to vomiting). However, it does not typically allow for rapid titration of drug effects due to slower and less predictable absorption.</li><li>\u2022 rectal route</li><li>\u2022 bypass</li><li>\u2022 first-pass metabolism</li><li>\u2022 oral administration</li><li>\u2022 useful when oral administration is not possible</li><li>\u2022 Option C: Transdermal Route</li><li>\u2022 Option C: Transdermal Route</li><li>\u2022 Transdermal drug delivery provides a continuous and controlled release of medication through the skin . While it allows for steady medication levels over a longer duration , it does not allow for rapid titration or moment-to-moment control due to the slow onset and offset of action inherent to this route.</li><li>\u2022 Transdermal drug delivery provides a continuous and controlled release of medication through the skin . While it allows for steady medication levels over a longer duration , it does not allow for rapid titration or moment-to-moment control due to the slow onset and offset of action inherent to this route.</li><li>\u2022 Transdermal drug delivery</li><li>\u2022 continuous</li><li>\u2022 controlled release of medication</li><li>\u2022 skin</li><li>\u2022 allows for steady medication levels</li><li>\u2022 longer duration</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 While the oral, rectal, and transdermal routes can deliver drugs effectively , they do not allow for the rapid titration of drug effects . The inhalational route, on the other hand, offers a distinct advantage in this regard.</li><li>\u2022 oral, rectal, and transdermal routes</li><li>\u2022 deliver drugs effectively</li><li>\u2022 not allow for the rapid titration</li><li>\u2022 drug effects</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "3b9b68be",
      "audio": ""
    },
    {
      "text": "Z track technique is used for?",
      "options": [
        {
          "label": "A",
          "text": "Depot injection of antipsychotics",
          "correct": true
        },
        {
          "label": "B",
          "text": "Monitoring of carbamazepine therapy",
          "correct": false
        },
        {
          "label": "C",
          "text": "Monitoring of lithium therapy",
          "correct": false
        },
        {
          "label": "D",
          "text": "Nicotine patch administration",
          "correct": false
        }
      ],
      "correct_answer": "A. Depot injection of antipsychotics",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Depot injection of antipsychotics</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B: Monitoring of carbamazepine therapy. This is incorrect. Monitoring carbamazepine therapy involves blood tests to measure the drug's concentration in the bloodstream . It is not related to the Z-track injection technique.</li><li>\u2022 Option B:</li><li>\u2022 Monitoring of carbamazepine therapy.</li><li>\u2022 blood tests to measure the drug's concentration in the bloodstream</li><li>\u2022 Option C: Monitoring of lithium therapy. This is also incorrect. Similar to carbamazepine, monitoring lithium therapy involves blood tests to measure lithium levels in the body , not related to any particular injection technique.</li><li>\u2022 Option C:</li><li>\u2022 Monitoring of lithium therapy.</li><li>\u2022 monitoring lithium therapy</li><li>\u2022 blood tests to measure lithium levels in the body</li><li>\u2022 Option D: Nicotine patch administration. This is incorrect. Nicotine patches are applied topically to the skin and do not require an injection technique like the Z-track method.</li><li>\u2022 Option D:</li><li>\u2022 Nicotine patch administration.</li><li>\u2022 applied topically to the skin</li><li>\u2022 Therefore, the correct answer is a. Depot injection of antipsychotics.</li><li>\u2022 a. Depot injection of antipsychotics.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 The Z-track technique is utilized in intramuscular injections to prevent leakage of medication into the subcutaneous tissue , which can reduce irritation and ensure a slower release of medication , making it especially beneficial for depot injections of antipsychotics.</li><li>\u27a4 Z-track technique</li><li>\u27a4 utilized in intramuscular injections</li><li>\u27a4 prevent leakage of medication</li><li>\u27a4 subcutaneous tissue</li><li>\u27a4 reduce irritation</li><li>\u27a4 ensure a slower release of medication</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "b0daa57a",
      "audio": ""
    },
    {
      "text": "Which is the most common cytochrome p450 enzyme associated with metabolism of drugs?",
      "options": [
        {
          "label": "A",
          "text": "CYP3A4",
          "correct": true
        },
        {
          "label": "B",
          "text": "CYP2D6",
          "correct": false
        },
        {
          "label": "C",
          "text": "CYP2C9",
          "correct": false
        },
        {
          "label": "D",
          "text": "CYP2C19",
          "correct": false
        }
      ],
      "correct_answer": "A. CYP3A4",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) CYP3A4</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B: CYP2D6 - Metabolizes nearly 20% drugs including tricyclic antidepressants, selective serotonin reuptake inhibitors etc.</li><li>\u2022 Option B: CYP2D6</li><li>\u2022 Metabolizes nearly 20% drugs</li><li>\u2022 tricyclic antidepressants,</li><li>\u2022 Option C: CYP2C9 - Important in the biotransformation of phenytoin and warfarin.</li><li>\u2022 Option C: CYP2C9</li><li>\u2022 biotransformation of phenytoin</li><li>\u2022 warfarin.</li><li>\u2022 Option D: CYP2C19 - Substrates include clopidogrel and omeprazole.</li><li>\u2022 Option D: CYP2C19</li><li>\u2022 Substrates</li><li>\u2022 clopidogrel and omeprazole.</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 Most common cytochrome p450 enzyme associated with metabolism of drugs is CYP3A4.</li><li>\u2022 common cytochrome p450 enzyme</li><li>\u2022 metabolism of drugs is CYP3A4.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "c1f01070",
      "audio": ""
    },
    {
      "text": "When two different chemicals act on two different receptors and their responses are opposite to each other it is called as:",
      "options": [
        {
          "label": "A",
          "text": "Physiological antagonism",
          "correct": true
        },
        {
          "label": "B",
          "text": "Chemical antagonism",
          "correct": false
        },
        {
          "label": "C",
          "text": "Pharmacological antagonism",
          "correct": false
        },
        {
          "label": "D",
          "text": "Competitive antagonism",
          "correct": false
        }
      ],
      "correct_answer": "A. Physiological antagonism",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Physiological antagonism</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Chemical Antagonism:</li><li>\u2022 Option B. Chemical Antagonism:</li><li>\u2022 This form of antagonism takes place when two drugs interact chemically to form an inactive compound. An example is the action of chelating agents like dimercaprol (BAL) or calcium disodium edetate, which bind to heavy metals in the body, such as arsenic or lead, to form a stable, inactive complex that can be excreted.</li><li>\u2022 This form of antagonism takes place when two drugs interact chemically to form an inactive compound. An example is the action of chelating agents like dimercaprol (BAL) or calcium disodium edetate, which bind to heavy metals in the body, such as arsenic or lead, to form a stable, inactive complex that can be excreted.</li><li>\u2022 form of antagonism</li><li>\u2022 two drugs interact chemically to form an inactive compound.</li><li>\u2022 Option C. Pharmacological Antagonism:</li><li>\u2022 Option C. Pharmacological Antagonism:</li><li>\u2022 This type of antagonism occurs when a drug (antagonist) binds to the same receptor as another drug (agonist) and inhibits its effect without activating the receptor itself. This can be competitive or non-competitive. An example would be naloxone's inhibition of opioid effects at the opioid receptor.</li><li>\u2022 This type of antagonism occurs when a drug (antagonist) binds to the same receptor as another drug (agonist) and inhibits its effect without activating the receptor itself. This can be competitive or non-competitive. An example would be naloxone's inhibition of opioid effects at the opioid receptor.</li><li>\u2022 antagonism occurs when a drug</li><li>\u2022 binds to the same receptor</li><li>\u2022 inhibits its effect without activating the receptor itself.</li><li>\u2022 Option D. Competitive Antagonism:</li><li>\u2022 Option D. Competitive Antagonism:</li><li>\u2022 This is a specific type of pharmacological antagonism where the antagonist competes with an agonist for binding to the same receptor site . The binding of the antagonist can be overcome by increasing the concentration of the agonist. An example is the use of atropine to block the effects of acetylcholine at muscarinic receptors.</li><li>\u2022 This is a specific type of pharmacological antagonism where the antagonist competes with an agonist for binding to the same receptor site . The binding of the antagonist can be overcome by increasing the concentration of the agonist. An example is the use of atropine to block the effects of acetylcholine at muscarinic receptors.</li><li>\u2022 specific type of pharmacological antagonism</li><li>\u2022 antagonist competes with an agonist for binding</li><li>\u2022 same receptor site</li><li>\u2022 binding of the antagonist</li><li>\u2022 overcome by increasing the concentration of the agonist.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 Physiological antagonism occurs when two drugs act on different receptors or by different mechanisms to produce opposite effects on the same physiological function.</li><li>\u27a4 Physiological antagonism</li><li>\u27a4 two drugs act on different receptors</li><li>\u27a4 different mechanisms to produce opposite effects</li><li>\u27a4 same physiological function.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "b1c733a3",
      "audio": ""
    },
    {
      "text": "A substance that has affinity, but does not have any intrinsic activity is called as a:",
      "options": [
        {
          "label": "A",
          "text": "Agonist",
          "correct": false
        },
        {
          "label": "B",
          "text": "Partial agonist",
          "correct": false
        },
        {
          "label": "C",
          "text": "Antagonist",
          "correct": true
        },
        {
          "label": "D",
          "text": "Inverse agonist",
          "correct": false
        }
      ],
      "correct_answer": "C. Antagonist",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Antagonist</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Agonists:</li><li>\u2022 Option A. Agonists:</li><li>\u2022 Agonists are compounds that bind to a receptor and produce a full biological response . They have maximum intrinsic activity, meaning they can produce the maximum response that the receptor is capable of eliciting. Agonists are often used therapeutically to mimic the action of naturally occurring substances.</li><li>\u2022 Agonists are compounds that bind to a receptor and produce a full biological response . They have maximum intrinsic activity, meaning they can produce the maximum response that the receptor is capable of eliciting. Agonists are often used therapeutically to mimic the action of naturally occurring substances.</li><li>\u2022 Agonists</li><li>\u2022 compounds that bind to a receptor</li><li>\u2022 produce a full biological response</li><li>\u2022 Option B. Partial Agonists:</li><li>\u2022 Option B. Partial Agonists:</li><li>\u2022 Partial agonists can bind to and partially activate a receptor , but they do not produce as great a response as full agonists, even when binding to all available receptors . They have sub-maximum intrinsic activity and can act as a functional antagonist in the presence of a full agonist because they can reduce the overall response of the system.</li><li>\u2022 Partial agonists can bind to and partially activate a receptor , but they do not produce as great a response as full agonists, even when binding to all available receptors . They have sub-maximum intrinsic activity and can act as a functional antagonist in the presence of a full agonist because they can reduce the overall response of the system.</li><li>\u2022 Partial agonists</li><li>\u2022 bind to and partially activate a receptor</li><li>\u2022 not produce as great a response as full agonists,</li><li>\u2022 binding to all available receptors</li><li>\u2022 Option D. Inverse Agonists:</li><li>\u2022 Option D. Inverse Agonists:</li><li>\u2022 Inverse agonists bind to the same receptor as agonists but produce the opposite effect . They decrease the activity of the receptor below its basal level , thus exhibiting negative intrinsic activity. Inverse agonists can be useful when the goal is to reduce or inhibit an unwanted or pathological basal activity of a receptor.</li><li>\u2022 Inverse agonists bind to the same receptor as agonists but produce the opposite effect . They decrease the activity of the receptor below its basal level , thus exhibiting negative intrinsic activity. Inverse agonists can be useful when the goal is to reduce or inhibit an unwanted or pathological basal activity of a receptor.</li><li>\u2022 Inverse agonists bind to the same receptor as agonists</li><li>\u2022 produce the opposite effect</li><li>\u2022 decrease the activity of the receptor</li><li>\u2022 below its basal level</li><li>\u2022 exhibiting negative intrinsic activity.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 Agonists induce maximal receptor responses, partial agonists elicit sub-maximal responses, antagonists bind without causing activation and prevent agonist binding, and inverse agonists bind to the same receptor as agonists but exert an opposite effect, reducing receptor activity below basal levels.</li><li>\u27a4 Agonists induce maximal receptor responses, partial agonists elicit sub-maximal responses,</li><li>\u27a4 antagonists bind without causing activation</li><li>\u27a4 prevent agonist binding,</li><li>\u27a4 inverse agonists bind to the same receptor</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "3f1e59e1",
      "audio": ""
    },
    {
      "text": "A 32-year-old male is brought to the emergency department after ingesting an overdose of a medication. In order to enhance drug clearance, you consider the modification of urinary pH as a therapeutic measure. Knowing that manipulating the urinary pH can increase the excretion of certain drugs by altering their ionization state, which of the following drugs would not have its excretion increased by alkalinization of the urine?",
      "options": [
        {
          "label": "A",
          "text": "Aspirin",
          "correct": false
        },
        {
          "label": "B",
          "text": "Methotrexate",
          "correct": false
        },
        {
          "label": "C",
          "text": "Morphine",
          "correct": true
        },
        {
          "label": "D",
          "text": "Phenobarbitone",
          "correct": false
        }
      ],
      "correct_answer": "C. Morphine",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Morphine</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 Option A. Aspirin : Aspirin (acetylsalicylic acid) is an acidic drug . Alkalinizing the urine with agents such as sodium bicarbonate can enhance its ionization and excretion.</li><li>\u2022 Option A.</li><li>\u2022 Aspirin</li><li>\u2022 Aspirin</li><li>\u2022 acidic drug</li><li>\u2022 Option B. Methotrexate : This is also an acidic drug , and alkalinization of the urine will increase its ionization , decreasing reabsorption and increasing elimination.</li><li>\u2022 Option B.</li><li>\u2022 Methotrexate</li><li>\u2022 acidic drug</li><li>\u2022 alkalinization of the urine will increase its ionization</li><li>\u2022 Option D. Phenobarbitone : This is an acidic drug , and like aspirin and methotrexate , it is more ionized in alkaline urine, leading to increased excretion.</li><li>\u2022 Option D.</li><li>\u2022 Phenobarbitone</li><li>\u2022 acidic drug</li><li>\u2022 aspirin and methotrexate</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 In cases of drug overdose , urinary alkalinization is utilized to increase the excretion of acidic drugs by enhancing their ionization , which does not apply to basic drugs like morphine that are better excreted in acidic conditions. Remember, the drugs ending with \u2018ine\u2019 are basic.</li><li>\u27a4 drug overdose</li><li>\u27a4 urinary alkalinization</li><li>\u27a4 increase the excretion of acidic drugs</li><li>\u27a4 enhancing their ionization</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "fb3f780d",
      "audio": ""
    },
    {
      "text": "A newly approved drug has just been released onto the market for widespread use. What phase of clinical trials includes the ongoing observation for rare and long-term adverse effects after a drug is commercially available?",
      "options": [
        {
          "label": "A",
          "text": "Phase I",
          "correct": false
        },
        {
          "label": "B",
          "text": "Phase II",
          "correct": false
        },
        {
          "label": "C",
          "text": "Phase III",
          "correct": false
        },
        {
          "label": "D",
          "text": "Phase IV",
          "correct": true
        }
      ],
      "correct_answer": "D. Phase IV",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Phase IV</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Phase I : Incorrect. Phase I trials are initial safety trials conducted on a small group of healthy volunteers or patients.</li><li>\u2022 Option A.</li><li>\u2022 Phase I</li><li>\u2022 initial safety trials conducted on a small group</li><li>\u2022 Option B. Phase II : Incorrect. Phase II trials are conducted to assess the drug's efficacy and side effects in a larger group of people.</li><li>\u2022 Option B.</li><li>\u2022 Phase II</li><li>\u2022 conducted to assess the drug's efficacy</li><li>\u2022 Option C. Phase III : Incorrect. Phase III trials are larger studies that confirm a drug\u2019s effectiveness , monitor side effects, and compare it to commonly used treatments.</li><li>\u2022 Option C.</li><li>\u2022 Phase III</li><li>\u2022 larger studies that confirm a drug\u2019s effectiveness</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 Phase IV clinical trials , or post-marketing surveillance, are conducted after a drug is approved and marketed to monitor for rare and long-term adverse effects and to ensure ongoing evaluation of the drug's risk-benefit profile in the general population.</li><li>\u27a4 Phase IV clinical trials</li><li>\u27a4 post-marketing surveillance,</li><li>\u27a4 conducted after a drug is approved</li><li>\u27a4 marketed to monitor for rare</li><li>\u27a4 long-term adverse effects</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "4ee9735b",
      "audio": ""
    },
    {
      "text": "Which of the following best defines \u201cmetabolism\u201d of a drug?",
      "options": [
        {
          "label": "A",
          "text": "Metabolic conversion of drug molecules to more water-soluble metabolites that are more readily excreted",
          "correct": true
        },
        {
          "label": "B",
          "text": "Modification of the drug molecule via oxidation, reduction, or hydrolysis",
          "correct": false
        },
        {
          "label": "C",
          "text": "Conjugation with endogenous compounds via the activity of transferases",
          "correct": false
        },
        {
          "label": "D",
          "text": "Measure of the fraction ( F) of administered dose of a drug that reaches the systemic circulation in the unchanged form",
          "correct": false
        }
      ],
      "correct_answer": "A. Metabolic conversion of drug molecules to more water-soluble metabolites that are more readily excreted",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Metabolic conversion of drug molecules to more water-soluble metabolites that are more readily excreted</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Modification of the drug molecule via oxidation, reduction, or hydrolysis:</li><li>\u2022 Option B. Modification of the drug molecule via oxidation, reduction, or hydrolysis:</li><li>\u2022 These processes describe Phase I biotransformation reactions, where functional groups are introduced or unmasked in the drug molecule, often resulting in a slight increase in water solubility.</li><li>\u2022 These processes describe Phase I biotransformation reactions, where functional groups are introduced or unmasked in the drug molecule, often resulting in a slight increase in water solubility.</li><li>\u2022 processes</li><li>\u2022 Phase I biotransformation reactions,</li><li>\u2022 Option C. Conjugation with endogenous compounds via the activity of transferases:</li><li>\u2022 Option C. Conjugation with endogenous compounds via the activity of transferases:</li><li>\u2022 This pertains to Phase II biotransformation reactions, where the drug or its Phase I metabolites are conjugated with endogenous substrates like glucuronic acid, sulfate, glycine, etc., significantly increasing their water solubility for excretion.</li><li>\u2022 This pertains to Phase II biotransformation reactions, where the drug or its Phase I metabolites are conjugated with endogenous substrates like glucuronic acid, sulfate, glycine, etc., significantly increasing their water solubility for excretion.</li><li>\u2022 pertains to Phase II biotransformation reactions,</li><li>\u2022 drug</li><li>\u2022 Phase I metabolites are conjugated</li><li>\u2022 endogenous substrates</li><li>\u2022 glucuronic acid, sulfate, glycine,</li><li>\u2022 Option D. Measure of the fraction (F) of administered dose of a drug that reaches the systemic circulation in the unchanged form:</li><li>\u2022 Option D. Measure of the fraction (F) of administered dose of a drug that reaches the systemic circulation in the unchanged form:</li><li>\u2022 This defines bioavailability, which is not a metabolic process but a pharmacokinetic parameter indicating the extent and rate at which the active moiety enters systemic circulation, reaching the site of action.</li><li>\u2022 This defines bioavailability, which is not a metabolic process but a pharmacokinetic parameter indicating the extent and rate at which the active moiety enters systemic circulation, reaching the site of action.</li><li>\u2022 bioavailability,</li><li>\u2022 not a metabolic process</li><li>\u2022 pharmacokinetic parameter</li><li>\u2022 extent and rate</li><li>\u2022 active moiety enters systemic circulation,</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 Drug metabolism encompasses the biochemical modification of pharmaceutical substances within the body to compounds that are easier to eliminate, typically through conversion to water-soluble metabolites via Phase I and Phase II reactions, and is distinct from bioavailability, which measures systemic drug availability.</li><li>\u27a4 Drug metabolism encompasses the biochemical modification</li><li>\u27a4 pharmaceutical substances</li><li>\u27a4 body to compounds</li><li>\u27a4 easier to eliminate,</li><li>\u27a4 conversion to water-soluble metabolites</li><li>\u27a4 Phase I and Phase II reactions,</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "b68a89a6",
      "audio": ""
    },
    {
      "text": "Identify the correct nature of drug B from the graph shown below?",
      "options": [
        {
          "label": "A",
          "text": "Competitive inhibitor",
          "correct": true
        },
        {
          "label": "B",
          "text": "Allosteric activator",
          "correct": false
        },
        {
          "label": "C",
          "text": "Allosteric inhibitor",
          "correct": false
        },
        {
          "label": "D",
          "text": "Inverse agonist",
          "correct": false
        }
      ],
      "correct_answer": "A. Competitive inhibitor",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/08/24/20.jpg"
      ],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Competitive inhibitor</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Allosteric activator:</li><li>\u2022 Option B. Allosteric activator:</li><li>\u2022 An allosteric activator binds to a different site than the active site on the receptor and enhances the effect of the drug . The graph shows that when drug A is combined with substance C, the efficacy of drug A is increased (higher maximum response), which suggests that C is an allosteric activator.</li><li>\u2022 An allosteric activator binds to a different site than the active site on the receptor and enhances the effect of the drug . The graph shows that when drug A is combined with substance C, the efficacy of drug A is increased (higher maximum response), which suggests that C is an allosteric activator.</li><li>\u2022 allosteric activator binds to a different site</li><li>\u2022 active site on the receptor</li><li>\u2022 enhances the effect of the drug</li><li>\u2022 graph</li><li>\u2022 drug A is combined with substance C,</li><li>\u2022 efficacy of drug A is increased</li><li>\u2022 Option C. Allosteric inhibitor:</li><li>\u2022 Option C. Allosteric inhibitor:</li><li>\u2022 An allosteric inhibitor also binds to a different site from the active site and decreases the effect of the drug . However, none of the interactions shown in the graph suggest a decrease in efficacy or a change in the maximal effect characteristic of allosteric inhibition.</li><li>\u2022 An allosteric inhibitor also binds to a different site from the active site and decreases the effect of the drug . However, none of the interactions shown in the graph suggest a decrease in efficacy or a change in the maximal effect characteristic of allosteric inhibition.</li><li>\u2022 allosteric inhibitor</li><li>\u2022 binds to a different site</li><li>\u2022 active site and decreases the effect of the drug</li><li>\u2022 Option D. Inverse agonist:</li><li>\u2022 Option D. Inverse agonist:</li><li>\u2022 An inverse agonist would bind to the same receptor as an agonist but would produce the opposite effect , causing a negative response below the baseline level of activity . The graph does not depict this kind of interaction.</li><li>\u2022 An inverse agonist would bind to the same receptor as an agonist but would produce the opposite effect , causing a negative response below the baseline level of activity . The graph does not depict this kind of interaction.</li><li>\u2022 inverse agonist</li><li>\u2022 bind to the same receptor</li><li>\u2022 agonist but would produce the opposite effect</li><li>\u2022 negative response below the baseline level of activity</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 The presence of a competitive inhibitor is indicated by a rightward, parallel shift in the dose-response curve, which implies that the inhibitor is competing with the primary drug for the same binding site, thereby increasing the dose of the drug needed to achieve the same effect.</li><li>\u27a4 presence of a competitive inhibitor</li><li>\u27a4 rightward, parallel shift in the dose-response curve,</li><li>\u27a4 inhibitor</li><li>\u27a4 competing with the primary drug</li><li>\u27a4 same binding site,</li><li>\u27a4 increasing the dose of the drug</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "a0c165a7",
      "audio": ""
    },
    {
      "text": "Match the following drugs/ligands with their appropriate transmembrane signaling mechanisms as shown in the image?",
      "options": [
        {
          "label": "A",
          "text": "A-4, B-5, C-3, D-2",
          "correct": false
        },
        {
          "label": "B",
          "text": "A-4, B-1, C-5, D-3",
          "correct": false
        },
        {
          "label": "C",
          "text": "A-2, B-4, C-3, D-5",
          "correct": false
        },
        {
          "label": "D",
          "text": "A-4, B-1, C-3, D-5",
          "correct": true
        }
      ],
      "correct_answer": "D. A-4, B-1, C-3, D-5",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/08/24/21.jpg",
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/10/screenshot-2024-05-10-181327.png"
      ],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) A-4, B-1, C-3, D-5</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A: Barbiturates</li><li>\u2022 Option A: Barbiturates</li><li>\u2022 Barbiturates bind to and modulate the GABA-A receptor, which is an ionotropic receptor (as indicated by label 4 in the image). This type of receptor allows for the influx of chloride ions into the neuron when activated, leading to hyperpolarization and decreased neuron excitability.</li><li>\u2022 Barbiturates bind to and modulate the GABA-A receptor, which is an ionotropic receptor (as indicated by label 4 in the image). This type of receptor allows for the influx of chloride ions into the neuron when activated, leading to hyperpolarization and decreased neuron excitability.</li><li>\u2022 Barbiturates bind</li><li>\u2022 modulate the GABA-A receptor,</li><li>\u2022 ionotropic receptor</li><li>\u2022 receptor allows for the influx of chloride ions</li><li>\u2022 neuron when activated,</li><li>\u2022 Option B: Aldosterone</li><li>\u2022 Option B: Aldosterone</li><li>\u2022 Aldosterone interacts with intracellular nuclear hormone receptors (as indicated by label 1 in the image). As a steroid hormone, it is lipid-soluble and can cross the cell membrane to directly regulate gene expression.</li><li>\u2022 Aldosterone interacts with intracellular nuclear hormone receptors (as indicated by label 1 in the image). As a steroid hormone, it is lipid-soluble and can cross the cell membrane to directly regulate gene expression.</li><li>\u2022 Aldosterone interacts</li><li>\u2022 intracellular nuclear hormone receptors</li><li>\u2022 Option C: Insulin</li><li>\u2022 Option C: Insulin</li><li>\u2022 Insulin acts through enzymatic receptors that have intrinsic tyrosine kinase activity (as indicated by label 3 in the image). Upon binding insulin, these receptors autophosphorylate and initiate a cascade of downstream signaling events.</li><li>\u2022 Insulin acts through enzymatic receptors that have intrinsic tyrosine kinase activity (as indicated by label 3 in the image). Upon binding insulin, these receptors autophosphorylate and initiate a cascade of downstream signaling events.</li><li>\u2022 Insulin</li><li>\u2022 enzymatic receptors</li><li>\u2022 intrinsic tyrosine kinase activity</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 Barbiturates (A) correspond to 4 (ionotropic receptors). Aldosterone (B) corresponds to 1 (intracellular receptors). Insulin (C) corresponds to 3 (enzymatic receptors with intrinsic tyrosine kinase activity). Epinephrine (D) corresponds to 5 (G-protein coupled receptors).</li><li>\u27a4 Barbiturates (A) correspond to 4 (ionotropic receptors).</li><li>\u27a4 Aldosterone (B) corresponds to 1 (intracellular receptors).</li><li>\u27a4 Insulin (C) corresponds to 3 (enzymatic receptors with intrinsic tyrosine kinase activity).</li><li>\u27a4 Epinephrine (D) corresponds to 5 (G-protein coupled receptors).</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "0c8c3035",
      "audio": ""
    },
    {
      "text": "A new drug X is a weakly acidic drug with a pKa of 6.5. If administered orally, at which of the following sites of absorption will the drug be able to readily pass through the membrane?",
      "options": [
        {
          "label": "A",
          "text": "Mouth (pH approximately 7.0)",
          "correct": false
        },
        {
          "label": "B",
          "text": "Stomach (pH of 2.5)",
          "correct": true
        },
        {
          "label": "C",
          "text": "Duodenum (pH approximately 6.1)",
          "correct": false
        },
        {
          "label": "D",
          "text": "Jejunum (pH approximately 8.0)",
          "correct": false
        }
      ],
      "correct_answer": "B. Stomach (pH of 2.5)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Stomach (pH of 2.5)</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Mouth (pH approximately 7.0): At this pH, the drug will be slightly more ionized than at its pKa, but still close to the pKa. Therefore, a significant proportion of the drug will be in its ionized, more water-soluble form, which cannot be absorbed easily.</li><li>\u2022 Option A.</li><li>\u2022 Mouth (pH approximately 7.0):</li><li>\u2022 drug will be slightly more ionized than at its pKa,</li><li>\u2022 Option C. Duodenum (pH approximately 6.1): The pH is slightly below the pKa. At this pH, some drug will be in its unionized form, facilitating good absorption, however a significant proprotional is still in ionized water soluble form.</li><li>\u2022 Option C.</li><li>\u2022 Duodenum (pH approximately 6.1):</li><li>\u2022 pH is slightly below the pKa.</li><li>\u2022 Option D. Jejunum (pH approximately 8.0): At this pH, which is significantly higher than the drug's pKa, the drug will be mostly in its ionized form . Ionized drugs are less lipid-soluble and have a harder time passing through lipid membranes, making this a less favorable site for absorption of a weakly acidic drug.</li><li>\u2022 Option D.</li><li>\u2022 Jejunum (pH approximately 8.0):</li><li>\u2022 higher than the drug's pKa,</li><li>\u2022 drug will be mostly in its ionized form</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 The most favorable site for absorption of Drug X would be in environments where the pH is lower than the drug's pKa, making the stomach the appropriate answer.</li><li>\u2022 most favorable site for absorption of Drug X</li><li>\u2022 environments</li><li>\u2022 pH is lower than the drug's pKa,</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "8928bd24",
      "audio": ""
    },
    {
      "text": "If 10 mg of naproxen produces the same analgesic response as 100 mg of ibuprofen, which of the following statements is correct?",
      "options": [
        {
          "label": "A",
          "text": "Naproxen is more efficacious than ibuprofen",
          "correct": false
        },
        {
          "label": "B",
          "text": "Naproxen is more potent than ibuprofen",
          "correct": true
        },
        {
          "label": "C",
          "text": "Naproxen is a full agonist, and ibuprofen is a partial agonist",
          "correct": false
        },
        {
          "label": "D",
          "text": "Naproxen is a better drug to take for pain relief than ibuprofen",
          "correct": false
        }
      ],
      "correct_answer": "B. Naproxen is more potent than ibuprofen",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Naproxen is more potent than ibuprofen</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Naproxen is more efficacious than ibuprofen:</li><li>\u2022 Option A. Naproxen is more efficacious than ibuprofen:</li><li>\u2022 Efficacy refers to the maximum effect a drug can produce . Since the statement is comparing equal analgesic responses and not the maximum possible effects, we cannot determine efficacy from the given information.</li><li>\u2022 Efficacy refers to the maximum effect a drug can produce . Since the statement is comparing equal analgesic responses and not the maximum possible effects, we cannot determine efficacy from the given information.</li><li>\u2022 Efficacy</li><li>\u2022 maximum effect a drug can produce</li><li>\u2022 Option C. Naproxen is a full agonist, and ibuprofen is a partial agonist:</li><li>\u2022 Option C. Naproxen is a full agonist, and ibuprofen is a partial agonist:</li><li>\u2022 Agonism relates to the ability of a drug to activate a receptor and produce a cellular response . Both naproxen and ibuprofen are full agonists at their respective targets, and their classification as full or partial agonists is not related to their potency or efficacy.</li><li>\u2022 Agonism relates to the ability of a drug to activate a receptor and produce a cellular response . Both naproxen and ibuprofen are full agonists at their respective targets, and their classification as full or partial agonists is not related to their potency or efficacy.</li><li>\u2022 Agonism</li><li>\u2022 ability of a drug to activate a receptor and produce a cellular response</li><li>\u2022 Option D. Naproxen is a better drug to take for pain relief than ibuprofen:</li><li>\u2022 Option D. Naproxen is a better drug to take for pain relief than ibuprofen:</li><li>\u2022 The \"better\" drug for pain relief depends on various factors , including efficacy, side effect profile , patient-specific factors , and more. Potency alone does not determine the overall appropriateness of a drug for pain relief.</li><li>\u2022 The \"better\" drug for pain relief depends on various factors , including efficacy, side effect profile , patient-specific factors , and more. Potency alone does not determine the overall appropriateness of a drug for pain relief.</li><li>\u2022 \"better\" drug for pain relief</li><li>\u2022 various factors</li><li>\u2022 efficacy, side effect profile</li><li>\u2022 patient-specific factors</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 Potency is determined by the amount of drug needed to produce a given effect , with more potent drugs requiring lower doses to achieve the same effect as compared with less potent drugs.</li><li>\u27a4 Potency</li><li>\u27a4 amount of drug needed to produce a given effect</li><li>\u27a4 more potent drugs</li><li>\u27a4 lower doses</li><li>\u27a4 same effect</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "ab1d4f62",
      "audio": ""
    },
    {
      "text": "Which of the following drugs should be sold only on prescription of a registered medical practitioner?",
      "options": [
        {
          "label": "A",
          "text": "Schedule H drugs",
          "correct": true
        },
        {
          "label": "B",
          "text": "Schedule X drugs",
          "correct": false
        },
        {
          "label": "C",
          "text": "Schedule J drugs",
          "correct": false
        },
        {
          "label": "D",
          "text": "Schedule Y drugs",
          "correct": false
        }
      ],
      "correct_answer": "A. Schedule H drugs",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Schedule H drugs</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B: Schedule X gives the names of psychotropic drugs requiring special licenses for manufacturing and sale .</li><li>\u2022 Option B:</li><li>\u2022 Schedule X</li><li>\u2022 names of psychotropic drugs</li><li>\u2022 special licenses</li><li>\u2022 manufacturing and sale</li><li>\u2022 Option C : Schedule J deals with a list of ailments for which no drugs claim prevention or cure.</li><li>\u2022 Option C</li><li>\u2022 Schedule J</li><li>\u2022 list of ailments</li><li>\u2022 no drugs claim prevention</li><li>\u2022 Option D: Schedule Y specifies requirements and guidelines on clinical trials , import and manufacture of new drugs.</li><li>\u2022 Option D:</li><li>\u2022 Schedule Y</li><li>\u2022 requirements and guidelines on clinical trials</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 Schedule H drugs , as defined by the Drugs and Cosmetics Act , 1940 and Rules , 1945 , are medications that require a prescription from a registered medical practitioner for their sale due to potential risk of misuse and safety concerns .</li><li>\u27a4 Schedule H drugs</li><li>\u27a4 Drugs and Cosmetics Act</li><li>\u27a4 1940 and Rules</li><li>\u27a4 1945</li><li>\u27a4 medications that require a prescription</li><li>\u27a4 registered medical practitioner</li><li>\u27a4 sale due to potential risk of misuse</li><li>\u27a4 safety concerns</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "896317bb",
      "audio": ""
    },
    {
      "text": "The volume of distribution of a drug is 500 mL and target plasma concentration of drug required is 5 g/L. If 20% of orally administered drug reaches systemic circulation, what will be the oral loading dose of this drug?",
      "options": [
        {
          "label": "A",
          "text": "1g",
          "correct": false
        },
        {
          "label": "B",
          "text": "5g",
          "correct": false
        },
        {
          "label": "C",
          "text": "12.5g",
          "correct": true
        },
        {
          "label": "D",
          "text": "25g",
          "correct": false
        }
      ],
      "correct_answer": "C. 12.5g",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans.\u00a0C) 125g</strong></p>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 To calculate the oral loading dose of a drug , multiply the desired plasma concentration by the volume of distribution and adjust for the drug's oral bioavailability.</li><li>\u27a4 calculate the oral loading dose of a drug</li><li>\u27a4 multiply</li><li>\u27a4 plasma concentration</li><li>\u27a4 volume of distribution</li><li>\u27a4 adjust for the drug's oral bioavailability.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "a983173d",
      "audio": ""
    },
    {
      "text": "Log DRC of four drugs is shown in the given diagram. Which of the following statements is correct about these drugs?",
      "options": [
        {
          "label": "A",
          "text": "Drug B is the most efficacious",
          "correct": false
        },
        {
          "label": "B",
          "text": "Drug A and C are equipotent",
          "correct": false
        },
        {
          "label": "C",
          "text": "Drug B is more efficacious and less potent than drug A",
          "correct": false
        },
        {
          "label": "D",
          "text": "Drug A and C are Equi efficacious",
          "correct": true
        }
      ],
      "correct_answer": "D. Drug A and C are Equi efficacious",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/08/24/9.jpg"
      ],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Drug A and C are Equi efficacious</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 Drug B reaches the lowest maximum effect , which means it is the least efficacious . However, its curve starts to rise at the lowest dose , which indicates it is the most potent. Drug A and Drug C : Both these drugs reach the same maximum effect , which means they are equi efficacious . However, Drug A reaches its half-maximal effect at a lower dose than Drug C, indicating that Drug A is more potent. Drug D : The curve for Drug D is positioned the furthest to the right , which means it is the least potent , as it requires a higher dose to produce its effect . However, it reaches the same maximum effect as Drugs A and C, indicating it is equi efficacious to them.</li><li>\u2022 Drug B reaches the lowest maximum effect , which means it is the least efficacious . However, its curve starts to rise at the lowest dose , which indicates it is the most potent.</li><li>\u2022 Drug B</li><li>\u2022 lowest maximum effect</li><li>\u2022 least efficacious</li><li>\u2022 curve starts to rise at the lowest dose</li><li>\u2022 Drug A and Drug C : Both these drugs reach the same maximum effect , which means they are equi efficacious . However, Drug A reaches its half-maximal effect at a lower dose than Drug C, indicating that Drug A is more potent.</li><li>\u2022 Drug A and Drug C</li><li>\u2022 drugs reach the same maximum effect</li><li>\u2022 equi efficacious</li><li>\u2022 Drug D : The curve for Drug D is positioned the furthest to the right , which means it is the least potent , as it requires a higher dose to produce its effect . However, it reaches the same maximum effect as Drugs A and C, indicating it is equi efficacious to them.</li><li>\u2022 Drug D</li><li>\u2022 positioned the furthest to the right</li><li>\u2022 least potent</li><li>\u2022 requires a higher dose to produce its effect</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 The efficacy of a drug is determined by the height of its curve on the y-axis , and potency is assessed by the position of the curve along the x-axis . Drugs A and C are equally efficacious but differ in potency, with Drug A being more potent than Drug C.</li><li>\u27a4 efficacy of a drug</li><li>\u27a4 height of its curve on the y-axis</li><li>\u27a4 potency is assessed by the position of the curve along the x-axis</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "3f235cf6",
      "audio": ""
    },
    {
      "text": "A 59-year-old man with a history of chronic obstructive pulmonary disease (COPD) and hypertension is being managed in an outpatient clinic. He has been prescribed a nonselective beta-blocker to manage his hypertension. Based on the receptor shown in the figure, which of the following drugs prescribed to the patient acts through this type of receptor?",
      "options": [
        {
          "label": "A",
          "text": "Glucocorticoids",
          "correct": false
        },
        {
          "label": "B",
          "text": "Estrogen",
          "correct": false
        },
        {
          "label": "C",
          "text": "Propranolol",
          "correct": true
        },
        {
          "label": "D",
          "text": "Nicotine",
          "correct": false
        }
      ],
      "correct_answer": "C. Propranolol",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/08/24/7_ybtpG0K.jpg"
      ],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Propranolol</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Glucocorticoids: Act through cytoplasmic receptors that, upon activation , translocate to the nucleus to affect gene transcription .</li><li>\u2022 Option A.</li><li>\u2022 Glucocorticoids:</li><li>\u2022 cytoplasmic receptors</li><li>\u2022 upon activation</li><li>\u2022 translocate to the nucleus</li><li>\u2022 affect gene transcription</li><li>\u2022 Option B. Estrogen: Binds to nuclear receptors which directly interact with DNA to regulate gene expression .</li><li>\u2022 Option B.</li><li>\u2022 Estrogen: Binds to nuclear receptors</li><li>\u2022 directly interact with DNA to regulate gene expression</li><li>\u2022 Option D . Nicotine: Primarily acts through nicotinic acetylcholine receptors , which are ionotropic receptors, not GPCRs.</li><li>\u2022 Option D</li><li>\u2022 Nicotine:</li><li>\u2022 nicotinic acetylcholine receptors</li><li>\u2022 ionotropic receptors,</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 Propranolol acts via G-protein coupled receptors , which are characterized by their seven-transmembrane domain structure .</li><li>\u27a4 Propranolol acts via G-protein coupled receptors</li><li>\u27a4 seven-transmembrane domain structure</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "25dde080",
      "audio": ""
    },
    {
      "text": "The microsomal enzyme involved in the metabolism of clopidogrel, and proton pump inhibitors is?",
      "options": [
        {
          "label": "A",
          "text": "CYP 1E6",
          "correct": false
        },
        {
          "label": "B",
          "text": "CYP2D6",
          "correct": false
        },
        {
          "label": "C",
          "text": "CYP2C19",
          "correct": true
        },
        {
          "label": "D",
          "text": "CYP 2C9",
          "correct": false
        }
      ],
      "correct_answer": "C. CYP2C19",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) CYP2C19</strong></p>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 The metabolism of clopidogrel and proton pump inhibitors primarily involves the CYP2C19 enzyme , and inhibitors of this enzyme can reduce the activation and efficacy of clopidogrel .</li><li>\u27a4 metabolism of clopidogrel</li><li>\u27a4 proton pump inhibitors</li><li>\u27a4 involves the CYP2C19 enzyme</li><li>\u27a4 inhibitors of this enzyme</li><li>\u27a4 reduce the activation</li><li>\u27a4 efficacy of clopidogrel</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "3c1ae948",
      "audio": ""
    },
    {
      "text": "A 30-year-old female with chronic pain is prescribed a new medication and advised to monitor its effects closely. She was educated on the pharmacokinetic profile of the medication using a plasma concentration versus time graph. Which of the following gives the rate of drug absorption in plasma concentration vs time graphs?",
      "options": [
        {
          "label": "A",
          "text": "Tmax",
          "correct": true
        },
        {
          "label": "B",
          "text": "Half life",
          "correct": false
        },
        {
          "label": "C",
          "text": "Area under the curve",
          "correct": false
        },
        {
          "label": "D",
          "text": "None",
          "correct": false
        }
      ],
      "correct_answer": "A. Tmax",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/10/screenshot-2024-05-10-154446.png"
      ],
      "explanation": "<p><strong>Ans.\u00a0A) Tmax</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Half-life : Incorrect. The half-life of a drug is the time required for the plasma concentration of the drug to reduce to half its maximum value , indicating the rate of drug elimination rather than absorption.</li><li>\u2022 Option B.</li><li>\u2022 Half-life</li><li>\u2022 half-life</li><li>\u2022 drug is the time required</li><li>\u2022 plasma concentration of the drug</li><li>\u2022 reduce to half</li><li>\u2022 maximum value</li><li>\u2022 Option C. Area under the curve (AUC) : Incorrect. The AUC represents the drug\u2019s total exposure over time and is related to the extent of drug absorption , not the rate.</li><li>\u2022 Option C.</li><li>\u2022 Area under the curve (AUC)</li><li>\u2022 AUC</li><li>\u2022 drug\u2019s total exposure over time</li><li>\u2022 extent of drug absorption</li><li>\u2022 Option D. None : Incorrect. Tmax is indeed a parameter that gives information about the rate of drug absorption .</li><li>\u2022 Option D.</li><li>\u2022 None</li><li>\u2022 Tmax</li><li>\u2022 parameter that gives information</li><li>\u2022 rate of drug absorption</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 Tmax on a plasma concentration versus time graph provides information about the rate of absorption of a drug , with a shorter Tmax indicating faster absorption .</li><li>\u27a4 Tmax</li><li>\u27a4 plasma concentration versus time graph</li><li>\u27a4 information about the rate of absorption of a drug</li><li>\u27a4 shorter Tmax</li><li>\u27a4 faster absorption</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "bf7f71ec",
      "audio": ""
    },
    {
      "text": "A 40-year-old male patient (70 kg) was recently diagnosed with infection involving methicillin-resistant S. aureus . He received 2000 mg of vancomycin as an IV loading dose. The peak plasma concentration of vancomycin was reported to be 28.5 mg/L. The apparent volume of distribution is:",
      "options": [
        {
          "label": "A",
          "text": "1 L/kg",
          "correct": true
        },
        {
          "label": "B",
          "text": "10 L/kg",
          "correct": false
        },
        {
          "label": "C",
          "text": "7 L/kg",
          "correct": false
        },
        {
          "label": "D",
          "text": "70 L/kg",
          "correct": false
        }
      ],
      "correct_answer": "A. 1 L/kg",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) 1 L/kg</strong></p>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 The volume of distribution (Vd) of a drug is calculated by dividing the loading dose by the peak plasma concentration and is expressed in relation to the patient's body weight to obtain the Vd in L/kg.</li><li>\u27a4 volume of distribution</li><li>\u27a4 calculated by dividing the loading dose</li><li>\u27a4 peak plasma concentration</li><li>\u27a4 expressed in relation</li><li>\u27a4 patient's body weight</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "ece9ccd1",
      "audio": ""
    },
    {
      "text": "Which is the true statement regarding pharmacokinetics?",
      "options": [
        {
          "label": "A",
          "text": "Loading dose depends upon half-life of drug",
          "correct": false
        },
        {
          "label": "B",
          "text": "Highly ionized drugs will have low volume of distribution",
          "correct": true
        },
        {
          "label": "C",
          "text": "Cytochrome oxidase enzyme is involved in drug metabolism",
          "correct": false
        },
        {
          "label": "D",
          "text": "Diazepam is the pro-drug",
          "correct": false
        }
      ],
      "correct_answer": "B. Highly ionized drugs will have low volume of distribution",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Highly ionized drugs will have low volume of distribution</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Loading dose depends upon half-life of drug:</li><li>\u2022 Option A. Loading dose depends upon half-life of drug:</li><li>\u2022 This statement is incorrect. The loading dose of a drug is determined by the desired plasma concentration and the volume of distribution , not the half-life. The half-life is more closely related to the maintenance dose and dosing frequency.</li><li>\u2022 This statement is incorrect. The loading dose of a drug is determined by the desired plasma concentration and the volume of distribution , not the half-life. The half-life is more closely related to the maintenance dose and dosing frequency.</li><li>\u2022 loading dose of a drug</li><li>\u2022 desired plasma concentration</li><li>\u2022 volume of distribution</li><li>\u2022 Option C. Cytochrome oxidase enzyme is involved in drug metabolism:</li><li>\u2022 Option C. Cytochrome oxidase enzyme is involved in drug metabolism:</li><li>\u2022 This statement is incorrect. The correct term is cytochrome P450 oxidase enzymes (often simply referred to as cytochrome P450 or CYP450). These are the enzymes most commonly involved in drug metabolism, particularly phase I reactions. Cytochrome oxidase , on the other hand, refers to a different group of enzymes that are part of the electron transport chain in mitochondria.</li><li>\u2022 This statement is incorrect. The correct term is cytochrome P450 oxidase enzymes (often simply referred to as cytochrome P450 or CYP450). These are the enzymes most commonly involved in drug metabolism, particularly phase I reactions. Cytochrome oxidase , on the other hand, refers to a different group of enzymes that are part of the electron transport chain in mitochondria.</li><li>\u2022 cytochrome P450 oxidase enzymes</li><li>\u2022 enzymes most commonly involved in drug metabolism,</li><li>\u2022 phase I reactions. Cytochrome oxidase</li><li>\u2022 different group of enzymes</li><li>\u2022 part of the electron transport chain in mitochondria.</li><li>\u2022 Option D. Diazepam is a pro-drug:</li><li>\u2022 Option D. Diazepam is a pro-drug:</li><li>\u2022 This statement is incorrect. Diazepam is not a pro-drug; it is an active drug. A pro-drug is an inactive compound that becomes active only after it is metabolized in the body. Diazepam, in contrast, is an active benzodiazepine and does not require metabolic conversion to elicit its pharmacological effect.</li><li>\u2022 This statement is incorrect. Diazepam is not a pro-drug; it is an active drug. A pro-drug is an inactive compound that becomes active only after it is metabolized in the body. Diazepam, in contrast, is an active benzodiazepine and does not require metabolic conversion to elicit its pharmacological effect.</li><li>\u2022 Diazepam is not a pro-drug;</li><li>\u2022 active drug.</li><li>\u2022 pro-drug is an inactive compound</li><li>\u2022 active only after it is metabolized in the body.</li><li>\u2022 Based on the above evaluations, the true statement regarding pharmacokinetics is: B. Highly ionized drugs will have low volume of distribution.</li><li>\u2022 B. Highly ionized drugs will have low volume of distribution.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 The volume of distribution of a drug is influenced by its ionization state, with highly ionized drugs typically having a low volume of distribution as they are less likely to penetrate cellular membranes and distribute into the body's tissues.</li><li>\u27a4 volume of distribution of a drug</li><li>\u27a4 influenced by its ionization state,</li><li>\u27a4 highly ionized drugs</li><li>\u27a4 low volume of distribution</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "d254db4b",
      "audio": ""
    },
    {
      "text": "Following are the criteria for Essential drugs EXCEPT?",
      "options": [
        {
          "label": "A",
          "text": "Satisfy priority health care needs of population",
          "correct": false
        },
        {
          "label": "B",
          "text": "Cost effective",
          "correct": false
        },
        {
          "label": "C",
          "text": "Should be available as a combination",
          "correct": true
        },
        {
          "label": "D",
          "text": "Available in all doses and formulations",
          "correct": false
        }
      ],
      "correct_answer": "C. Should be available as a combination",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Should be available as a combination</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Satisfy priority health care needs of the population:</li><li>\u2022 Option A. Satisfy priority health care needs of the population:</li><li>\u2022 This is a core criterion for Essential Medicines. These drugs are chosen because they meet the most important healthcare needs of the majority of the population. They are selected based on the disease prevalence and public health importance.</li><li>\u2022 This is a core criterion for Essential Medicines. These drugs are chosen because they meet the most important healthcare needs of the majority of the population. They are selected based on the disease prevalence and public health importance.</li><li>\u2022 core criterion for Essential Medicines.</li><li>\u2022 Option B. Cost-effective:</li><li>\u2022 Option B. Cost-effective:</li><li>\u2022 Essential Medicines should be cost-effective, meaning they provide the best health benefits at the lowest cost . This does not mean they are always the cheapest available, but that their cost is justifiable by the level of benefit they provide in the context of the health system's overall budget.</li><li>\u2022 Essential Medicines should be cost-effective, meaning they provide the best health benefits at the lowest cost . This does not mean they are always the cheapest available, but that their cost is justifiable by the level of benefit they provide in the context of the health system's overall budget.</li><li>\u2022 Essential Medicines</li><li>\u2022 cost-effective,</li><li>\u2022 provide the best health benefits at the lowest cost</li><li>\u2022 Option D. Available in all doses and formulations:</li><li>\u2022 Option D. Available in all doses and formulations:</li><li>\u2022 Essential Medicines should be available in appropriate formulations that suit all age groups and populations, taking into account different dosage forms like tablets, syrups, or injectables to ensure that everyone who needs the medicine can receive it in a form that is effective and usable.</li><li>\u2022 Essential Medicines should be available in appropriate formulations that suit all age groups and populations, taking into account different dosage forms like tablets, syrups, or injectables to ensure that everyone who needs the medicine can receive it in a form that is effective and usable.</li><li>\u2022 Essential Medicines</li><li>\u2022 available in appropriate formulations</li><li>\u2022 age groups and populations,</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 Essential Medicines should address the priority health care needs, be cost-effective , and be available in appropriate formulations for the entire population, with a preference for single compounds over combinations unless there is a clear rationale for the latter.</li><li>\u27a4 Essential Medicines</li><li>\u27a4 address the priority health care needs,</li><li>\u27a4 cost-effective</li><li>\u27a4 available in appropriate formulations for the entire population,</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "a18f4bae",
      "audio": ""
    },
    {
      "text": "All the following are advantages of enteric coated tablets except:",
      "options": [
        {
          "label": "A",
          "text": "To prolong half-life of drug",
          "correct": true
        },
        {
          "label": "B",
          "text": "To protect the acid labile drugs from acid secretion",
          "correct": false
        },
        {
          "label": "C",
          "text": "To protect stomach from irritant effects of drug",
          "correct": false
        },
        {
          "label": "D",
          "text": "To increase the absorption of drugs preferentially absorbed distal to stomach",
          "correct": false
        }
      ],
      "correct_answer": "A. To prolong half-life of drug",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) To prolong half-life of drug</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. To protect acid-labile drugs from acid secretion:</li><li>\u2022 Option B. To protect acid-labile drugs from acid secretion:</li><li>\u2022 Correct . Acid-labile drugs are those that are unstable and can be destroyed by stomach acid. Enteric coatings resist the acidic environment of the stomach and dissolve in the higher pH of the intestine, thus protecting these drugs until they reach a more neutral pH environment where they can be absorbed without being degraded.</li><li>\u2022 Correct . Acid-labile drugs are those that are unstable and can be destroyed by stomach acid. Enteric coatings resist the acidic environment of the stomach and dissolve in the higher pH of the intestine, thus protecting these drugs until they reach a more neutral pH environment where they can be absorbed without being degraded.</li><li>\u2022 Correct</li><li>\u2022 Option C. To protect the stomach from irritant effects of the drug:</li><li>\u2022 Option C. To protect the stomach from irritant effects of the drug:</li><li>\u2022 Correct. Some drugs can irritate the stomach lining. An enteric coating prevents the drug from being released in the stomach, thus reducing the risk of gastric irritation or ulceration.</li><li>\u2022 Correct. Some drugs can irritate the stomach lining. An enteric coating prevents the drug from being released in the stomach, thus reducing the risk of gastric irritation or ulceration.</li><li>\u2022 Correct.</li><li>\u2022 Option D. To increase the absorption of drugs preferentially absorbed distal to the stomach:</li><li>\u2022 Option D. To increase the absorption of drugs preferentially absorbed distal to the stomach:</li><li>\u2022 Correct. Drugs that are absorbed better in the intestine than in the stomach can benefit from enteric coating, which ensures that the drug bypasses the stomach and dissolves at the intended site of absorption.</li><li>\u2022 Correct. Drugs that are absorbed better in the intestine than in the stomach can benefit from enteric coating, which ensures that the drug bypasses the stomach and dissolves at the intended site of absorption.</li><li>\u2022 Correct.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 The primary advantages of enteric-coated tablets are to protect acid-labile drugs from gastric acid , prevent gastric irritation by the drug, and ensure drug release in the intestines; however, they do not affect the drug's half-life.</li><li>\u27a4 protect acid-labile drugs</li><li>\u27a4 gastric acid</li><li>\u27a4 prevent gastric irritation</li><li>\u27a4 ensure drug release in the intestines;</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "454b2cab",
      "audio": ""
    },
    {
      "text": "A Patient is taking rosuvastatin for dyslipidemia. Which of these drugs should be avoided in this patient?",
      "options": [
        {
          "label": "A",
          "text": "Clarithromycin",
          "correct": true
        },
        {
          "label": "B",
          "text": "Oxycodone",
          "correct": false
        },
        {
          "label": "C",
          "text": "Rivaroxaban",
          "correct": false
        },
        {
          "label": "D",
          "text": "Adalimumab",
          "correct": false
        }
      ],
      "correct_answer": "A. Clarithromycin",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Clarithromycin</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Oxycodone:</li><li>\u2022 Option B. Oxycodone:</li><li>\u2022 Oxycodone is an opioid analgesic. While opioids can be associated with various side effects, they do not significantly interact with the metabolism of statins like rosuvastatin.</li><li>\u2022 Oxycodone is an opioid analgesic. While opioids can be associated with various side effects, they do not significantly interact with the metabolism of statins like rosuvastatin.</li><li>\u2022 Oxycodone</li><li>\u2022 opioid analgesic.</li><li>\u2022 Option C. Rivaroxaban:</li><li>\u2022 Option C. Rivaroxaban:</li><li>\u2022 Rivaroxaban is an anticoagulant that works as a direct factor Xa inhibitor. It does not have a known interaction with rosuvastatin that would contraindicate their concurrent use.</li><li>\u2022 Rivaroxaban is an anticoagulant that works as a direct factor Xa inhibitor. It does not have a known interaction with rosuvastatin that would contraindicate their concurrent use.</li><li>\u2022 Rivaroxaban</li><li>\u2022 anticoagulant</li><li>\u2022 direct factor Xa inhibitor.</li><li>\u2022 Option D. Adalimumab:</li><li>\u2022 Option D. Adalimumab:</li><li>\u2022 Adalimumab is a monoclonal antibody used to treat autoimmune diseases. It does not interact with the CYP3A4 enzyme system and would not affect rosuvastatin levels.</li><li>\u2022 Adalimumab is a monoclonal antibody used to treat autoimmune diseases. It does not interact with the CYP3A4 enzyme system and would not affect rosuvastatin levels.</li><li>\u2022 Adalimumab</li><li>\u2022 monoclonal antibody</li><li>\u2022 treat autoimmune diseases.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 When prescribing rosuvastatin, it is important to avoid concurrent use with clarithromycin due to the risk of increased rosuvastatin levels from CYP3A4 inhibition, which can lead to serious side effects such as myopathy.</li><li>\u27a4 prescribing rosuvastatin,</li><li>\u27a4 avoid concurrent use with clarithromycin</li><li>\u27a4 risk of increased rosuvastatin levels from CYP3A4 inhibition,</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "e2e3e0a7",
      "audio": ""
    },
    {
      "text": "Which of the following antimicrobials should not be given to a chronic asthmatic patient managed on theophylline therapy?",
      "options": [
        {
          "label": "A",
          "text": "Erythromycin",
          "correct": true
        },
        {
          "label": "B",
          "text": "Cefotaxime",
          "correct": false
        },
        {
          "label": "C",
          "text": "Cotrimoxazole",
          "correct": false
        },
        {
          "label": "D",
          "text": "Amoxicillin",
          "correct": false
        }
      ],
      "correct_answer": "A. Erythromycin",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Erythromycin</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Cefotaxime:</li><li>\u2022 Option B. Cefotaxime:</li><li>\u2022 Cefotaxime is a cephalosporin antibiotic and does not significantly inhibit the metabolism of theophylline . It is generally considered safe to use in patients taking theophylline.</li><li>\u2022 Cefotaxime is a cephalosporin antibiotic and does not significantly inhibit the metabolism of theophylline . It is generally considered safe to use in patients taking theophylline.</li><li>\u2022 Cefotaxime</li><li>\u2022 cephalosporin antibiotic</li><li>\u2022 not</li><li>\u2022 inhibit the metabolism of theophylline</li><li>\u2022 Option C. Cotrimoxazole:</li><li>\u2022 Option C. Cotrimoxazole:</li><li>\u2022 Cotrimoxazole (trimethoprim-sulfamethoxazole) can also increase theophylline levels by reducing its clearance . While it may not be as strong of an inhibitor as some other medications, caution is still advised when prescribing it to patients on theophylline therapy.</li><li>\u2022 Cotrimoxazole (trimethoprim-sulfamethoxazole) can also increase theophylline levels by reducing its clearance . While it may not be as strong of an inhibitor as some other medications, caution is still advised when prescribing it to patients on theophylline therapy.</li><li>\u2022 Cotrimoxazole</li><li>\u2022 increase theophylline levels</li><li>\u2022 reducing its clearance</li><li>\u2022 Option D. Amoxicillin:</li><li>\u2022 Option D. Amoxicillin:</li><li>\u2022 Amoxicillin is a penicillin antibiotic that does not interfere with the metabolism of theophylline and is safe to use in asthmatic patients on theophylline.</li><li>\u2022 Amoxicillin is a penicillin antibiotic that does not interfere with the metabolism of theophylline and is safe to use in asthmatic patients on theophylline.</li><li>\u2022 Amoxicillin</li><li>\u2022 penicillin antibiotic</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 When prescribing medication to a patient on theophylline therapy , it is essential to avoid erythromycin due to its potential to inhibit theophylline metabolism and increase the risk of theophylline toxicity .</li><li>\u27a4 prescribing medication to a patient</li><li>\u27a4 theophylline therapy</li><li>\u27a4 essential to avoid erythromycin</li><li>\u27a4 potential to inhibit theophylline metabolism</li><li>\u27a4 increase the risk of theophylline toxicity</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "eef4f373",
      "audio": ""
    },
    {
      "text": "Which of the drugs shown in the graph below has the highest potency?",
      "options": [
        {
          "label": "A",
          "text": "Drug X",
          "correct": true
        },
        {
          "label": "B",
          "text": "Drug Y",
          "correct": false
        },
        {
          "label": "C",
          "text": "Drug Z",
          "correct": false
        },
        {
          "label": "D",
          "text": "Equal for drug X and Y",
          "correct": false
        }
      ],
      "correct_answer": "A. Drug X",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/08/24/23.jpg"
      ],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Drug X</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Drug Y</li><li>\u2022 Option B. Drug Y</li><li>\u2022 Drug Y is less potent than Drug X because its curve starts to rise at a higher dose than that of Drug X. However, Drug Y has the same efficacy as Drug X because the maximum height of the curve (maximum response) is the same.</li><li>\u2022 Drug Y is less potent than Drug X because its curve starts to rise at a higher dose than that of Drug X. However, Drug Y has the same efficacy as Drug X because the maximum height of the curve (maximum response) is the same.</li><li>\u2022 Drug Y</li><li>\u2022 less potent</li><li>\u2022 Drug X because its curve starts to rise at a higher dose than that of Drug X.</li><li>\u2022 Option C. Drug Z</li><li>\u2022 Option C. Drug Z</li><li>\u2022 Drug Z is the least potent because its curve starts to rise at the highest dose among the three drugs. Additionally, it has lower efficacy because the maximum height of its curve is less than that of Drugs X and Y.</li><li>\u2022 Drug Z is the least potent because its curve starts to rise at the highest dose among the three drugs. Additionally, it has lower efficacy because the maximum height of its curve is less than that of Drugs X and Y.</li><li>\u2022 Drug Z</li><li>\u2022 least potent</li><li>\u2022 curve starts to rise at the highest dose</li><li>\u2022 three drugs.</li><li>\u2022 Option D. Equal for drug X and Y</li><li>\u2022 Option D. Equal for drug X and Y</li><li>\u2022 This option is incorrect with respect to potency; while Drug X and Drug Y have equal efficacy, Drug X is more potent than Drug Y.</li><li>\u2022 This option is incorrect with respect to potency; while Drug X and Drug Y have equal efficacy, Drug X is more potent than Drug Y.</li><li>\u2022 Drug X and Drug Y have equal efficacy,</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 The potency of a drug is determined by the amount of drug needed to produce an effect, and is indicated by the position of the dose-response curve on the dose axis; the drug whose curve starts at the lowest dose is the most potent. Efficacy, however, is determined by the maximum response a drug can prod</li><li>\u27a4 potency of a drug</li><li>\u27a4 position of the dose-response curve on the dose axis;</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "44d1f495",
      "audio": ""
    },
    {
      "text": "What happens when you double the dose of a drug that follows first order kinetics?",
      "options": [
        {
          "label": "A",
          "text": "Half-life remains the same and plasma concentration doubles",
          "correct": true
        },
        {
          "label": "B",
          "text": "Both half-life and plasma concentration double",
          "correct": false
        },
        {
          "label": "C",
          "text": "Both half-life and plasma concentration remain the same",
          "correct": false
        },
        {
          "label": "D",
          "text": "Half-life doubles and plasma concentration remains the same",
          "correct": false
        }
      ],
      "correct_answer": "A. Half-life remains the same and plasma concentration doubles",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Half-life remains the same and plasma concentration doubles</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B . Both half-life and plasma concentration double. This is incorrect because, in first-order kinetics , the half-life of a drug is independent of its concentration .</li><li>\u2022 Option B</li><li>\u2022 Both half-life and plasma concentration double.</li><li>\u2022 first-order kinetics</li><li>\u2022 half-life of a drug</li><li>\u2022 independent of its concentration</li><li>\u2022 Option C. Both half-life and plasma concentration remain the same. This is incorrect because while the half-life remains the same, the plasma concentration will double if the dose is doubled.</li><li>\u2022 Option C.</li><li>\u2022 Both half-life and plasma concentration remain the same.</li><li>\u2022 half-life remains the same, the plasma concentration</li><li>\u2022 Option D. Half-life doubles and plasma concentration remains the same. This is incorrect. In first-order kinetics , the half-life of a drug does not change with the dose, and the plasma concentration will change proportionally with the dose.</li><li>\u2022 Option D.</li><li>\u2022 Half-life doubles and plasma concentration remains the same.</li><li>\u2022 first-order kinetics</li><li>\u2022 half-life of a drug does not change with the dose,</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 For drugs that follow first-order kinetics, increasing the dose leads to a proportional increase in plasma concentration, but the half-life , which is a function of the drug's properties and the body's ability to metabolize or excrete it, remains constant.</li><li>\u2022 drugs that follow first-order kinetics,</li><li>\u2022 increasing</li><li>\u2022 dose leads to a proportional increase in plasma concentration,</li><li>\u2022 half-life</li><li>\u2022 function of the drug's properties</li><li>\u2022 body's ability to metabolize</li><li>\u2022 remains constant.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "2db06d27",
      "audio": ""
    },
    {
      "text": "A patient was on clopidogrel for stroke prophylaxis. However, he developed an episode of stroke even when on an adequate dose of clopidogrel. A defect in which of the following enzymes can lead to such a scenario?",
      "options": [
        {
          "label": "A",
          "text": "CYP3A4",
          "correct": false
        },
        {
          "label": "B",
          "text": "CYP2D6",
          "correct": false
        },
        {
          "label": "C",
          "text": "CYP2C19",
          "correct": true
        },
        {
          "label": "D",
          "text": "CYP2E1",
          "correct": false
        }
      ],
      "correct_answer": "C. CYP2C19",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) CYP2C19</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. CYP3A4: This enzyme is involved in the metabolism of various drugs , but it is not the primary enzyme responsible for the activation of clopidogrel. While CYP3A4 contributes to the metabolism of clopidogrel, its genetic polymorphism is not typically associated with reduced effectiveness of clopidogrel in stroke prevention.</li><li>\u2022 Option A. CYP3A4:</li><li>\u2022 metabolism of various drugs</li><li>\u2022 not the primary enzyme responsible for the activation of clopidogrel.</li><li>\u2022 Option B. CYP2D6: This enzyme metabolizes many drugs , particularly psychotropic medications . It is not significantly involved in the metabolism of clopidogrel, and its variation does not typically impact the effectiveness of clopidogrel in stroke prophylaxis.</li><li>\u2022 Option B. CYP2D6:</li><li>\u2022 enzyme metabolizes many drugs</li><li>\u2022 psychotropic medications</li><li>\u2022 Option D. CYP2E1: This enzyme is involved in the metabolism of certain toxins and drugs , including ethanol and acetaminophen , but it does not play a significant role in the metabolism of clopidogrel. Variations in CYP2E1 are not typically associated with the effectiveness of clopidogrel in stroke prevention.</li><li>\u2022 Option D. CYP2E1:</li><li>\u2022 enzyme</li><li>\u2022 metabolism of certain toxins and drugs</li><li>\u2022 ethanol and acetaminophen</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 A defect in CYP2C19 is the most likely cause of the reduced effectiveness of clopidogrel in this patient's stroke prophylaxis . Testing for CYP2C19 polymorphisms can be considered in patients who experience thrombotic events despite being on clopidogrel therapy. Alternative antiplatelet therapy may be required in patients with such genetic variations.</li><li>\u2022 defect in CYP2C19</li><li>\u2022 cause of the reduced effectiveness</li><li>\u2022 clopidogrel</li><li>\u2022 stroke prophylaxis</li><li>\u2022 Testing</li><li>\u2022 CYP2C19 polymorphisms</li><li>\u2022 thrombotic events</li><li>\u2022 clopidogrel therapy.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "c1ad3c72",
      "audio": ""
    },
    {
      "text": "Which of the following is not a criterion for essential drug?",
      "options": [
        {
          "label": "A",
          "text": "It must be cost effective",
          "correct": false
        },
        {
          "label": "B",
          "text": "Its efficacy must have been proven in clinical trials",
          "correct": false
        },
        {
          "label": "C",
          "text": "Fixed drug combinations are better than single drugs",
          "correct": true
        },
        {
          "label": "D",
          "text": "It is useful for a public health problem",
          "correct": false
        }
      ],
      "correct_answer": "C. Fixed drug combinations are better than single drugs",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Fixed drug combinations are better than single drugs</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. It must be cost-effective:</li><li>\u2022 Option A. It must be cost-effective:</li><li>\u2022 Correct . An essential drug should provide the best possible health benefits at the lowest possible cost.</li><li>\u2022 Correct . An essential drug should provide the best possible health benefits at the lowest possible cost.</li><li>\u2022 Correct</li><li>\u2022 Option B. Its efficacy must have been proven in clinical trials:</li><li>\u2022 Option B. Its efficacy must have been proven in clinical trials:</li><li>\u2022 Correct. An essential drug should have a proven track record of efficacy based on sound scientific evidence from clinical trials.</li><li>\u2022 Correct. An essential drug should have a proven track record of efficacy based on sound scientific evidence from clinical trials.</li><li>\u2022 Correct.</li><li>\u2022 Option D. It is useful for a public health problem:</li><li>\u2022 Option D. It is useful for a public health problem:</li><li>\u2022 Correct . Essential drugs are those that address the most important needs within a public health context.</li><li>\u2022 Correct . Essential drugs are those that address the most important needs within a public health context.</li><li>\u2022 Correct</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 Essential drugs must be cost-effective, proven effective in clinical trials, suitable for addressing public health problems , and usually are single agents unless there's a clear benefit for a Fixed Dose Combination .</li><li>\u27a4 Essential drugs</li><li>\u27a4 cost-effective,</li><li>\u27a4 effective in clinical trials,</li><li>\u27a4 addressing public health problems</li><li>\u27a4 clear benefit for a Fixed Dose Combination</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "220ee2be",
      "audio": ""
    },
    {
      "text": "As an Indian medical intern, which of the following is the correct format for prescription of alprazolam?",
      "options": [
        {
          "label": "A",
          "text": "Tablet alprazolam 0.5 mg once a day before bedtime for 7 days",
          "correct": true
        },
        {
          "label": "B",
          "text": "Tablet alprazolam 0.5 mg HS for 7 days",
          "correct": false
        },
        {
          "label": "C",
          "text": "Tablet alprazolam 500 mcg one tablet OD for 7 days",
          "correct": false
        },
        {
          "label": "D",
          "text": "Tablet alprazolam \u00bd mg tablet HS daily",
          "correct": false
        }
      ],
      "correct_answer": "A. Tablet alprazolam 0.5 mg once a day before bedtime for 7 days",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Tablet alprazolam 0.5 mg once a day before bedtime for 7 days</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Tablet alprazolam 0.5 mg HS for 7 days:</li><li>\u2022 Option B. Tablet alprazolam 0.5 mg HS for 7 days:</li><li>\u2022 While HS (hora somni) means 'at bedtime', it's an abbreviation and should be avoided in prescriptions to prevent any confusion.</li><li>\u2022 While HS (hora somni) means 'at bedtime', it's an abbreviation and should be avoided in prescriptions to prevent any confusion.</li><li>\u2022 HS</li><li>\u2022 'at bedtime',</li><li>\u2022 abbreviation</li><li>\u2022 avoided in prescriptions to prevent any confusion.</li><li>\u2022 Option C. Tablet alprazolam 500 mcg one tablet OD for 7 days:</li><li>\u2022 Option C. Tablet alprazolam 500 mcg one tablet OD for 7 days:</li><li>\u2022 Here, ' OD' stands for once daily which is an abbreviation and should be avoided. While 'mcg' is the correct designation for micrograms, it is better practice to use milligrams for clarity, especially when it is a standard dosage as with alprazolam.</li><li>\u2022 Here, ' OD' stands for once daily which is an abbreviation and should be avoided. While 'mcg' is the correct designation for micrograms, it is better practice to use milligrams for clarity, especially when it is a standard dosage as with alprazolam.</li><li>\u2022 OD' stands for once daily</li><li>\u2022 an abbreviation and should be avoided.</li><li>\u2022 'mcg' is the correct designation for micrograms,</li><li>\u2022 Option D. Tablet alprazolam \u00bd mg tablet HS daily:</li><li>\u2022 Option D. Tablet alprazolam \u00bd mg tablet HS daily:</li><li>\u2022 The use of fractions (\u00bd mg) can be confusing and should be avoided; the dosage should be written in decimals (0.5 mg). Additionally, 'HS' is again used, which should be avoided in place of plain language instructions.</li><li>\u2022 The use of fractions (\u00bd mg) can be confusing and should be avoided; the dosage should be written in decimals (0.5 mg). Additionally, 'HS' is again used, which should be avoided in place of plain language instructions.</li><li>\u2022 use of fractions</li><li>\u2022 confusing and should be avoided;</li><li>\u2022 dosage should be written in decimals</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 The correct format for prescription writing is to clearly state the drug name, dosage in milligrams, frequency, and duration without the use of abbreviations or symbols that could be misinterpreted.</li><li>\u27a4 correct format for prescription writing</li><li>\u27a4 clearly state the drug name, dosage in milligrams, frequency, and duration</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "154c3c26",
      "audio": ""
    },
    {
      "text": "Rate of administration of a drug is equal to the rate of elimination. How will you calculate the dosing rate of the drug to maintain steady state concentration?",
      "options": [
        {
          "label": "A",
          "text": "Dosing rate= Vd x target plasma concentration",
          "correct": false
        },
        {
          "label": "B",
          "text": "Dosing rate= CL x target plasma concentration",
          "correct": true
        },
        {
          "label": "C",
          "text": "Dosing rate= Vd/target plasma concentration",
          "correct": false
        },
        {
          "label": "D",
          "text": "Dosing rate = CL/target plasma concentration",
          "correct": false
        }
      ],
      "correct_answer": "B. Dosing rate= CL x target plasma concentration",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Dosing rate = CL x target plasma concentration</strong></p>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 To maintain a steady-state concentration of a drug , the dosing rate should be calculated as the product of the drug's clearance (CL) and the target plasma concentration .</li><li>\u27a4 maintain a steady-state concentration of a drug</li><li>\u27a4 dosing rate</li><li>\u27a4 calculated as the product of the drug's clearance</li><li>\u27a4 target plasma concentration</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "f5af783f",
      "audio": ""
    },
    {
      "text": "Which of the following is not an example of the clinical importance of enzyme induction?",
      "options": [
        {
          "label": "A",
          "text": "Phenobarbitone is used in the treatment of neonatal jaundice",
          "correct": false
        },
        {
          "label": "B",
          "text": "Phenytoin is contraindicated in acute intermittent porphyria",
          "correct": false
        },
        {
          "label": "C",
          "text": "Tolerance occurs to anticonvulsant action of carbamazepine in few doses",
          "correct": false
        },
        {
          "label": "D",
          "text": "Omeprazole increases metabolism and thus inhibits the action of clopidogrel",
          "correct": true
        }
      ],
      "correct_answer": "D. Omeprazole increases metabolism and thus inhibits the action of clopidogrel",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Omeprazole increases the metabolism and thus inhibits the action of clopidogrel.</strong></p>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 The concept of enzyme induction is clinically important, as it can inform treatment decisions, such as using phenobarbitone for neonatal jaundice due to its inducing effects, avoiding phenytoin in porphyria, and being aware of potential tolerance to drugs like carbamazepine . Conversely, enzyme inhibition , such as the interaction between omeprazole and clopidogrel, can significantly impact drug efficacy.</li><li>\u27a4 enzyme induction</li><li>\u27a4 inform treatment</li><li>\u27a4 using phenobarbitone</li><li>\u27a4 neonatal jaundice</li><li>\u27a4 its inducing effects, avoiding phenytoin</li><li>\u27a4 porphyria,</li><li>\u27a4 aware of potential tolerance</li><li>\u27a4 carbamazepine</li><li>\u27a4 enzyme inhibition</li><li>\u27a4 interaction between omeprazole and clopidogrel,</li><li>\u27a4 impact drug efficacy.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "a83d8104",
      "audio": ""
    },
    {
      "text": "The extent to which ionization of a drug takes place is dependent upon pKa of the drug and the pH of the solution in which the drug is dissolved. Which of the following statements is NOT correct?",
      "options": [
        {
          "label": "A",
          "text": "pKa of a drug is the pH at which the drug is 50% ionized",
          "correct": false
        },
        {
          "label": "B",
          "text": "Small changes of pH near the pKa of a weak acidic drug will not affect its degree of ionization",
          "correct": true
        },
        {
          "label": "C",
          "text": "Knowledge of pKa of a drug is useful in predicting its behavior in various body fluids",
          "correct": false
        },
        {
          "label": "D",
          "text": "Phenobarbitone with a pKa of 7.2 is largely unionized at acid pH and will be about 40% non-ionized in plasma",
          "correct": false
        }
      ],
      "correct_answer": "B. Small changes of pH near the pKa of a weak acidic drug will not affect its degree of ionization",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Small changes of pH near the pKa of a weak acidic drug will not affect its degree of ionization</strong></p>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 The ionization of a drug in the body is critical to its pharmacokinetics and can be predicted by knowing the pKa of the drug and the pH of the environment; however, small changes in pH near the pKa can significantly affect the drug's ionization state.</li><li>\u27a4 The ionization of a drug in the body is critical to its pharmacokinetics and can be predicted by knowing the pKa of the drug and the pH of the environment; however, small changes in pH near the pKa can significantly affect the drug's ionization state.</li><li>\u27a4 ionization of a drug</li><li>\u27a4 its pharmacokinetics</li><li>\u27a4 predicted by knowing the pKa</li><li>\u27a4 drug</li><li>\u27a4 pH of the environment;</li><li>\u27a4 small changes in pH near the pKa</li><li>\u27a4 affect the drug's</li><li>\u27a4 ionization state.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "5e9025a7",
      "audio": ""
    },
    {
      "text": "A 70 Kg person was started on a drug with Vd =10 L and exhibits first-order elimination kinetics. The rate of drug clearance is calculated to be 6.93 L/hr. It is determined that repeating the second dose when 75% of the drug is eliminated will minimize toxicity while maintaining trough levels above the minimum inhibitory concentration. Based on these research findings, which of the following is the most appropriate dosing interval for this drug?",
      "options": [
        {
          "label": "A",
          "text": "1 hour",
          "correct": false
        },
        {
          "label": "B",
          "text": "2 hours",
          "correct": true
        },
        {
          "label": "C",
          "text": "1 day",
          "correct": false
        },
        {
          "label": "D",
          "text": "12 hours",
          "correct": false
        }
      ],
      "correct_answer": "B. 2 hours",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) 2 hours</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 To determine the dosing interval for this drug , we need to first calculate the half-life (t1/2) of the drug. We can use the formula:</li><li>\u2022 dosing interval for this drug</li><li>\u2022 first calculate the half-life (t1/2)</li><li>\u2022 t1/2 = 0.693 x Vd / clearance</li><li>\u2022 t1/2 = 0.693 x Vd / clearance</li><li>\u2022 where Vd is the volume of distribution and clearance is the rate of drug clearance.</li><li>\u2022 Vd</li><li>\u2022 volume of distribution</li><li>\u2022 clearance</li><li>\u2022 rate of drug clearance.</li><li>\u2022 Substituting the given values, we get:</li><li>\u2022 Substituting</li><li>\u2022 values,</li><li>\u2022 t1/2 = 0.693 x 10 / 6.93 t1/2 = 1 hour</li><li>\u2022 t1/2</li><li>\u2022 1 hour</li><li>\u2022 The time to eliminate 75% of the drug would be 2 half-lives (in 1 half-life 50 percent is eliminated and in 2 half-lives 75 percent will be eliminated ) . Therefore, the time to eliminate 75% of the drug would be:</li><li>\u2022 time to eliminate 75% of the drug</li><li>\u2022 2 half-lives</li><li>\u2022 1 half-life 50 percent</li><li>\u2022 eliminated</li><li>\u2022 2 half-lives 75 percent</li><li>\u2022 eliminated</li><li>\u2022 time to eliminate 75% of the drug</li><li>\u2022 t = 2 x t1/2 = 2 x 1 = 2 hours</li><li>\u2022 t = 2 x t1/2</li><li>\u2022 2 hours</li><li>\u2022 So, the appropriate dosing interval would be around 2 hours to ensure that 75% of the previous dose is eliminated before the next dose is given.</li><li>\u2022 dosing interval</li><li>\u2022 around 2 hours</li><li>\u2022 75% of the previous dose</li><li>\u2022 eliminated before</li><li>\u2022 next</li><li>\u2022 dose is given.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 For a drug with first-order elimination kinetics , a dosing interval should be set based on its half-life to minimize toxicity and maintain effective drug concentrations.</li><li>\u27a4 first-order elimination kinetics</li><li>\u27a4 dosing interval</li><li>\u27a4 its half-life</li><li>\u27a4 minimize toxicity</li><li>\u27a4 maintain effective drug concentrations.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "43934c1a",
      "audio": ""
    },
    {
      "text": "Which of the following drugs should be given in sustained release oral dosage form?",
      "options": [
        {
          "label": "A",
          "text": "An anti-arrhythmic drug with a plasma half-life of 10 seconds used for acute treatment of PSVT.",
          "correct": false
        },
        {
          "label": "B",
          "text": "An anti-inflammatory drug with a plasma half-life of 24 hr",
          "correct": false
        },
        {
          "label": "C",
          "text": "A hypnotic drug with a plasma half-life of 2 hours",
          "correct": false
        },
        {
          "label": "D",
          "text": "An antihypertensive with a plasma half-life of 3 hours",
          "correct": true
        }
      ],
      "correct_answer": "D. An antihypertensive with a plasma half-life of 3 hours",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) An antihypertensive with a plasma half-life of 3 hours</strong></p>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 Sustained release oral dosage forms are most appropriate for drugs that have a short plasma half-life and are used for chronic conditions, such as an antihypertensive with a 3-hour half-life, to maintain consistent therapeutic levels and improve patient compliance with less frequent dosing.</li><li>\u27a4 Sustained release</li><li>\u27a4 forms</li><li>\u27a4 short plasma half-life</li><li>\u27a4 used for chronic</li><li>\u27a4 antihypertensive with a 3-hour half-life,</li><li>\u27a4 consistent therapeutic levels</li><li>\u27a4 improve patient compliance with less frequent dosing.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "c98e8e2b",
      "audio": ""
    },
    {
      "text": "A new drug Z is being tested in animals for Anti-diabetic activity. When drug Z was given in a dose of 10 mg, 50 mice got the expected effect among the 100 who received the drug. However, at 100 mg dose, half of the animals died. Which of the following statements about drug Z is INCORRECT?",
      "options": [
        {
          "label": "A",
          "text": "The final dose of drug Z in humans should be between 10 mg and 100 mg",
          "correct": true
        },
        {
          "label": "B",
          "text": "ED50 of drug Z is 10 mg",
          "correct": false
        },
        {
          "label": "C",
          "text": "LD50 of drug Z is 100 mg",
          "correct": false
        },
        {
          "label": "D",
          "text": "Therapeutic index of drug Z is around 10",
          "correct": false
        }
      ],
      "correct_answer": "A. The final dose of drug Z in humans should be between 10 mg and 100 mg",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) The final dose of drug Z in humans should be between 10 mg and 100 mg.</strong></p>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 The therapeutic index (TI) of drug Z is 10 , determined by the ratio of the LD50 (dose lethal to 50% of subjects) to the ED50 (dose effective in 50% of subjects) , but the appropriate dose for humans cannot be extrapolated directly from animal data without further clinical investigation.</li><li>\u27a4 therapeutic index (TI)</li><li>\u27a4 drug Z</li><li>\u27a4 10</li><li>\u27a4 ratio of the LD50 (dose lethal to 50% of subjects) to the ED50</li><li>\u27a4 effective in 50% of subjects)</li><li>\u27a4 dose for humans</li><li>\u27a4 cannot</li><li>\u27a4 extrapolated</li><li>\u27a4 from animal data without</li><li>\u27a4 clinical investigation.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "9ef20367",
      "audio": ""
    },
    {
      "text": "Experiments show that 50% of an oral 100-mg dose of Drug A is absorbed in a 60-kg test subject. However, the fractional bioavailability was only 0.2. Assuming a liver blood flow of 1500 mL/min, which of the following is the hepatic clearance of Drug A in this situation?",
      "options": [
        {
          "label": "A",
          "text": "300 mL/min",
          "correct": false
        },
        {
          "label": "B",
          "text": "450 mL/min",
          "correct": false
        },
        {
          "label": "C",
          "text": "600 mL/min",
          "correct": false
        },
        {
          "label": "D",
          "text": "900 mL/min",
          "correct": true
        }
      ],
      "correct_answer": "D. 900 mL/min",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) 900 mL/min</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Absorption and Bioavailability : 50% of the 100 mg dose of Drug A is absorbed, so 50 mg reaches the liver. The fractional bioavailability (F) is 0.2 , meaning 20% of the absorbed drug reaches the systemic circulation , or 20 mg . Amount Extracted by the Liver : 50 mg of the absorbed drug reaches the liver, and 20 mg exits into the systemic circulation. Therefore, the amount extracted by the liver is: 50\u2009mg \u2212 20 \u2009mg = 30\u2009mg Hepatic Extraction Ratio (ER) : The hepatic extraction ratio is the fraction of the drug extracted by the liver : ER = Amount extracted by the liver/Amount reaching the liver = 30\u2009mg / 50\u2009mg = 0.6 Hepatic Clearance (Cl\u2095) : Hepatic clearance is given by the formula: CL = Liver Blood Flow (Q) \u00d7 Extraction Ratio Given that the liver blood flow (Q) is 1500 mL/min (or 1.5 L/min) and the extraction ratio (ER) is 0.6 : CL = 1500\u2009mL/min \u00d7 0.6 = 900\u2009mL/min</li><li>\u2022 Absorption and Bioavailability : 50% of the 100 mg dose of Drug A is absorbed, so 50 mg reaches the liver. The fractional bioavailability (F) is 0.2 , meaning 20% of the absorbed drug reaches the systemic circulation , or 20 mg .</li><li>\u2022 Absorption and Bioavailability :</li><li>\u2022 Absorption and Bioavailability</li><li>\u2022 50% of the 100 mg dose of Drug A is absorbed, so 50 mg reaches the liver. The fractional bioavailability (F) is 0.2 , meaning 20% of the absorbed drug reaches the systemic circulation , or 20 mg .</li><li>\u2022 50% of the 100 mg dose of Drug A is absorbed, so 50 mg reaches the liver.</li><li>\u2022 50% of the 100 mg dose</li><li>\u2022 50 mg</li><li>\u2022 The fractional bioavailability (F) is 0.2 , meaning 20% of the absorbed drug reaches the systemic circulation , or 20 mg .</li><li>\u2022 fractional bioavailability (F)</li><li>\u2022 0.2</li><li>\u2022 20%</li><li>\u2022 systemic circulation</li><li>\u2022 20 mg</li><li>\u2022 Amount Extracted by the Liver : 50 mg of the absorbed drug reaches the liver, and 20 mg exits into the systemic circulation. Therefore, the amount extracted by the liver is: 50\u2009mg \u2212 20 \u2009mg = 30\u2009mg</li><li>\u2022 Amount Extracted by the Liver :</li><li>\u2022 Amount Extracted by the Liver</li><li>\u2022 50 mg of the absorbed drug reaches the liver, and 20 mg exits into the systemic circulation. Therefore, the amount extracted by the liver is: 50\u2009mg \u2212 20 \u2009mg = 30\u2009mg</li><li>\u2022 50 mg of the absorbed drug reaches the liver, and 20 mg exits into the systemic circulation.</li><li>\u2022 50 mg</li><li>\u2022 20 mg</li><li>\u2022 Therefore, the amount extracted by the liver is: 50\u2009mg \u2212 20 \u2009mg = 30\u2009mg</li><li>\u2022 amount extracted by the liver</li><li>\u2022 Hepatic Extraction Ratio (ER) : The hepatic extraction ratio is the fraction of the drug extracted by the liver : ER = Amount extracted by the liver/Amount reaching the liver = 30\u2009mg / 50\u2009mg = 0.6</li><li>\u2022 Hepatic Extraction Ratio (ER) :</li><li>\u2022 Hepatic Extraction Ratio (ER)</li><li>\u2022 The hepatic extraction ratio is the fraction of the drug extracted by the liver : ER = Amount extracted by the liver/Amount reaching the liver = 30\u2009mg / 50\u2009mg = 0.6</li><li>\u2022 The hepatic extraction ratio is the fraction of the drug extracted by the liver :</li><li>\u2022 hepatic extraction ratio</li><li>\u2022 fraction of the drug extracted by the liver</li><li>\u2022 ER = Amount extracted by the liver/Amount reaching the liver = 30\u2009mg / 50\u2009mg = 0.6</li><li>\u2022 Hepatic Clearance (Cl\u2095) : Hepatic clearance is given by the formula: CL = Liver Blood Flow (Q) \u00d7 Extraction Ratio Given that the liver blood flow (Q) is 1500 mL/min (or 1.5 L/min) and the extraction ratio (ER) is 0.6 : CL = 1500\u2009mL/min \u00d7 0.6 = 900\u2009mL/min</li><li>\u2022 Hepatic Clearance (Cl\u2095) :</li><li>\u2022 Hepatic Clearance (Cl\u2095)</li><li>\u2022 Hepatic clearance is given by the formula: CL = Liver Blood Flow (Q) \u00d7 Extraction Ratio Given that the liver blood flow (Q) is 1500 mL/min (or 1.5 L/min) and the extraction ratio (ER) is 0.6 : CL = 1500\u2009mL/min \u00d7 0.6 = 900\u2009mL/min</li><li>\u2022 Hepatic clearance is given by the formula:</li><li>\u2022 CL = Liver Blood Flow (Q) \u00d7 Extraction Ratio</li><li>\u2022 Given that the liver blood flow (Q) is 1500 mL/min (or 1.5 L/min) and the extraction ratio (ER) is 0.6 :</li><li>\u2022 liver blood flow (Q)</li><li>\u2022 1500 mL/min</li><li>\u2022 extraction ratio (ER)</li><li>\u2022 0.6</li><li>\u2022 CL = 1500\u2009mL/min \u00d7 0.6 = 900\u2009mL/min</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 To calculate the hepatic clearance of a drug , apply the formula hepatic clearance = hepatic extraction ratio \u00d7 hepatic blood flow, using the fraction of the drug dose absorbed and the fractional bioavailability to determine the extraction ratio .</li><li>\u27a4 hepatic clearance of a drug</li><li>\u27a4 hepatic clearance = hepatic extraction ratio \u00d7 hepatic blood flow,</li><li>\u27a4 fraction of the drug</li><li>\u27a4 absorbed and the fractional bioavailability</li><li>\u27a4 extraction ratio</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "09f60603",
      "audio": ""
    },
    {
      "text": "Which of the following figures correctly represent the relationship between clearance and plasma concentration for a drug following first order kinetics?",
      "options": [
        {
          "label": "A",
          "text": "a",
          "correct": true
        },
        {
          "label": "B",
          "text": "b",
          "correct": false
        },
        {
          "label": "C",
          "text": "c",
          "correct": false
        },
        {
          "label": "D",
          "text": "d",
          "correct": false
        }
      ],
      "correct_answer": "A. a",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/05/03/screenshot-2023-05-03-111308.jpg"
      ],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Figure a represents a scenario where clearance is independent of plasma concentration . This is consistent with first-order kinetics, where a constant fraction of the drug is eliminated per unit time. Figure b suggests that clearance increases linearly with increasing plasma concentration, which would imply dose-dependent kinetics , not first-order kinetics. Figure c and d both show clearance changing with plasma concentration , which suggests non-linear kinetics.</li><li>\u2022 Figure a represents a scenario where clearance is independent of plasma concentration . This is consistent with first-order kinetics, where a constant fraction of the drug is eliminated per unit time.</li><li>\u2022 Figure a</li><li>\u2022 clearance is independent of plasma concentration</li><li>\u2022 first-order kinetics,</li><li>\u2022 constant fraction of the drug</li><li>\u2022 eliminated</li><li>\u2022 unit time.</li><li>\u2022 Figure b suggests that clearance increases linearly with increasing plasma concentration, which would imply dose-dependent kinetics , not first-order kinetics.</li><li>\u2022 Figure b</li><li>\u2022 clearance increases linearly</li><li>\u2022 increasing plasma concentration,</li><li>\u2022 dose-dependent kinetics</li><li>\u2022 Figure c and d both show clearance changing with plasma concentration , which suggests non-linear kinetics.</li><li>\u2022 Figure c and d</li><li>\u2022 show clearance</li><li>\u2022 with plasma concentration</li><li>\u2022 non-linear kinetics.</li><li>\u2022 Therefore, the figure that correctly represents the relationship between clearance and plasma concentration for a drug following first-order kinetics is: Figure a .</li><li>\u2022 the figure</li><li>\u2022 correctly represents</li><li>\u2022 relationship between clearance and plasma concentration</li><li>\u2022 first-order kinetics</li><li>\u2022 Figure a</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 In first-order kinetics, the clearance of a drug remains constant regardless of plasma concentration , which is depicted as a horizontal line parallel to the plasma concentration axis in a graph of clearance versus plasma concentration.</li><li>\u27a4 first-order kinetics,</li><li>\u27a4 clearance of a drug</li><li>\u27a4 constant</li><li>\u27a4 plasma concentration</li><li>\u27a4 horizontal</li><li>\u27a4 line parallel to the plasma concentration</li><li>\u27a4 axis</li><li>\u27a4 clearance versus plasma concentration.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "e6882c55",
      "audio": ""
    },
    {
      "text": "Phenytoin is a drug that follows zero order kinetics at high doses and first order kinetics at low doses. Suppose 400 mg phenytoin is present in the body and its rate of elimination at this dose is 200 mg/hr., how much will remain in plasma after 2 hours?",
      "options": [
        {
          "label": "A",
          "text": "100 mg",
          "correct": false
        },
        {
          "label": "B",
          "text": "50 mg",
          "correct": false
        },
        {
          "label": "C",
          "text": "Zero",
          "correct": false
        },
        {
          "label": "D",
          "text": "Cannot be predicted from this information",
          "correct": true
        }
      ],
      "correct_answer": "D. Cannot be predicted from this information",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Cannot be predicted from this information.</strong></p>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 For drugs like phenytoin , which exhibit zero-order kinetics at higher doses and first-order kinetics at lower doses , the specific plasma concentration at which this shift occurs must be known to accurately predict plasma levels after a given period.</li><li>\u27a4 phenytoin</li><li>\u27a4 exhibit zero-order kinetics at higher doses</li><li>\u27a4 first-order kinetics at lower doses</li><li>\u27a4 plasma concentration</li><li>\u27a4 shift</li><li>\u27a4 accurately predict plasma levels</li><li>\u27a4 given period.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "3af39273",
      "audio": ""
    },
    {
      "text": "Which of the following drugs would most likely need a loading dose to help reach therapeutic levels?",
      "options": [
        {
          "label": "A",
          "text": "Acetaminophen, t (1/2) = 2 h",
          "correct": false
        },
        {
          "label": "B",
          "text": "Aspirin, t (1/2) = 15 min",
          "correct": false
        },
        {
          "label": "C",
          "text": "Digitoxin, t (1/2) = 161 h",
          "correct": true
        },
        {
          "label": "D",
          "text": "Adenosine, t (1/2) = 10 s",
          "correct": false
        }
      ],
      "correct_answer": "C. Digitoxin, t (1/2) = 161 h",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Digitoxin, t1/2= 161 hrs</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Aspirin (t\u00bd = 15 minutes) : Aspirin has a very short half-life, meaning it rapidly reaches steady-state levels with regular dosing. A loading dose is typically unnecessary because the drug accumulates quickly.</li><li>\u2022 Aspirin (t\u00bd = 15 minutes)</li><li>\u2022 Acetaminophen (t\u00bd = 2 hours) : While acetaminophen has a longer half-life compared to aspirin, it still reaches therapeutic levels relatively quickly with regular dosing, making a loading dose unnecessary.</li><li>\u2022 Acetaminophen (t\u00bd = 2 hours)</li><li>\u2022 Adenosine (t\u00bd = 10 seconds) : Adenosine has an extremely short half-life and is used for acute, rapid-onset effects, such as in the treatment of supraventricular tachycardia. Because of its immediate action and short duration, no loading dose is needed.</li><li>\u2022 Adenosine (t\u00bd = 10 seconds)</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Drugs with a long half-life (such as digitoxin) require a loading dose to achieve therapeutic concentrations quickly. This is particularly important in clinical scenarios where immediate drug effects are needed. For drugs with short half-lives, a loading dose is typically unnecessary because steady-state levels are rapidly reached with regular dosing.</li><li>\u27a4 long half-life</li><li>\u27a4 loading dose</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "1476e507",
      "audio": ""
    },
    {
      "text": "Constant intravenous infusion (at a rate of 200 mg/hour) of a drug with half-life of 1 hour is started and plasma concentration is measured at different intervals. If steady state plasma concentration is 400 \u00b5g/dl, what was the likely plasma concentration at 2 hours\u2019 time after starting the infusion?",
      "options": [
        {
          "label": "A",
          "text": "100 \u00b5g/dl",
          "correct": false
        },
        {
          "label": "B",
          "text": "150 \u00b5g/dl",
          "correct": false
        },
        {
          "label": "C",
          "text": "200 \u00b5g/dl",
          "correct": false
        },
        {
          "label": "D",
          "text": "300 \u00b5g/dl",
          "correct": true
        }
      ],
      "correct_answer": "D. 300 \u00b5g/dl",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) 300 \u00b5g/dl</strong></p>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 During constant intravenous infusion , plasma concentration of a drug with a half-life of 1 hour at 2 hours is likely to be 75% of the steady-state concentration due to exponential accumulation.</li><li>\u27a4 constant intravenous infusion</li><li>\u27a4 plasma concentration</li><li>\u27a4 half-life of 1 hour at 2 hours</li><li>\u27a4 75%</li><li>\u27a4 steady-state concentration</li><li>\u27a4 exponential accumulation.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "770967d4",
      "audio": ""
    },
    {
      "text": "Time for peak plasma concentration (Tmax) indicates?",
      "options": [
        {
          "label": "A",
          "text": "The rate of elimination",
          "correct": false
        },
        {
          "label": "B",
          "text": "The rate of absorption",
          "correct": true
        },
        {
          "label": "C",
          "text": "The duration of effect",
          "correct": false
        },
        {
          "label": "D",
          "text": "The extent of absorption",
          "correct": false
        }
      ],
      "correct_answer": "B. The rate of absorption",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) The rate of absorption</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. The rate of elimination: Incorrect. The rate of elimination is more closely related to the drug's half-life (t1/2), which is the time required for the plasma concentration of the drug to reduce to half its initial value . Tmax does not provide direct information about the rate at which the drug is eliminated from the body.</li><li>\u2022 Option A. The rate of elimination:</li><li>\u2022 Incorrect.</li><li>\u2022 rate of elimination</li><li>\u2022 closely related to the drug's half-life (t1/2),</li><li>\u2022 time required for the plasma concentration</li><li>\u2022 reduce to half its initial value</li><li>\u2022 Tmax does not</li><li>\u2022 information</li><li>\u2022 rate at</li><li>\u2022 drug is eliminated</li><li>\u2022 Option C. The duration of effect: Incorrect . The duration of effect of a drug is influenced by its half-life and the duration of interaction with its target receptors , not just the time to reach peak concentration. Tmax alone does not provide complete information about how long a drug's effects will last.</li><li>\u2022 Option C. The duration of effect:</li><li>\u2022 Incorrect</li><li>\u2022 duration of effect of a drug</li><li>\u2022 its half-life and the duration of</li><li>\u2022 interaction</li><li>\u2022 target receptors</li><li>\u2022 not</li><li>\u2022 time to reach peak concentration.</li><li>\u2022 Tmax</li><li>\u2022 does not</li><li>\u2022 complete</li><li>\u2022 information</li><li>\u2022 long a drug's effects</li><li>\u2022 last.</li><li>\u2022 Option D. The extent of absorption: Incorrect. The extent of absorption is more accurately indicated by the area under the curve (AUC) or the total plasma concentration of the drug over time . Tmax tells us when the peak concentration occurs but does not indicate the total amount of drug absorbed.</li><li>\u2022 Option D. The extent of absorption:</li><li>\u2022 Incorrect.</li><li>\u2022 extent of absorption</li><li>\u2022 more</li><li>\u2022 indicated</li><li>\u2022 area under the curve</li><li>\u2022 total plasma concentration</li><li>\u2022 drug over time</li><li>\u2022 Tmax</li><li>\u2022 peak concentration</li><li>\u2022 does not</li><li>\u2022 indicate</li><li>\u2022 total amount of drug absorbed.</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 Tmax is a pharmacokinetic parameter that indicates the time at which a drug reaches its maximum concentration in plasma , reflecting the rate of absorption from the site of administration into the systemic circulation.</li><li>\u2022 Tmax</li><li>\u2022 pharmacokinetic</li><li>\u2022 indicates the time</li><li>\u2022 drug</li><li>\u2022 its maximum concentration in plasma</li><li>\u2022 reflecting the rate of absorption</li><li>\u2022 site of administration</li><li>\u2022 systemic circulation.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "358d8f02",
      "audio": ""
    },
    {
      "text": "All the following factors tend to increase the volume of distribution of a drug EXCEPT:",
      "options": [
        {
          "label": "A",
          "text": "High plasma protein binding",
          "correct": true
        },
        {
          "label": "B",
          "text": "Low ionization at physiological pH values",
          "correct": false
        },
        {
          "label": "C",
          "text": "High lipid solubility",
          "correct": false
        },
        {
          "label": "D",
          "text": "High tissue binding",
          "correct": false
        }
      ],
      "correct_answer": "A. High plasma protein binding",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) High plasma protein binding.</strong></p>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 While high lipid solubility, low ionization , and high tissue binding increase a drug's volume of distribution , high plasma protein binding generally decreases it.</li><li>\u27a4 high lipid solubility,</li><li>\u27a4 low ionization</li><li>\u27a4 high tissue binding increase</li><li>\u27a4 drug's volume of distribution</li><li>\u27a4 high plasma protein</li><li>\u27a4 binding</li><li>\u27a4 decreases it.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "3b2fca36",
      "audio": ""
    },
    {
      "text": "Which of the following would up-regulate postsynaptic \u03b21 adrenergic receptors?",
      "options": [
        {
          "label": "A",
          "text": "Daily use of amphetamine causes norepinephrine to be released",
          "correct": false
        },
        {
          "label": "B",
          "text": "A disease that causes an increase in the activity of norepinephrine neurons",
          "correct": false
        },
        {
          "label": "C",
          "text": "Daily use of isoproterenol, a \u03b21 receptor agonist",
          "correct": false
        },
        {
          "label": "D",
          "text": "Daily use of propranolol, a \u03b21 receptor antagonist",
          "correct": true
        }
      ],
      "correct_answer": "D. Daily use of propranolol, a \u03b21 receptor antagonist",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Daily use of propranolol, a \u03b21 receptor antagonist</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Daily use of amphetamine causes norepinephrine to be released:</li><li>\u2022 Option A.</li><li>\u2022 Daily use of amphetamine causes norepinephrine to be released:</li><li>\u2022 Amphetamine increases the release of norepinephrine (NE), among other catecholamines. Chronic exposure to increased levels of neurotransmitters typically leads to a down-regulation of receptors to reduce sensitivity , not up-regulation.</li><li>\u2022 Amphetamine increases the release of norepinephrine (NE), among other catecholamines. Chronic exposure to increased levels of neurotransmitters typically leads to a down-regulation of receptors to reduce sensitivity , not up-regulation.</li><li>\u2022 Amphetamine increases</li><li>\u2022 release of norepinephrine</li><li>\u2022 Chronic exposure</li><li>\u2022 increased levels of neurotransmitters</li><li>\u2022 leads to a down-regulation of receptors</li><li>\u2022 reduce sensitivity</li><li>\u2022 Option B. A disease that causes an increase in the activity of norepinephrine neurons:</li><li>\u2022 Option B.</li><li>\u2022 A disease that causes an increase in the activity of norepinephrine neurons:</li><li>\u2022 Similarly, a disease that causes sustained increases in norepinephrine activity would typically lead to down-regulation of adrenergic receptors as the body attempts to maintain homeostasis and reduce overstimulation.</li><li>\u2022 Similarly, a disease that causes sustained increases in norepinephrine activity would typically lead to down-regulation of adrenergic receptors as the body attempts to maintain homeostasis and reduce overstimulation.</li><li>\u2022 sustained increases in norepinephrine activity</li><li>\u2022 lead to down-regulation of adrenergic receptors as the body</li><li>\u2022 maintain homeostasis</li><li>\u2022 reduce overstimulation.</li><li>\u2022 Option C. Daily use of isoproterenol, a \u03b21 receptor agonist:</li><li>\u2022 Option C.</li><li>\u2022 Daily use of isoproterenol, a \u03b21 receptor agonist:</li><li>\u2022 Chronic exposure to an agonist like isoproterenol usually results in down-regulation of receptors . The nervous system tends to reduce the number of receptors in response to overstimulation to decrease sensitivity.</li><li>\u2022 Chronic exposure to an agonist like isoproterenol usually results in down-regulation of receptors . The nervous system tends to reduce the number of receptors in response to overstimulation to decrease sensitivity.</li><li>\u2022 Chronic exposure</li><li>\u2022 agonist like isoproterenol</li><li>\u2022 down-regulation of receptors</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 Chronic exposure to a \u03b21 receptor antagonist like propranolol can lead to the up-regulation of postsynaptic \u03b21 adrenergic receptors as the body compensates for reduced receptor activation.</li><li>\u27a4 Chronic exposure to a \u03b21 receptor antagonist</li><li>\u27a4 propranolol</li><li>\u27a4 lead to the up-regulation of postsynaptic \u03b21 adrenergic receptors</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "f1adb62f",
      "audio": ""
    },
    {
      "text": "A patient, Rajesh with a history of wheezing, coughing and shortness of breath is being evaluated in the asthma clinic. Several drug treatments with different routes are under consideration. Which of the following statements about routes of administration is most correct?",
      "options": [
        {
          "label": "A",
          "text": "Administration of a bronchodilator drug by inhaled aerosol is usually associated with more adverse effects than administration of this drug by mouth",
          "correct": false
        },
        {
          "label": "B",
          "text": "Bioavailability of most drugs is greater with rectal administration than with sublingual administration",
          "correct": false
        },
        {
          "label": "C",
          "text": "Administration of a drug by transdermal patch is often faster but is associated with more first pass metabolism than oral administration",
          "correct": false
        },
        {
          "label": "D",
          "text": "The first pass effect is the result of elimination of a drug after administration and before it enters systemic circulation",
          "correct": true
        }
      ],
      "correct_answer": "D. The first pass effect is the result of elimination of a drug after administration and before it enters systemic circulation",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) The first pass effect is the result of elimination of a drug after administration and before it enters systemic circulation</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. is incorrect because inhaled aerosol administration of bronchodilator drugs is associated with fewer adverse effects than oral administration , as it allows for targeted delivery of the drug to the site of action in the lungs, with minimal systemic absorption.</li><li>\u2022 Option A.</li><li>\u2022 incorrect</li><li>\u2022 inhaled aerosol administration</li><li>\u2022 fewer adverse effects</li><li>\u2022 oral administration</li><li>\u2022 allows for targeted delivery of the drug</li><li>\u2022 site of action in the lungs,</li><li>\u2022 minimal systemic</li><li>\u2022 absorption.</li><li>\u2022 Option B. is incorrect because sublingual administration generally results in greater bioavailability than rectal administration, as the sublingual route allows for rapid absorption of the drug into the bloodstream through the rich network of blood vessels under the tongue , bypassing the first-pass metabolism in the liver.</li><li>\u2022 Option B.</li><li>\u2022 incorrect</li><li>\u2022 sublingual administration</li><li>\u2022 greater bioavailability</li><li>\u2022 rectal administration,</li><li>\u2022 sublingual route</li><li>\u2022 rapid absorption of the drug</li><li>\u2022 bloodstream</li><li>\u2022 rich network of blood vessels</li><li>\u2022 tongue</li><li>\u2022 bypassing</li><li>\u2022 first-pass metabolism in the liver.</li><li>\u2022 Option C. is incorrect because transdermal administration of a drug is associated with slower onset of action than oral administration, as the drug must penetrate the skin barrier to enter systemic circulation.</li><li>\u2022 Option C.</li><li>\u2022 incorrect</li><li>\u2022 transdermal administration</li><li>\u2022 slower onset of action</li><li>\u2022 oral</li><li>\u2022 administration,</li><li>\u2022 drug</li><li>\u2022 penetrate the skin</li><li>\u2022 enter systemic circulation.</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 First pass effect refers to the metabolism of a drug within the liver that significantly reduces the bioavailability of the drug before it reaches systemic circulation , as opposed to comparing routes of administration and their impact on drug delivery and metabolism.</li><li>\u2022 First pass effect</li><li>\u2022 metabolism of a drug</li><li>\u2022 liver</li><li>\u2022 reduces</li><li>\u2022 bioavailability of the drug before</li><li>\u2022 systemic circulation</li><li>\u2022 comparing routes of administration</li><li>\u2022 their impact</li><li>\u2022 drug delivery</li><li>\u2022 metabolism.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "5c39b851",
      "audio": ""
    }
  ]
}